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Abstract 
 
Microbe resistence is a serious issue, especially as they have become resistant to 
most well known drugs. Therefore this is considered as a global problem and is now 
dealt with at a poitical level. Since no new classes of antimicrobial agents have 
been discovered in the past three deacdes, the development of new drugs is 
extremely urgent. Therefore the aim of this project was to synthesise derivatives of 
benzimidazole, and then assesses their antimicrobial activities in vitro by using disc 
(well) diffusion and MICs tests.  
A total of 69 benzimidazole derivatives, with substituents at positions 1, 2, and 5, 
were synthesised, characterised and tested against selected bacteria and fungi. In 
addition, six bezimidazole silver complexes were prepared and evaluated for their 
antimicrobial behavior. 
The SAR showed that the antimicrobial activity of the compounds depended on the 
substituents attached to the bicyclic heterocycle. Some promising results were 
obtained. In particular, 5 compounds displayed antibacterial activity against two 
MRSA strains with MIC values corresponding to ciprofloxacin, which can be 
considered significant. The compounds have some common features; four possess 
5-chloro or 5-bromo substituents; two are derivatives of (S)-2-
ethanaminebenzimidazole and the others are derivative of one 2-(chloromethyl)-1H-
 
 
ii 
 
benzo[d]imidazole, (1H-benzo[d]imidazol-2-yl)methanethiol and 2-(methoxymethyl)-
1-methyl-1H-benzo[d]imidazole. 
The results from the antifungal screening were very interesting as there were 26 
compounds, including two silver complexes, which were potent fungicides against 
the selected fungal species. They showed equivalent or greater potentency in their 
MIC values than amphotericin B. In particular, the 5-fluoro, 5-chloro and 5-bromo 
benzimidazole showed broad spectrum activity. 
 
 
 
 
 
 
 
 
 
 
 
 
Materials from this thesis were presented at the following symposiums: 
F. A. S. Alasmary,1 N. Karodia,1 and A. M. Snelling2. Synthesis and study of the 
antibacterial activity of some new benzimidazole derivatives. 2nd Bradford Royal 
Society of Chemistry Postgraduate Symposium , University of Bradford, UK , 24th 
October 2012 (First prize poster winner). 
F. A. S. Alasmary,1 N. Karodia,1 and A. M. Snelling2. Synthesis and study of the 
antibacterial activity of some new benzimidazole derivatives. SLS Research and 
Development Symposium, University of Bradford, UK, 20th March 2013. 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 
I would like to thank my supervisors Dr Nazira Karodia and Dr Anna Snelling for 
giving me this opportunity to work on this interesting project and their constructive 
comments which greatly improved this present study. I would also like to express 
my gratitude to Miss Leeanne Rayner for her help on training me in the microbiology 
lab and past and present memebers of Lab M17, especially Dr Ahmed Mansoury. 
My sincere thanks also go to everyone who helped me through this project. 
 
I also thank my sponsors, the Saudi Culture Bureau and King Saud University. 
 
Finally, special thanks to my family, particularly my parents, brothers and my loving 
husband without them I would not have been able to complete this project. To my 
friend Mariam Waleed, a special appreciation, for always supports me. 
 
 
 
 
iv 
 
CONTENTS 
ABSTRACT ........................................................................................................... I 
CONTENTS ........................................................................................................ IV 
LIST OF FIGURES .............................................................................................. X 
LIST OF TABLES ............................................................................................. XIII 
ABBREVIATIONS .......................................................................................... XVIII 
1. INTRODUCTION ............................................................................................ 1 
1.1 MICROORGANISMS ............................................................................................. 1 
1.1.1 Bacteria ......................................................................................................... 1 
1.1.2 Fungi ............................................................................................................. 4 
1.2 INHIBITION OF GROWTH OF MICROORGANISMS ...................................................... 5 
1.3 ANTIMICROBIAL CHEMOTHERAPY ......................................................................... 7 
1.3.1 Use of natural products ................................................................................. 7 
1.3.2 Semi-synthetic compounds ........................................................................... 8 
1.3.3 Entirely synthetic compounds ........................................................................ 9 
1.4 MODES OF ACTION OF ANTIBACTERIAL AGENTS ................................................... 10 
1.4.1 Antibiotics which inhibit cell wall synthesis .................................................. 10 
1.4.2 Antibiotics which function as inhibitors of cell membrane functions ............. 11 
1.4.3 Antibiotics which inhibit protein synthesis .................................................... 11 
1.4.4 Antibiotics that inhibit the synthesis of nucleic acids .................................... 13 
1.4.5 Antibiotics that inhibit metabolic pathways .................................................. 13 
1.5 MODES OF ACTION OF ANTIFUNGAL AGENTS ....................................................... 13 
1.5.1 Sterol synthesis inhibitors ............................................................................ 14 
1.5.1.1 Fungal ergosterol synthesis inhibitors ........................................... 14 
1.5.1.2 Squalene epoxidase inhibitors ...................................................... 16 
1.5.2 Cell wall synthesis inhibitors ........................................................................ 16 
1.5.2.1 Ergosterol disruptors ..................................................................... 16 
1.5.2.2 Glucan synthesis inhibitors ........................................................... 16 
1.5.2.3 Chitin synthesis inhibitors.............................................................. 17 
1.5.3 Nuclic acid and /or protein synthesis inhibitors ............................................ 17 
1.5.3.1 Nucleic acid synthesis inhibitors ................................................... 17 
1.5.3.2 Protein synthesis inhibitors ........................................................... 18 
1.5.3.3 Microtubule synthesis inhibitors .................................................... 18 
1.6 ANTIBIOTIC RESISTANCE ................................................................................... 18 
1.6.1 In bacteria ................................................................................................... 18 
1.6.1.1 Increasing resistance in bacteria and the increasing financial cost 21 
1.6.1.2 Challenges in development of new antibiotics ............................... 24 
1.6.2 In fungi ........................................................................................................ 27 
1.7 ANTIMICROBIAL STEWARDSHIP .......................................................................... 29 
1.8 THE NEED TO DEVELOP NEW DRUGS .................................................................. 31 
1.9 BENZIMIDAZOLES IN MEDICINAL CHEMISTRY ....................................................... 33 
1.9.1 The structure of benzimidazole ................................................................... 33 
1.9.2 Properties of benzimidazole ........................................................................ 34 
1.9.3 Synthesis of benzimidazoles ....................................................................... 35 
1.10 BENZIMIDAZOLES IN MEDICINAL CHEMISTRY ...................................................... 37 
 
 
v 
 
1.10.1 Benzimidazole and derivatives as Antimicrobial  and other medicinal 
agents .................................................................................................................... 41 
1.10.1.1 Benzimidazole derivatives possessing the amino group.............. 43 
1.10.1.2 Bezimidazole derivatives possessing the sulfide group ............... 44 
1.10.1.3 Benzimidazole possessing N-alkyl and N-acyl derivatives .......... 45 
1.10.1.4 Benzimidazole complexes ........................................................... 48 
1.11 PROGRAMME OF STUDY .................................................................................... 51 
1.11.1 Design of an antimicrobial inhibitor .............................................................. 51 
1.11.2 Aims and objectives .................................................................................... 52 
2 MATERIALS AND METHODS ..................................................................... 56 
2.1 INDEX OF COMPOUNDS SYNTHESISED AND PURIFIED ........................................... 56 
2.2 MATERIALS FOR SYNTHESIS .............................................................................. 58 
2.2.1 Reagents .................................................................................................... 58 
2.2.2 Purification of Solvents ................................................................................ 58 
2.2.3 Instrumentation ........................................................................................... 58 
2.2.3.1 Nuclear magnetic spectroscopy (NMR) ......................................... 58 
2.2.3.2 Infrared spectra (IR) ...................................................................... 59 
2.2.3.3 Mass spectrometry (MS) ............................................................... 59 
2.2.3.4 Melting points (m.p.) ..................................................................... 59 
2.2.3.5 Elemental analysis ........................................................................ 59 
2.2.4 Chromatography ......................................................................................... 59 
2.2.4.1 Thin layer chromatography (TLC) ................................................. 59 
2.2.4.2 Column chromatography ............................................................... 59 
2.3 PROCEDURES FOR SYNTHESIS .......................................................................... 60 
2.3.1 General procedure for the synthesis of 2-substituted benzimidazoles ......... 60 
2.3.2 General Procedure for the synthesis of N-Methylbenzimidazoles ................ 60 
2.3.3 General Procedure for the synthesis of N-bromoalkyl-2-(chloromethyl)-
1H-benzo[d]imidazole ............................................................................................ 61 
2.3.4 General Procedure for the synthesis of silver complexes of 
benzimidazole ........................................................................................................ 61 
2.3.5 Synthesis of 2- aminomethylbenzimidazole derivatives ............................... 62 
2.3.6 Synthesis of 2-ethanaminebenzimidazole derivatives ................................. 66 
2.3.7 Synthesis of 5-substituted-benzimidazole derivatives .................................. 69 
2.3.8 Synthesis of 2-hydroxymethylbenzimidazole derivatives ............................. 73 
2.3.9 Synthesis of 2-carboxylic acid benzimidazole derivatives ............................ 78 
2.3.10 Synthesis of N-methyl-2-methanolbenzimidazole derivatives ...................... 83 
2.3.11 Synthesis of 2- Chloromethylbenzimidazole derivatives .............................. 89 
2.3.12 Synthesis of 2-ethylbenzimidazole derivatives ............................................ 93 
2.3.13 Synthesis of 2-methanethiolbenzimidazole derivatives ................................ 95 
2.3.14 Synthesis of 1-oxidebenzimidazole derivatives ........................................... 96 
2.3.15 Synthesis of benzoxazole derivatives .......................................................... 97 
2.3.16 Synthesis of benzothiozole derivative .......................................................... 98 
2.3.17 Synthesis of N-bromoalkyl-2-chloromethylbenzimidazole derivatives .......... 99 
2.3.18 Synthesis of silver complexs of 2-carboxylic acid-benzimidazole 
derivatives ........................................................................................................... 101 
2.4 MATERIALS AND METHODS FOR MICROBIOLOGICAL EVALUATION ........................ 104 
2.4.1 Screening for Antibacterial activity ............................................................ 104 
2.4.1.1 Materials ..................................................................................... 104 
2.4.1.2 Bacterial strains used in this project ............................................ 104 
 
 
vi 
 
2.4.1.3 Culture media and incubation conditions ..................................... 104 
2.4.1.4 Ciprofloxacin ............................................................................... 104 
2.4.1.5 Disc diffusion tests ...................................................................... 105 
2.4.1.6 Agar dilution method for determining Minimum Inhibitory 
Concentration (MICs) ................................................................................ 107 
2.4.2 Screening for antifungal activity ................................................................. 109 
2.4.2.1 Materials ..................................................................................... 109 
2.4.2.2 Fungal strains used in this project ............................................... 109 
2.4.2.3 Culture media and incubation conditions ..................................... 110 
2.4.2.4 Amphotericin B ........................................................................... 110 
2.4.2.5 Screening for antifungal activity by the well diffusion method ...... 111 
2.4.2.6 Determination of Minimum Inhibitory Concentration Test (MIC) of 
compounds against fungi .......................................................................... 111 
2.4.3 The series of compounds screened for Antimicrobial activity..................... 112 
3 SYNTHESIS ............................................................................................... 120 
3.1 INTRODUCTION ............................................................................................... 120 
3.2 CHARACTERISATION OF PRODUCTS ................................................................. 121 
3.2.1 1H NMR spectroscopy ............................................................................... 121 
3.2.2 Mass spectra of benzimidazoles ............................................................... 125 
3.2.3 IR spectra ................................................................................................. 125 
3.3 SYNTHESIS OF BENZIMIDAZOLES...................................................................... 126 
3.3.1 5-Substituted benzimidazoles ................................................................... 126 
3.3.2 (1H-Benzimidazole-2-yl)-methanol derivatives .......................................... 129 
3.3.3 Reactions of (1H-benzimidazole-2-yl)methanol ......................................... 132 
3.3.3.1 Conversion to chloromethyl group ............................................... 132 
3.3.3.2 Oxidation of the hydroxyl group .................................................. 135 
3.3.3.3 N-Alkylation and O-alkylation of (1H-benzimidazole-2-yl)methanol ... 
  ................................................................................................... 136 
3.4 1H-(BENZIMIDAZOLE-2-YL)ALKYLAMINES .......................................................... 138 
3.4.1 Formation of (1H-benzimidazole-2-yl)alkylamines ..................................... 138 
3.4.2 Glycine and alanine derived benzimidazoles ............................................. 139 
3.4.3 Spectral characterisation of (1H-benzimidazole-2-yl)alkylamines .............. 140 
3.5 (1H-BENZIMIDAZOLE-2-YL)-ETHYL DERIVATIVES ................................................ 143 
3.6 (1H-BENZIMIDAZOLE-2-YL)-METHANTHIOL DERIVATIVES .................................... 144 
3.7 1H-BENZOTHIAZOLE-2-YL)-METHANOL DERIVATIVES ......................................... 147 
3.8 N-BROMOALKYLATION OF (1H-BENZIMIDAZOLE-2-YL)-CHLOROMETHYL .............. 148 
3.9 5-NITRO-1(3)-OXIDEBENZIMIDAZOLES .............................................................. 151 
3.10 BENZOXAZOLE DERIVATIVES ........................................................................... 152 
3.11 SYNTHESIS OF SILVER COMPLEX OF BENZIMIDAZOLE DERIVATIVES ..................... 154 
4 BIOLOGICAL EVALUATION ..................................................................... 158 
4.1 INTRODUCTION ............................................................................................... 158 
4.2 ANTIBACTERIAL STUDY ................................................................................... 158 
4.2.1 Screening for antibacterial activity by disc diffusion tests .......................... 158 
4.2.1.1 Results of disc diffusion tests of 2- aminoalkylbenzimidazole 
derivatives (series 1 and 2) ....................................................................... 160 
4.2.1.2 Results of Disc diffusion tests of 2-methanolbenzimidazole 
derivatives (series 4) ................................................................................. 162 
 
 
vii 
 
4.2.1.3 Results of Disc diffusion tests of 2-carboxylic acid-benzimidazole 
derivatives (series 5) ................................................................................. 162 
4.2.1.4 Results of Disc diffusion tests of N-methyl-2-(methanol, 
methoxy)benzimidazole derivatives (series 6) ........................................... 162 
4.2.1.5 Results of Disc diffusion tests of 2-chloromethylbenzimidazole 
derivatives (series 7) ................................................................................. 166 
4.2.1.6 Compounds which did not display any antibacterial activity (series 3 
and 13)  ................................................................................................... 166 
4.2.1.7 Results of Disc diffusion tests of 2-methylthiolbenzimidazole 
derivatives (series 9) ................................................................................. 168 
4.2.1.8 Results of Disc diffusion tests of benzoxazole derivatives (series 11) 
  ................................................................................................... 168 
4.2.1.9 Results of Disc diffusion tests of benzothiazole derivative (series 12)
  ................................................................................................... 168 
4.2.1.10 Conclusion ................................................................................ 172 
4.2.2 Results of agar dilution MIC tests .............................................................. 172 
4.2.2.1 MIC results of the 2-amino-alkylbenzimidazole derivatives (series 1 
and 2)  ................................................................................................... 174 
4.2.2.2 MIC results of the N-methyl-2-methanolbenzimidazole derivatives 
(series 6) ................................................................................................... 174 
4.2.2.3 MIC results of the 2-cholromethylbenzimidazole derivatives (series 
7)  ................................................................................................... 175 
4.2.2.4 MIC results of the 2-methylthiolbenzimidazole derivatives (series 9) . 
  ................................................................................................... 175 
4.2.2.5 MIC results of the benzoxazole derivatives (series 11) ............... 175 
4.2.2.6 MIC results of the benzothaizole derivative (series 12) ............... 176 
4.2.2.7 Conclusion .................................................................................. 183 
4.3 ANTIFUNGAL STUDY ........................................................................................ 183 
4.3.1 Screening for antifungal activity by well diffusion tests .............................. 183 
4.3.1.1 Results of well diffusion tests of the 2-amino alkylbenzimidazole 
derivatives (series 1 and 2) ....................................................................... 184 
4.3.1.2 Results of well diffusion tests of the 5-substituted-benzimidazole 
derivatives (series 3) ................................................................................. 185 
4.3.1.3 Results of well diffusion tests of the 2-methanolbenzimidazole 
derivatives (series 4) ................................................................................. 187 
4.3.1.4 Results of well diffusion tests of the 2-carboxylic acid-benzimidazole 
derivatives (series 5) ................................................................................. 187 
4.3.1.5 Results of well diffusion tests of the N-methyl-2-
methanolbenzimidazole derivatives (series 6) ........................................... 187 
4.3.1.6 Results of well diffusion tests of the 2-chloromethylbenzimidazole 
derivatives (series 7) ................................................................................. 188 
4.3.1.7 Results of well diffusion tests of the 2-ethylbenzimidazole 
derivatives (series 8) ................................................................................. 188 
4.3.1.8 Results of well diffusion tests of the 2-methanthiolbenzimidazole 
derivatives (series 9) ................................................................................. 189 
4.3.1.9 Results of well diffusion testsof the silver complexes (series 13). 189 
 
 
viii 
 
4.3.1.10 Results of well diffusion test of the N-oxidebenzimidazole 
derivatives (series 10) ............................................................................... 189 
4.3.1.11 Results of well diffusion tests of the benzoxazole derivatives 
(series 11) ................................................................................................. 190 
4.3.1.12 Results of well diffusion tests of the benzothiazole derivative 
(series 12) ................................................................................................. 190 
4.3.1.13 Conclusion ................................................................................ 196 
4.3.2 MICs of antifungal of compounds .............................................................. 196 
4.3.2.1 MIC results of the 2-amino-alkylbenzimidazole derivatives (series 1 
and 2)  ................................................................................................... 201 
4.3.2.2 MIC results of the 5-substituted benzimidazole derivatives (series 3) 
  ................................................................................................... 201 
4.3.2.3 MIC results of the 2-methanolbenzimidazole derivatives (series 4) ... 
  ................................................................................................... 203 
4.3.2.4 MIC results of the2-carboxylic acid benzimidazole derivatives 
(series 5) ................................................................................................... 203 
4.3.2.5 MIC results of the N – methyl-2- methanol-benzimidazole 
derivatives (series 6) ................................................................................. 205 
4.3.2.6 MIC results of the 2-chloromethylbenzimidazole derivatives (series 
7)  ................................................................................................... 205 
4.3.2.7 MIC results of the 2-ethanebenzimidazole derivatives (series 48)207 
4.3.2.8 MIC results of the silver complexes (series 13) ........................... 207 
4.3.2.9 MIC results of the 2-methanthiolbenzimidazole derivatives (series 9) 
  ................................................................................................... 208 
4.3.2.10 MIC results of the N-oxidebenzimdazole derivatives (series 10) 208 
4.3.2.11 MIC result of the benzoxazole derivative (series 11) ................. 210 
4.3.2.12 Conclusion ................................................................................ 210 
5 DISCUSSION AND FUTURE WORK ........................................................ 212 
5.1 DISCUSSION ................................................................................................... 212 
5.1.1 Factors affecting the yield ......................................................................... 212 
5.1.2 Attempts to improve the yield .................................................................... 215 
5.2 METHODOLOGY FOR BIOLOGICAL EVALUATION.................................................. 218 
5.3 ANTIMICROBIAL ACTIVITY IN RELATION TO MOLARITY ......................................... 219 
5.4 STRUCTURE ACTIVITY RELATIONSHIPS (SAR) .................................................. 230 
5.4.1 Effect of substituents on the structure ....................................................... 230 
5.4.2 Antibacterial evaluation ............................................................................. 235 
5.4.2.1 The effect of substituent at position 5 .......................................... 235 
5.4.2.2 The effect of the substituent at position 2 .................................... 236 
5.4.2.3 The effect of the substituent at position 1 .................................... 239 
5.4.2.4 The antibacterial activity of silver complexes............................... 239 
5.4.2.5 The effect of different heterocycles ............................................. 240 
5.4.3 Antifungal evaluation ................................................................................. 241 
5.4.3.1 The effect of the substituent at position 5 .................................... 241 
5.4.3.2 The effect of the substituent at position 2 .................................... 245 
5.4.3.3 The effect of the substituent at position 1 .................................... 246 
 
 
ix 
 
5.4.3.4 The activity of the silver complexes ............................................. 249 
5.4.3.5 The effect of different heterocycles ............................................. 249 
5.5 NEXT GENERATION OF ANTIMICROBIAL AGENTS OF BENZIMIDAZOLE AND FUTURE 
WORK  ..................................................................................................................... 250 
5.5.1 Next generation antibacterial ..................................................................... 250 
5.5.2 Next generation antifungal ........................................................................ 252 
5.5.3 Biological future work ................................................................................ 253 
5.6 CONCLUSIONS ............................................................................................... 257 
6 REFERENCES ........................................................................................... 259 
 
  
 
 
x 
 
LIST OF FIGURES 
 
Figure  1.1 Differences in the cell wall of a) Gram +ve and b) Gram -ve bacteria. 
Source: (Bauman, 2010). ....................................................................................... 3 
Figure  1.2 Illustration of fungal morphology. Source: (Bauman, 2010) ............................ 5 
Figure  1.3 Main cellular targets for inhibiting bacteria. Source: (Bauman, 2010) ........... 10 
Figure  1.4 The summary of mechanisms by which antimicrobials inhibit protein 
synthesis by targeting prokaryotic ribosomes. Source:(Bauman, 2010). .............. 13 
Figure  1.5 Targets for antifungal therapy. Source:(Kathiravan et al., 2012)................... 14 
Figure  1.6 Chitin structure and diversity in fungi. Source: (Lenardon et al., 2010). ........ 17 
Figure  1.7 General mechanisms of antibiotic resistance in bacteria. Source: (Todar, 
2008). .................................................................................................................. 21 
Figure  1.8 Rise in reports to Health Protection Agency of resistance to methicillin in 
S. aureus from bacteremia cases, England and Wales, 1992-2005 (voluntary 
laboratory reports). Source: (Health Protection Agency, 2006). ........................... 23 
Figure  1.9 National decline in reported cases of meticillin-resistant Staphylococcus 
aureus (MRSA), England, 2001 to 2011. Source: (Department of Health, 
2013a) ................................................................................................................. 23 
Figure  1.10 Molecular mechanisms of fungal biofilm resistance. Source: (Ramage et 
al., 2012). ............................................................................................................ 28 
Figure  1.11 National antifungal consumption (1000 DDD) in the years 2000–11 in 
Denmark. The hospital use in percentage of the total use in the study period 
2010–11 is indicated in parenthesis for each compound. Source: (Arendrup et 
al., 2013). ............................................................................................................ 29 
Figure  1.12 Antibiotics: dates of the discoveries. Source: (BBC, 2013). ........................ 32 
Figure  1.13 The chemical structure of benzimidazole. .................................................. 33 
Figure  1.14 Benzimidazole, a multifunctional nucleus. Source:(Bansal and Silakari, 
2012) ................................................................................................................... 33 
Figure  1.15 Hydrogen bonding network of benzimidazole ............................................. 34 
Figure  1.16 Pyridine and pyrrole type nitrogens of benzimidazole ................................ 34 
Figure  1.17 Synthesis of benzimidazole ........................................................................ 35 
Figure  1.18 Synthesis of 2-substituted benzimidazole according to Bahrami et al., 
(2008) .................................................................................................................. 35 
Figure  1.19 Synthesis of benzimidazole according to Alinezhad et al. (2012a) ............. 36 
Figure  1.20 Synthesis of 2-substituted benzimidazole according to Saha  et al. 
(2009) .................................................................................................................. 36 
 
 
xi 
 
Figure  1.21 Synthesis of 1,2-substituted benzimidazole and benzothiazoles 
according to Zhang et al. (2012a) ........................................................................ 37 
Figure  1.22 Endoscopic visualization of hookworms in the duodenum. Source: 
(Sudha and Christian, 2009) ................................................................................ 37 
Figure  1.23 Examples of benzimidazole derivatives as anti-helminth drugs 
according to Cho and Lopes (2013) ..................................................................... 38 
Figure  1.24 Omeprazole ............................................................................................... 41 
Figure  1.25 Analogues of benzimidazole ribonucleoside according to Williams et al. 
(2003) .................................................................................................................. 42 
Figure  1.26 Lansoprazole ............................................................................................. 42 
Figure  1.27 Structure of 2-amino benzimidazole derivatives synthesised by 
Podunavac-Kuzmanovic and Cvetkovic (2007) .................................................... 43 
Figure  1.28 Structure of methyl 5-fluoro-6-(4-methylpiperidin- 1-yl)-1H-
benzimidazole-2-carbamate according to Kus et al. (2001) .................................. 44 
Figure  1.29 4,6-Dichloro(bromo)-2-(4-nitrobenzylthio)-1H-benzimidazole derivatives 
studied by Andrzejewska et al. (2004) ................................................................. 44 
Figure 1.30 7-Chloro-4-(((5-methoxy-1H-benzo[d]imidazol-2-
yl)sulfinyl)methyl)pyrrolo[1,2-a]quinoxaline according to Vidaillac et al. (2007) .... 45 
Figure  1.31 Structure of 1,2 disubstituted benzimidazole derivatives according to 
Das et al. (2005) (Das et al., 2005) ...................................................................... 46 
Figure  1.32 Structure of thiazolyl-benzimidazole derivatives according to Pawar et 
al. (2004) ............................................................................................................. 46 
Figure  1.33 Structure of 4-(5,6-dichloro-1H-benzimidazole-2-yl)-N-substituted 
benzamidazole derivatives according to Ozden et al. (2004) ............................... 47 
Figure  1.34 Structure of 1,2,4-triazalo[ 2,3-a] benzimidazole derivatives synthesised 
by Mohamed et al. (2006) .................................................................................... 47 
Figure  1.35 Structure of 2-(6-flurochroman-2yl)-1-alkyl/ acyl/ aroyl 1H-
benzimidazoles studied by Kumar et al. (2006) .................................................... 48 
Figure  1.36 Structure of benzimidazol-2-ylidene carbene complexes of Ag(I) 
screened by Özdemir et al. (2010) ....................................................................... 49 
Figure  1.37 Structure of Benzimidazole derived Cu(II) complex studied by Arjmand 
et al. (2005) ......................................................................................................... 49 
Figure  1.38 1,2 and 5 benzimidazole derivatives available for this project .................... 51 
Figure  1.39 Group 1 target; benzimidazole derivatives ................................................. 54 
Figure  1.40 Group 2 target; 2-methanol benzimidazole derivatives ............................... 55 
Figure  1.41 Group 3 target; silver benzimidazole complexes ........................................ 55 
Figure  1.42 Group 4 target; N-bromoalkyl-benzimidazole derivatives ........................... 55 
 
 
xii 
 
Figure  2.1 Structure of ciprofloxacin............................................................................ 105 
Figure  2.2 .Structure of amphotericin B ....................................................................... 111 
Figure  3.1 Retrosynthetic analysis of benzimidazole ................................................... 120 
Figure  3.2 An expansion of the aromatic region of the 1H spectrum of FAS24 ............ 122 
Figure  3.3 An expansion of the aromatic region of the 1H spectrum of FAS62 ............ 124 
Figure  3.4 Fragmentations pattern of compound FAS49 ............................................. 125 
Figure  3.5 Proposed mechanism for the formation of 5-methylbenzimidazole ............. 128 
Figure  3.6 Proposed mechanism for the chlorination of hydroxyl group ...................... 133 
Figure  3.7 Summary of the reactions of (1H-benzimidazole-2-yl)-methanol ................ 138 
Figure  3.8 Synthesis of (1H-benzimidazole-2-yl)alkylamine ........................................ 139 
Figure  3.9 Expansion of aromatic region showing the incomplete ring closure of a 
(S)-1-(5-nitro-1H-benzimidazole-2-yl)ethanamine (FAS14) ................................ 141 
Figure  3.10 Synthesis of silver complexes .................................................................. 155 
Figure  4.1 Example of disc diffusion test: .................................................................... 159 
Figure  4.2 MIC screening by agar dilution of FAS47 at 64μg/ml VS the growth 
control................................................................................................................ 174 
Figure  5.1 Distribution of yield according to the number of compounds ...................... 213 
Figure  5.2 Resonance structures of 4-nitro-1,2-phenylenediamine ............................. 215 
Figure  5.3 Synthesis of N-bromodecyl-2-chloromethylbenzimidazole FAS75 .............. 217 
Figure  5.4 Structure of 5-methoxy-2-[(4-methylbenzyl)sulfanyl]-1H-benzimidazole ..... 231 
Figure  5.5 Structure of 2-(5-substituted-1H-benzo[d]imidazol-2-yl)-6-
methoxyphenols. (Tavman et al., 2009) ............................................................. 231 
Figure  5.6 Structure of N-(2-methyl-4,5,7-substituted-1H-benzo[d]imidazol-6-
yl)benzenesulfonamides (González-Chávez et al., 2011) .................................. 232 
Figure  5.7 Structure of 5-nitro-1H-benzimidazole-N-oxides ......................................... 233 
Figure  5.8 Structure of 2-[(2-nitro-1-phenylalkyl)thiomethyl]benzimidazole 
derivatives ......................................................................................................... 237 
Figure  5.9 Structures of the most active compounds against MRSA bacteria species 251 
Figure  5.10 Proposed next generation antibacterial agents ........................................ 252 
Figure  5.11 Structures of the most active compounds against fungal species ............. 253 
Figure  5.12 Proposed of some of the next generation of antifungal agents ................. 253 
Figure  5.13 How antibiotic resistance happens. Source: (Centers for Disease 
Control and Prevention, 2013) ........................................................................... 256 
Figure  5.14 Examples of how antibiotic resistance spreads. Source: (Centers for 
Disease Control and Prevention, 2013) ............................................................. 257 
 
 xiii 
 
LIST OF TABLES 
 
Table 1.1 Key Mechanisms of bacterial resistance against some drugs. Source: 
(Silver, 2011). ...................................................................................................... 20 
Table 1.2 Development of new antibiotics during the last three decades. Source: 
(Franco, 2009). .................................................................................................... 25 
Table 1.3 Implementation of antimicrobial stewardship strategies in UK hospitals – 
progress over two decades. Source: (Department of Health, 2013a) ................... 30 
Table 2.1.Details of strains of bacteria used in this project .......................................... 106 
Table 2.2. Details of how the doubling dilution plates were prepared for the MIC 
assays ............................................................................................................... 108 
Table 2.3. Details of fungal strains used in this project ............................................... 110 
Table 2.4. Details of the series of compounds screened for antimicrobial activity ....... 113 
Table 3.1 Reaction times, yields and melting points for 5-substituted benzimidazoles 127 
Table 3.2 Assignment of the 1H NMR spectra of 5-substituted benzimidazoles ........... 127 
Table 3.3 Assignment of the 13C NMR spectra of 5-substituted benzimidazoles ......... 128 
Table 3.4 Reaction time, yields and melting points of (1H-benzimidazole-2-
yl)methanol and derivatives ............................................................................... 129 
Table 3.5 Assignment of the 1H NMR spectra of the 1H-Benzimidazole-2-
yl)methanol  derivatives ..................................................................................... 130 
Table 3.6 Assignment of the 13C NMR spectra of the 1H-Benzimidazole-2-
yl)methanolderivatives ....................................................................................... 131 
Table 3.7 Comparison of reaction times, yields and melting points for 5-substituted-
2-H-benzimidazoles. .......................................................................................... 133 
Table 3.8 Assignment of the 1H NMR spectra of the 2-chloromethylbenzimidazole 
derivatives ......................................................................................................... 134 
Table 3.9 Assignment of the 13C NMR spectra of the 2-chloromethylbenzimidazole 
derivatives ......................................................................................................... 134 
Table 3.10 Assignment of the 1H NMR spectra of the benzimidazole-2-carboxylic 
acids .................................................................................................................. 135 
Table 3.11 Assignment of the 13C NMR spectra of the benzimidazole-2-carboxylic 
acids .................................................................................................................. 136 
Table 3.12 Reaction time, yields and melting points of N-methyl (1H-benzimidazole-
2-yl)-methanol and derivatives ........................................................................... 137 
Table 3.13 Assignment of the 1H NMR spectra of the N-methyl-(1H-benzimidazole-
2-yl)methanol derivatives ................................................................................... 137 
 xiv 
 
Table 3.14 Assignment of the 13C NMR spectra of the N-methyl-(1H-benzimidazole-
2-yl)methanol ..................................................................................................... 138 
Table 3.15 Reaction times, yields and melting points of (1H-benzimidazole-2-
yl)alkylamines .................................................................................................... 140 
Table 3.16 Assignment of the 1H NMR spectra of (1H-benzimidazole-2-
yl)alkylamines .................................................................................................... 142 
Table 3.17.Assignment of the 13C NMR spectra of selected (1H-benzimidazole-2-
yl)alkylamines .................................................................................................... 142 
Table 3.18 Reaction time, yields and melting points of 2- ethylbenzimidazole 
derivatives ......................................................................................................... 143 
Table 3.19 Assignment of the 1H NMR spectra of the 2- ethylbenzimidazole 
derivatives ......................................................................................................... 143 
Table 3.20 Assignment of the 13C NMR spectra of the 2- ethylbenzimidazole 
derivatives ......................................................................................................... 144 
Table 3.21 Reaction time, yields and melting points of 2- 
methanethiolbenzimidazole derivatives.............................................................. 145 
Table 3.22 Assignment of the 1H NMR spectra of the 2- methanethiolbenzimidazole 
derivatives ......................................................................................................... 145 
Table 3.23 Assignment of the 13C NMR spectra of the2- methanethiolbenzimidazole 
derivatives ......................................................................................................... 145 
Table 3.24 Comparison of 1H NMR spectra of 2- methanethiolbenzimidazole 
derivatives with their analogues ......................................................................... 146 
Table 3.25 Comparison of 13C NMR spectra of 2- methanethiolbenzimidazole 
derivatives with their analogues ......................................................................... 146 
Table 3.26 Reaction time, yields and melting points of benzothiazole derivative ......... 147 
Table 3.27 Assignment of the 1H NMR spectra of the benzothiazole derivative .......... 147 
Table 3.28 Assignment of the 13C NMR spectra of the benzothiazole derivative ......... 147 
Table 3.29 Comparison of 1H NMR spectra of benzothaizole derivatives with 
benzimidazole derivatives .................................................................................. 148 
Table 3.30 Comparison of 13C NMR spectra of benzothaizole derivatives with 
benzimidazole derivatives .................................................................................. 148 
Table 3.31 Comparison of yields and melting points of N-bromoalkyl-2-
chloromethylbenzimidazole derivatives .............................................................. 150 
Table 3.32 Assignment of the 1H NMR spectra of the N-bromoalkyl-2-
chloromethylbenzimidazole derivatives .............................................................. 150 
Table 3.33 Comparison of yields and melting points of 1-oxidebenzimidazole 
derivatives ......................................................................................................... 151 
 xv 
 
Table 3.34 Assignment of the 1H NMR spectra of the 1-oxidebenzimidazole 
derivatives ......................................................................................................... 151 
Table 3.35 Assignment of the 13C NMR spectra of the 1-oxidebenzimidazole 
derivatives ......................................................................................................... 152 
Table 3.36 Comparison of 1H NMR spectra of 1-oxidebenzimidazole derivative with 
its N-methyl analogue ........................................................................................ 152 
Table 3.37 Comparison of 13C NMR spectra of 1-oxidebenzimidazole derivative with 
its N-methyl analogue ........................................................................................ 152 
Table 3.38 Comparison of yields and melting points of benzoxazole derivatives ........ 153 
Table 3.39 Assignment of the 1H NMR spectra of the benzoxazole derivatives ........... 153 
Table 3.40 Assignment of the 13C NMR spectra of the benzoxazole derivatives ......... 154 
Table 3.41 Comparison of 1H NMR spectra of benzoxazole derivative with its 
analogue ............................................................................................................ 154 
Table 3.42 Comparison of 13C NMR spectra of benzoxazole derivative with its 
analogue ............................................................................................................ 154 
Table 3.43 Assignment of the 1H NMR spectra of the silver complexes ...................... 156 
Table 3.44 The IR [cm-1] data for the ligand benzimidazole FAS29, 30, 19, 21 and its 
complexes FAS69-74. ....................................................................................... 157 
Table 4.1 Disc diffusion test results for the most active compounds of 2-amino-
alkylbenzimidazole derivatives ........................................................................... 161 
Table 4.2 Disc diffusion test results of the most active 2-methanolbenzimidazole 
derivatives ......................................................................................................... 163 
Table 4.3 Disc diffusion test result of the most active 2-carboxylic acid-
benzimidazole derivative ................................................................................... 164 
Table 4.4 Disc diffusion test results of the most active N-methyl-2-
methanolbenzimidazole derivatives ................................................................... 165 
Table 4.5 Disc diffusion test results of the most active Chloromethybenzimidazole 
derivatives ......................................................................................................... 167 
Table 4.6 Disc diffusion test results of 2-methylthiolbenzimidazole derivatives ........... 169 
Table 4.7 Disc diffusion test results of benzoxazole derivatives .................................. 170 
Table 4.8 Disc diffusion tests of a benzothaizole derivative ........................................ 171 
Table 4.9 The most active compounds which were taken forward to determination of 
MICs .................................................................................................................. 173 
Table 4.10 MIC tests of the most active 2-alkylaminobenzimidazole derivatives ......... 177 
Table 4.11 MIC tests of the most active N-methyl- 2-methanolbenzimidazole 
derivatives ......................................................................................................... 178 
Table 4.12 MIC tests of the 2-chloromethylbenzimidazole derivatives ........................ 179 
 xvi 
 
Table 4.13 MIC testsof the most active compound of the2-methylthiolbenzimidazole 
derivatives ......................................................................................................... 180 
Table 4.14 MIC tests of the most active compound of the benzoxazole derivative ...... 181 
Table 4.15 MIC tests of the benzothaizole derivative .................................................. 182 
Table 4.16 Antifungal activity of the 2-aminoalkylbenzimidazole derivatives ............... 186 
Table 4.17 Antifungal activity for the 5-substituted-benzimidazole derivatives ............ 186 
Table 4.18 Antifungal activity for 2-methanolbenzimidazole-derivatives ...................... 191 
Table 4.19 Antifungal activity for 2-carboxylic acid-benzimidazole-derivatives ............ 191 
Table 4.20 Antifungal activity of N-methyl-2-methanolbenzimidazole derivatives ........ 192 
Table 4.21 Antifungal activity of 2-chloromethylbenzimidazole derivatives .................. 192 
Table 4.22 Antifungal activity of 2-methanebenzimidazole derivatives ........................ 193 
Table 4.23 Antifungal activity of 2-methanthiolbenzimidazole derivatives ................... 193 
Table 4.24 Antifungal activity of silver complexes ....................................................... 194 
Table 4.25 Antifungal activity of N-oxidbenzimidazole derivatives ............................... 194 
Table 4.26 Antifungal activity of benzoxazole derivative ............................................. 195 
Table 4.27 Antifungal activity of benzothiazole derivative ........................................... 195 
Table 4.28 The most active compounds which were taken forwardfor MIC 
determination ..................................................................................................... 197 
Table 4.29 MIC results of the2-aminoalkylbenzimidazole derivatives .......................... 202 
Table 4.30 MIC results of the 5-substituted-benzimidazole derivatives ....................... 202 
Table 4.31 MIC results for the 2-methanolbenzimidazole derivatives. ......................... 204 
Table 4.32 MIC results for the 2-carboxylic acid-benzimidazole derivatives ................ 204 
Table 4.33 MIC results for the N-methyl-2- methanolbenzimidazole derivatives ......... 206 
Table 4.34 MIC results for the 2-chloromethylbenzimidazole derivatives .................... 206 
Table 4.35 MIC results of the 2-ethanebenzimidazole derivative ................................ 207 
Table 4.36 MIC results of the silver complexes ........................................................... 208 
Table 4.37 MIC results of the 2-methanthiolbenzimidazole derivative ......................... 209 
Table 4.38 MIC results of the N-oxidebenzimdazole derivative ................................... 209 
Table 4.39 MIC results of the benzoxazole derivative ................................................. 210 
Table 5.1 Reactions conducted in ionic liquids and in a microwave ............................ 217 
Table 5.2 Summary of the relationship of activity of most active compound tested 
with their molarity against the bacterial strains ................................................... 222 
Table 5.3 Summary of the relationship of activity of most active compound tested 
with their molarity against the fungal strains ...................................................... 224 
Table 5.4 The effect of each substituent on the benzimidazole ring ............................ 234 
Table 5.5 Comparisons between different compounds in term of their antifungal 
activity ............................................................................................................... 244 
 xvii 
 
Table 5.6 Comparisons between different compounds in term of their antifungal 
activity ............................................................................................................... 248 
 
 
 xviii 
 
ABBREVIATIONS 
 
ATP Adenosine tri phosphate 
 
AZT Azidothymidine 
 
BDCRB Bromo homologue -(1-β-D-ribofuranosyl) benzimidazole   
 
C. difficile  Clostridium difficile 
 
CV Crystal violet 
 
d doublet 
 
DMSO Dimethylsulphoxide  
 
DNA   Deoxyribonucleic acid 
 
Eq. equivalent 
 
HEPA High Efficiency Particulate Air 
 
HCMV  Human Cytomegalovirus-(1-β-D-ribofuranosyl) benzimidazole 
 
HGT Horizontal gene transmission 
 
HOAc Acetic acid 
 
HPK Histidine Protein Kinase  
 
MDR Multidrug-resistant 
 
MIC This is a term in microbiology which defines the lowest concentration of 
an antimicrobial that will inhibit the visible growth of a microorganism 
after overnight incubation 
 
mRNA messenger ribonucleic acid 
 
MRSA  methicillin-resistant Staphylococcus aureus  
 
m.p. Melting point 
 
MS Mass spectrometry 
 
NAD Nicotinamide Adenine  Dinucleotide  
 
NMR Nuclear Magnetic Resonance 
 
PABA Para-aminobenzoic acid 
 
PBP Penicillin-Binding Proteins 
 
q Quartet 
 
 xix 
 
RNA Ribonucleic acid 
 
RR  Response Regulator  
 
tRNA transfer ribonucleic acid 
 
s Singlet 
 
t Triplet  
 
TCRB  2, 5, 6-trichloro-(1-β-D-ribofuranosyl) benzimidazole  
 
TCS  Two-Component System 
 
VRE  vancomycin-resistant Enterococcus  
 
 
 
1 
 
1.  INTRODUCTION 
1.1 Microorganisms 
‘Microorganism’ is an umbrella term used to signify a large range of small, 
replicating biological entities. The term is applied to viruses, bacteria, fungi, algae 
and protozoa (Nicklin et al., 1999). Microorganisms were first identified 
approximately 300 years ago by van Leeuwenhoek followed by important 
discoveries by Pasteur and Koch. The term covers both prokaryotic and eukaryotic 
organisms. The prokaryotic bacteria are divided into 2 biological domains, namely 
the Archaea and the Bacteria, of which the bacterial group is of significant 
importance to humans. They have numerous beneficial uses, including involvement 
in processes like nitrogen fixation, methanogenesis and waste degradation. They 
are also used in the production of wine, cheese, antibiotics, vaccines, in 
nanotechnology for therapeutic purposes and in sewage treatment (Mongillo, 2007). 
 
1.1.1 Bacteria  
Some bacterial genera can infect humans and cause disease.  Bacteria are 
classified into two groups based on the type of nutrition, autotrophic and 
heterotrophic bacteria, and are also classified based on their morphology, habitat, or 
their need for oxygen (aerobic or anaerobic bacteria). The current classification of 
bacteria into 24 different phyla is based on cell morphology (e.g. spherical cocci, 
rod-shaped bacilli, spiral spirochetes, curved rods called vibrios), habitat, DNA, 
physiological and biochemical characteristics. Another factor that is used to classify 
bacteria is their motility. Modern sub-classification is based on analysis of the 
sequence of the 16SrRNA gene (Nicklin et al., 1999, Madigan et al., 2000). 
Bacteria can be divided into two main groups based on cell wall structure. The cell 
membrane is protected by the rigid cell wall. The cell wall of Gram +ve bacteria has 
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a very thick layer composed of peptidoglycan while the peptidoglycan layer of Gram 
-ve bacteria is thinner. Also, Gram -ve bacteria possess another outer membrane 
which functions as a permeability barrier. The section between the inner and outer 
membranes is referred to as the periplasmic space, which Gram +ve bacteria lack. 
Gram -ve bacteria store enzymes in the periplasmic space that carry out extra-
cellular digestion which is necessary in order to move big molecules across the 
outer membrane or cell membrane (Figure 1.1).  
The two types of cell wall can be distinguished by a Gram stain. When a Gram stain 
is carried out, Gram +ve bacteria retain the color of crystal violet when washed, 
while Gram -ve ones do not and then accept a counter-stain. This difference is 
observed because of basic structural differences in the cell wall of both types 
(Figure 1.1). Bacterial cell membranes are the site for oxidative phosphorylation as 
bacteria possess no mitochondria. Crystal violet separates into CV+ and chloride  
(Cl-) ions in solutions. These ions cross the cell wall and cell membrane of both 
types of bacteria and when the iodine is added, it reacts with CV+ and forms large 
molecules in the cell wall. The alcohol applied next reacts with the lipids in the cell 
membrane. In Gram -ve bacteria, the outer membrane as well as the peptidoglycan 
layer is exposed, and the CV-I molecules are lost with the outer membrane. In Gram 
+ve bacteria there is dehydration and the CV-I molecules are retained by the 
peptidoglycan. Thus Gram +ve bacteria retain the purple color which Gram -ve ones 
lose (Guilfoile, 2006, Bauman, 2010).  
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Figure  1.1 Differences in the cell wall of a) Gram +ve and b) Gram -ve bacteria. Source: 
(Bauman, 2010). 
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1.1.2 Fungi  
Fungi such as molds, mushrooms, and yeast are like bacteria in that they have cell 
walls, unlike protozoa. Fungi are different from animals for having cell walls, and 
different from plants as well for not performing photosynthesis. The study of fungi is 
called mycology. In contrast to bacteria, fungi are eukaryotic cells. The main target 
for the antifungal drugs is the cell wall, which is composed of about 90% of the 
carbohydrates glucan, mannan, and chitin. Chitin is a strong, flexible, nitrogenous 
polysaccharide. 
The thallus is the vegetative body of the fungus, and its morphology is different 
between the molds and yeasts. The thallus of molds is large and composed of long, 
branched, and tubular filaments called hyphae. In contrast to molds, the thallus of 
yeasts is small, globular, and composed of a single cell. The environmental 
conditions such as temperature or carbon dioxide concentration, affect the fungi 
which can produce two types of thallus, this phenomena is called dimorphic (which 
means “two shaped”). Many pathogenic fungi are dimorphic (Figure 1.2) such as 
Histoplasma capsulatum, which causes histoplasmosis, a respiratory disease 
(Müller and Polak, 2003, Bauman, 2010).  
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Figure  1.2 Illustration of fungal morphology. Source: (Bauman, 2010) 
 
1.2 Inhibition of growth of microorganisms  
The inhibition of microorganisms is carried out by several different methods. In order 
to carry out efficient control of microorganisms in various sensitive situations such 
as hospital, laboratory and industrial environments, inhibition is essential and has to 
be effective. Food also has to be kept preserved in a manner which inhibits the 
growth of microorganisms, so as to prevent spoilage and infections in humans. The 
methods used to inhibit microorganisms include chemical procedures, utilisation of 
various physical techniques as well as the use of chemotherapeutic agents. The 
main aim of inhibition of microorganisms is to achieve either sanitisation, 
disinfection, a sterile environment or sterilization of equipment or the preservation of 
food (Block, 2001). 
Disinfectants like liquid germicides, ethylene oxide gas, formaldehyde infused 
steam, hydrogen peroxide and gases such as chlorine dioxide and ozone are all 
used in hospitals to achieve sterilization. Many of these chemicals are used as 
disinfectants for sensitive hospital equipment which cannot be sterilized by using 
harsh physical agents like heat. Disinfectants should only be used on non-living 
objects since they are usually harmful to human beings. Antiseptics are used to 
disinfect living tissue such as human skin before surgery or the administration of 
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therapeutic agents that need to be given directly through subcutaneous injection or 
intravenous routes as well as for cleaning hands. Chemical disinfectants and 
antiseptics can reduce microbial populations by a significant proportion but they 
mostly lack any sporicidal action. Thus, disinfectants and antiseptics are unable to 
carry out true chemical sterilization (Nicklin et al., 1999, Block, 2001, Bauman, 
2010). 
Physical agents used in inhibition of microorganisms include the use of high 
temperatures in the form of both moist and dry heat. Moist heat is far more efficient 
at destroying microorganisms and inhibiting their growth than dry heat. This is 
because the mechanism of action for moist heat is the denaturation as well as 
coagulation of vital cell enzymes and proteins, leading to a faster destruction of 
microorganisms. Dry heat kills microorganisms by using the mechanism of oxidation 
of several components. As a result dry heat takes far longer to destroy 
microorganisms. An autoclave is used to reach a higher temperature than boiling 
water for sterilization purposes since this is able to kill both spores and vegetative 
cells. Incineration is used for the disposal of extremely hazardous waste material 
(Block, 2001, Pelczar et al., 2009, Bauman, 2010). 
Radiation in the form of electron beams, gamma rays and x-rays are used to 
sterilize packaging materials and products enclosed inside them. Ultraviolet 
radiation is also used to kill and inhibit the growth of microorganisms. Filtration can 
be used to sterilize liquids and air. Membrane filters are used to sterilize heat-
sensitive liquid reagents in the laboratory. High efficiency particulate air (HEPA) 
filters are used in safety equipment especially when handling infectious and 
hazardous materials. If vegetative cells of microorganisms are subjected to 
desiccation, their growth is usually arrested and they are inhibited. This process is 
used in the preservation of several kinds of food items. Food items which contain 
high concentrations of either sugar or salt also have a desiccating effect on 
microorganisms. The high concentrations of solutes result in the removal of water 
Chapter 1     Introduction 
7 
 
from the microbial cells through the process of osmosis thus inhibiting their growth. 
Refrigeration is also used as a physical agent to inhibit the growth of 
microorganisms in food items. Many genera of Gram -ve cocci such as Neisseria 
are extremely susceptible to desiccation. Staphylococcus and most other species of 
the Gram +ve bacteria are quite resistant to desiccation. A process known as 
lysophylization in which the microorganisms are desiccated and quickly frozen 
under a vacuum is utilized to preserve cultures of microorganisms in laboratories 
(Pelczar et al., 2009, Bauman, 2010). 
 
1.3 Antimicrobial chemotherapy   
1.3.1 Use of natural products 
There is evidence that many natural products were used as remedies for ailments in 
the pre-antibiotic period. Ancient Chinese herbalists made use of a very powerful 
anti-malaria medicine, qinghaosu (artemisinin). Qinghaosu was made from the 
Artemisia plants and utilized as a cure for many ailments by the Chinese for 
thousands of years (Aminov, 2010). Antimicrobial action is exhibited by several 
other Chinese traditional remedies (Aminov, 2010). Natural quinine found in the 
bark of the Cinchona tree was utilized in Europe and South America to cure malaria. 
Another good example of the use of natural products as antimicrobial agents is the 
use of red soil in Jordan which has been known throughout time to possess 
antimicrobial activity. In past times and even at present they are used to treat skin 
diseases. Research carried out on this resulted in the identification of several 
bacterial species which produce antibiotics and give this gives red soil its 
antimicrobial capacity (Rahman, 1998, Aminov, 2010). With the advent of increasing 
microbial resistance to antibiotics, there is always need for new antimicrobial 
agents. The identification of new active antimicrobial compounds from these 
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traditional remedies may be very useful in combating antibiotic resistance in 
microorganisms, which is a big issue in present day medicine (Rahman, 1998, 
Aminov, 2010). 
 
1.3.2 Semi-synthetic compounds 
Semi-synthetic compounds have been produced to make natural compounds more 
potent, decrease the side effects, and increase the antibacterial spectrum and to 
cope with the ever increasing problem of resistance development by bacteria. The 
antibiotic era began with Fleming’s discovery of natural penicillin produced by the 
mould Penicillium notatum (Ligon, 2004, Greenwood et al., 2007). The antimicrobial 
chemical which is active in natural penicillins is 6-amino-penicillianic acid, which is 
modified to improve such attributes as activity, acid stability, toxicity and half-life in 
the body. Many semi-synthetic types of penicillin have been made by researchers 
by attaching different chemical side chains to the 6-amino-penicillianic acid core. 
Examples of such semi-synthetic compounds include phenthicillin, methicillin, 
clavulanic acid, sulbactam, cephalosporins, carbapenems, ampicillin and 
amoxicillin. Aminoglycosides are produced by actinomycetes that were first isolated 
from soil microbes and are further modified to produce several semi-synthetic 
antimicrobial compounds that inhibit protein synthesis. Some examples of semi-
synthetic derivatives made from aminoglycosides include the antibiotics kanamycin, 
amikacin and dibekacin. Tetracyclines are also produced by actinomycetes and are 
in turn used to produce semi-synthetic compounds such as chlortetracycline, 
oxytetracycline and doxycycline. Macrolides obtained from actinomycetes are used 
in making semi-synthetic drugs like erythromycin (Dax, 1997, Finch et al., 2003, 
Hooper and Rubinstein, 2003, Bryskier, 2005, Lorian, 2005, Greenwood et al., 
2007, Aminov, 2010). 
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1.3.3 Entirely synthetic compounds 
The synthetic compound sold under the brand name of Salvarsan was used 
extensively to treat syphilis before the discovery of penicillins and other antibiotics 
(Lloyd et al., 2005). Sulfonamides and their derivatives have long been used to treat 
several diseases.  Some of the other groups of synthetic compounds which are 
prevalent in clinical practice include synthetic quinolones such as nalidixic acid 
which are used as antibacterials. Fluoroquinolones like ciprofloxacin and 
oxazolidinones such as linezoild are also widely used. Many other synthetic 
compounds find use against bacterial infections and these include nitrofurans and 
isoniazids. Alkaloids are another group of synthetic compounds that are used 
against some kinds of bacterial infections.  Alkaloids exhibit antibacterial action 
against several Gram +ve and Gram -ve bacterial infections. Alkaloids are also 
frequently used in treating infections caused by oral bacteria and certain fungal as 
well as protozoan infections also. Because the treatment of viral infections with 
conventional antibiotics does not work, that has led to the development of synthetic 
compounds such as vidarabine, acyclovir and AZT in antiviral therapy. Protozoan 
infections are able to thrive in humans because of the ability of the parasite to exist 
in different forms at various stages of its life cycle and also because of the 
similarities of the organism to human cells as both are eukaryotic. As a result it is 
difficult to use traditional antimicrobial agents against protozoan infections. Several 
synthetic compounds such as quinacrine, diiodohydroxyquin, pentamidine and 
metronidazole are used in anti-protozoan therapy. The same problem exists in the 
treatment of infections caused by fungi and helminths. Synthetic compounds are 
thus used in chemotherapy against fungi and helminth infections also (Saxton, 
1971, Clitherow et al., 2003, Cordell, 2008, Perry, 2008). 
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1.4 Modes of action of antibacterial agents 
Antibiotics are antimicrobial agents which are used in clinical care for many kinds of 
infections caused by microorganisms. They are generally classified into groups 
based on either their chemical structure or their modes of action. Antibiotics are 
known as “bactericidal” if they kill the target bacteria and as “bacteriostatic” if the 
mode of action is to reversibly inhibit the growth and proliferation of bacteria. The 
range of bacteria against which an antibiotic shows activity is known as “its 
spectrum.” The following sections review the main modes of action of antibiotics 
which are summarised in Figure 1.3: 
 
 
Figure  1.3 Main cellular targets for inhibiting bacteria. Source: (Bauman, 2010) 
 
1.4.1 Antibiotics which inhibit cell wall synthesis 
The cell wall of bacteria is made up of a layer of peptidoglycan. Several antibiotics 
work by using the action of the β-lactam ring. This ring inhibits the process of 
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peptidoglycan formation by irreversibly binding to the enzymes that cross-link 
peptidoglycan subunits. The particular enzymes are referred to as penicillin-binding 
proteins (PBPs) and are usually anchored to the cell wall or membrane. When the 
β-lactam ring binds to PBPs, the process of cell wall synthesis is inhibited. 
Antibiotics which use this mechanism of action have a broad spectrum and can be 
used against both Gram +ve as well as Gram -ve bacterial infections. Examples of 
antibiotics belonging to this group are the β-lactam antibiotics (such as penicillin, 
ampicillin, cefazolin, cefuroxime, cefotetan, cefotaxime, ceftriaxone, ceftazidime and 
cefepime) and monobactams like aztreonam, plus carbapenems such as imipenem 
and meropenem (Greenwood et al., 2007). 
 
1.4.2 Antibiotics which function as inhibitors of cell membrane 
functions 
A good example of such an antibiotic is daptomycin. It acts by binding and 
disrupting the cell membrane of Gram +ve cocci like methicillin-resistant 
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). 
However it is not able to act on Gram -ve bacilli since it cannot penetrate the outer 
membrane and as such is not effective against them. Polymyxins disrupt cell 
membranes and are more active against Gram -ve bacteria, with very little activity 
against Gram +ve bacteria. They are no longer widely used in medicine, although 
sometimes they are employed against strains that are resistant to more modern 
drugs (Lorian, 2005, Karaiskos et al., 2013, Rogers et al., 2013).  
 
1.4.3 Antibiotics which inhibit protein synthesis 
These antibiotics target the process of bacterial protein synthesis and seriously 
damage the metabolism of the cell. The bacterial cell uses ribosomes to translate 
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information from messenger RNA templates into proteins. Many antimicrobial 
agents exploit differences between prokaryotic and eukaryotic ribosomes in 
structure and size, to selectively target bacterial protein translation. Bacterial 
ribosomes are 70S and composed of 30S and 50S subunits, while the eukaryotic 
ribosomes are 80S with 60S and 40S subunits. 30S and 50S subunits of ribosomes 
play a role in: 
o Initiation of protein synthesis. 
o Codon recognition. 
o Docking of tRNA-amino acid complexes. 
o 50S subunit contains the enzymatic portion that actually forms peptide 
bonds between amino acids. 
Aminoglycosides and tetracyclines are types of antimicrobial agent which use the 
30S ribosomal subunit as a target for inhibition of protein synthesis.  
Aminoglycosides such as streptomycin and gentamicin change the shape of the 
30S subunit, and then it is impossible for the ribosomes to read the codons of 
mRNA correctly. Chloramphenicol blocks the active site of the 50S subunit which 
prevents translation. Some other drugs block ribosomal subunits from attaching to 
mRNA; such as fomiversen (Figure 1.4). 
 
Chapter 1     Introduction 
13 
 
Figure  1.4 The summary of mechanisms by which antimicrobials inhibit protein synthesis by 
targeting prokaryotic ribosomes. Source:(Bauman, 2010). 
1.4.4 Antibiotics that inhibit the synthesis of nucleic acids 
The nucleic acids DNA and RNA are essential for life and are built from purine and 
pyrimidine nucleotides. Many drugs, such as actinomycin, can block either 
replication of DNA or its transcription into RNA. Nucleotide analogues are drugs 
which interfere with the function of nucleic acid. Other drugs like rifampicin function 
by binding to and inhibiting the action of RNA polymerases during the synthesis of 
RNA from a DNA template. Fluoroquinolones are one of the broad-spectrum 
antibiotics which inhibit bacteria by binding to one of the two essential enzymes for 
the replication of DNA; DNA gyrase or DNA topoisomerase IV (Drlica, 1999).  
 
1.4.5 Antibiotics that inhibit metabolic pathways 
Sulfonamides act as anti-metabolic drugs and are structural analogues of para-
aminobenzoic acid (PABA).  PABA is essential for the synthesis of nucleotides 
required for DNA and RNA synthesis. As analogues of PABA, sulfonamides 
compete with PABA molecules for the active site of the enzyme involved in the 
production of dihydrofolic acid. This competition leads to a decrease in the 
production of tetrahydrofolic acid, and thus of DNA and RNA, which then leads to 
cell death. Some other drugs such as trimethoprim, interfere with nucleic acid 
synthesis, by binding to the enzyme that converts dihydrofolic acid to tetrahydrofolic 
acid (Hooper and Rubinstein, 2003, Lorian, 2005, Pelczar et al., 2009, Bauman, 
2010). 
 
1.5 Modes of action of antifungal agents 
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Unlike bacteria, both fungi and human cells are eukaryotic. Fungi make β-glucan, 
but human cells do not, so any drugs that target β-glucan biosynthesis; might have 
low side-effects. Different classes of drugs target the plasma membrane, sterol 
biosynthesis, DNA biosynthesis, and β-glucan biosynthesis. Drugs known as 
fungistatic drugs are those that inhibit growth; whereas fungicidal drugs kill fungal 
pathogens (Graybill et al., 1997). The following sections review the main modes of 
action of antifungal drugs and these are also summarised in Figure 1.5 (Kathiravan 
et al., 2012): 
 
 
Figure  1.5 Targets for antifungal therapy. Source:(Kathiravan et al., 2012). 
 
1.5.1 Sterol synthesis inhibitors 
1.5.1.1 Fungal ergosterol synthesis inhibitors 
The major component of the fungal cell membrane is ergosterol which is a sterol. 
Fungicide drugs such as azole, ketoconazole, itraconazole, fluconazole, 
voriconazole, posoconazole and ravuconazole are demethylase inhibitors which 
inhibit the lanosterol 14 α-demethylase ((CYP51A1, P45014DM) which is a 
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cytochrome P450, an enzyme that converts lanosterol to cholesterol); which will 
result in decreased ergosterol synthesis (Kathiravan et al., 2012, Rajput and 
Karuppayil, 2013).   
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1.5.1.2 Squalene epoxidase inhibitors 
Squalene epoxidase is a key flavin adenine dinucleotide (FAD)-dependent enzyme 
of ergosterol and cholesterol biosynthetic pathways (Nowosielski et al., 2011), which 
together with squalene cyclase, converts squalene to lanosterol. It is an attractive 
potential target for drugs such as morpholine, amorolfine, and terbinafine used to 
inhibit the growth of pathogenic fungi or to lower cholesterol levels (Kathiravan et 
al., 2012). 
 
1.5.2 Cell wall synthesis inhibitors 
1.5.2.1 Ergosterol disruptors 
The polyenes such as amphotericin B, and nystatin are fungicidal drugs and have 
the broadest spectrum of antifungal activity, which disrupt the fungal plasma 
membrane. This results in increased membrane permeability, by forming a complex 
with ergosterol. This will lead to leakage of the cytoplasmic contents and end with 
death of the fungal cell (Kathiravan et al., 2012).  
 
1.5.2.2 Glucan synthesis inhibitors 
One of the major components that strengthen the cell wall is glucan. D-Glucose 
monomers attached to each other by β-1,3-glucan or β-1,6-glucan linkages to form 
the glucan polysaccharide. The glucan synthesis inhibitors such as echinocandins, 
caspofungin, micafungin, and anidulafungin are lipopeptide class inhibitors that 
block fungal cell wall synthesis by inhibiting the enzyme β-1,3-glucan synthase via 
noncompetitive inhibition. The blockage of glucan synthase results in a decrease in 
the incorporation of glucose to the glucan, and leads to disruption of the structure of 
the cell wall, resulting in osmotic instability and death of the cells (Cabello et al., 
2001, Kathiravan et al., 2012).   
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1.5.2.3 Chitin synthesis inhibitors 
The insoluble polymer consisting of β-1,4-homopolymer of N-acetylglucosamine that 
folds in an anti-parallel manner forming intra-chain hydrogen bonds is called chitin, 
which is important in determining cell shape. Chitin chains are cross-linked 
covalently to β-1,3-glucan in order to strengthen the cell-wall, to form the inner 
skeleton of most fungi (Figure 1.6). Chitin synthase is an attractive target for the 
antifungal agents like polyoxins and nikkomycin, because it is essential for the fungi, 
and does not exist in human cells (Lenardon et al., 2010, Kathiravan et al., 2012).  
 
 
Figure  1.6 Chitin structure and diversity in fungi. Source: (Lenardon et al., 2010). 
 
1.5.3 Nuclic acid and /or protein synthesis inhibitors 
1.5.3.1 Nucleic acid synthesis inhibitors 
Flucytosine is an antifungal drug synthesised in the 1950's, which is transported into 
the fungal cell by a cytosine permease. This molecule is converted in the cytoplasm 
to 5-fluorouracil by a cytosine deaminase, and into 5-fluorouridylic acid by another 
enzyme (UMP pyrophosphorylase), which then disrupts the protein synthesis by 
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phosphorylation and interferes with RNA. Moreover, 5-fluorouracil inhibits 
thymidylate synthase, an enzyme involved in DNA synthesis and the nuclear 
division process; by converting to 5-fluorodeoxyuridine monophosphate (Vermes et 
al., 2000, Kathiravan et al., 2012).  
 
1.5.3.2 Protein synthesis inhibitors 
Sordarins is a natural product first isolated from the mould Sordaria araneosa in 
1971; it selectively inhibits fungal protein synthesis. It blocks the function of fungal 
translation Elongation Factor 2, which is a protein encoded by the Eukaryotic 
Elongation Factor 2 gene (eEF2). This protein is important and catalyses the 
movement of the ribosome along the mRNA, and for the translocation of peptidyl 
tRNA from the A to P site of the ribosome (Shastry et al., 2001, Kathiravan et al., 
2012). 
 
1.5.3.3 Microtubule synthesis inhibitors 
Microtubules are dynamic polymers of α- and β-tubulin dimers. They form a highly 
organized cellular skeleton in all eukaryotic cells. The agents like griseofulvin and 
vinblastin interact with β-tubulin, which then inhibit fungal mitosis (Rathinasamy et 
al., 2010, Kathiravan et al., 2012). 
 
1.6 Antibiotic resistance 
1.6.1 In bacteria  
Different kinds of resistance are developed by bacteria through the use of various 
mechanisms which keep evolving and confer resistance to currently used 
antibiotics. Some of these mechanisms include the chemical modification of the 
antibiotic, rendering the antibiotic ineffective by physically removing it from the cell, 
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modification of the target site and blocking or reducing uptake of the drug into the 
cell. The most common mechanism of antibiotic resistance is through the production 
of enzymes which are capable of inactivating the antibiotic. A good example is the 
production of penicillinase which cleaves the β-lactam ring of penicillins. Some 
bacteria carry out the modification of an existing cellular enzyme in such a way that 
it modifies the structure of the antibiotic by addition of an extra molecule, or it simply 
fails to interact with the target in an effective manner. Another mechanism of action 
which is used by several species of bacteria is the change or alteration of the target 
site. Some bacteria develop antibiotic resistance by making the target site 
unavailable to the antibiotic. This can be achieved by preventing penetration to 
targets like the cell wall and ribosomes. Antibiotic resistance can also be caused by 
simply shifting the cell metabolism to an alternative biochemical pathway. This 
mechanism of action is referred to as a metabolic by-pass and an example of this is 
resistance to trimethoprim (Guilfoile, 2006, Pelczar et al., 2009, Aminov, 2010, 
Bauman, 2010). 
Bacteria have the ability to control the entry of tiny molecules into the cell and this 
capacity is enhanced in Gram -ve bacteria due to their outer membranes. Gram +ve 
bacteria control the influx of antibiotics by physiological methods. Some antibiotics 
are active only when they are inside the body. Nitrofuran resistance is developed by 
mutations of genes which code for cellular reductase enzymes. Enterococci and 
Staphylococcus aureus develop resistance to the glycopeptide antibiotic 
vancomycin through the use of a strategy called antibiotic evasion (Jayaraman, 
2009). 
The antibiotic “resistome” is the sum of the possible mechanisms of resistance to 
bacterial drugs, via chemical modification or breakdown of antibiotics, target 
protection, efflux, or specific changes to the target (Figure 1.7). The source of the 
antibacterial resistance can be endogenous or exogenous. Endogenous is from 
‘within’ the pathogen, by mutation. Exogenous resistance is where new resistance 
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mechanisms are acquired from other bacteria, (e.g. environmental organisms, 
antibiotic producers, commensals, nonhuman pathogens) by horizontal gene 
transmission. As an example of diverse resistance mechanisms, bacteria can have 
a class-specific efflux mechanism or target protection/modification to resist 
tetracycline as shown in Table 1.1 (Silver, 2011).  
 
Table  1.1 Key Mechanisms of bacterial resistance against some drugs. Source: (Silver, 
2011). 
Origin Mechanism Examples of affected drug classes affected 
Exogenous 
Class-specific efflux Tetracycline, macrolides 
Class-specific 
degradation/modification 
β-Lactams, aminoglycosides, chloramphenicol, 
streptogramin A, metronidazole (for anaerobes), 
fosfomycin 
Target protection/modification 
Tetracycline, macrolides, lincosamides, 
oxazolidinones, 
streptogramin B 
Replacement with reduced-
affinity target 
β-Lactams, vancomycin, trimethoprim, mupirocin, 
sulfonamides 
Sequestration of target Fluoroquinolones, fusidic acid 
Endogenous 
Single mutations reducing 
target affinity 
Rifamycin, streptomycin, trimethoprim (for 
Gram+ve 
organisms), fusidic acid 
Multistep mutations reducing 
affinity or 
remodeling of target 
Fluoroquinolones, oxazolidinones, daptomycin, 
vancomycin, 
polymyxin, β-lactams (for transformable species) 
General efflux mechanism Most classes for Pseudomonas; many classes for other species 
Reduced uptake (porin or 
permease loss) Carbapenems, fosfomycin 
Loss of activation Metronidazole (for H. pylori)  
Upregulation of target Fosfomycin 
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Figure  1.7 General mechanisms of antibiotic resistance in bacteria. Source: (Todar, 2008). 
 
1.6.1.1 Increasing resistance in bacteria and the increasing financial 
cost 
Rollo et al in 1952 noted the possibility of resistance emergence under laboratory 
conditions and concluded that: “Syphilis has now been treated with arsenicals for 
about 40 years without any indications of an increased incidence of arsenic-
resistant infections, and this work gives grounds for hoping that the widespread use 
of penicillin will equally not result in an increasing incidence of infections resistant to 
penicillin”. But this did not apply to other pathogenic bacteria, where they found it 
not only became resistant to original penicillin, but even to the semi-synthetic 
penicillins such as cephalosporins, and newer carbapenems (Aminov, 2010). 
Earlier, when Fleming discovered penicillin, he found that some bacteria were 
already resistant and he warned that the misuse of penicillin could lead to increased 
resistance amongst bacteria (French, 2010).  
Multidrug-resistant (MDR) pathogens constitute an emerging threat with increasing 
incidence and uncertain outcome. Examples of these pathogns are glycopeptide-
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resistant MRSA and enterococci, and toxin-hyperproducing Clostridium difficile 
which is a species of Gram+ve bacteria that causes severe diarrhea and other 
intestinal disease. The characterisation of MDR is through their heterogeneity, 
increasing virulence, resistance to even reserve agents and spread within and 
between hospitals and the community (French, 2010). But after the introduction of 
methicillin and other penicillinase-stable penicillins in the 1960s, the global problem 
of the multidrug-resistant (MDR) ‘hospital Staphylococcus’ reduced, and outbreaks 
of gentamicin-resistant Klebsiella and other Gram -ve organisms seen in the 1970s, 
waned in the 1980s with the introduction of newer aminoglycosides, cephalosporins 
and quinolones (French, 2010). 
The extensive resistance problems are due in part to negligent antibiotic use and 
poor infection control practice and it is an inevitable consequence of wide spread 
antibiotic use (French, 2010). There are some factors which increases the 
resistance rate; availability of viable resistant variants and the intensity of selection 
pressure imposed by antimicrobial treatment (Lipsitch, 2001).  
An association has been found between antibiotic resistance and adverse outcomes 
in the order of a 1.3 to 2 times increase in mortality, morbidity, and costs for patient 
care with drug resistant infections, compared with susceptible infections (Franco, 
2009). 
Every year in the US, there are about 23 million kg of antibiotics prescribed in total, 
and the annual cost of treating antibiotic-resistant infections has been calculated at 
more than US $ 4 billion and 18% of the total antibacterial medicines prescribed in 
the US in 1992 were for respiratory illnesses (Franco, 2009).     
The increasing prevalence of antibiotic resistance in bacteria is one of the greatest 
challenges in medicine (Figure 1.8). Despite extensive efforts, few totally new 
therapeutic agents have emerged over the past decade. There is thus great interest 
in developing derivatives of existing agents with enhanced activity, or that are less 
susceptible to bacterial resistance mechanisms. A study by Knight et al., (2012) at 
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St George’s Hospital, London, as cited in the report published by Department of 
Health in UK (2013), showed that when the hospital reduced the prescription of 
quinolones to paitents, the cases of meticillin-resistant Staphylococcus aureus 
(MRSA) in England declined (Figure 1.9) (Department of Health, 2013a). 
 
 
Figure  1.8 Rise in reports to Health Protection Agency of resistance to methicillin in S. 
aureus from bacteremia cases, England and Wales, 1992-2005 (voluntary laboratory 
reports). Source: (Health Protection Agency, 2006). 
 
 
Figure  1.9 National decline in reported cases of meticillin-resistant Staphylococcus aureus 
(MRSA), England, 2001 to 2011. Source: (Department of Health, 2013a) 
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1.6.1.2 Challenges in development of new antibiotics 
Excessive use of antibiotics like sulfonamides in the treatment of bacterial infections 
over several decades has led to the development of severe resistance in several 
bacterial species. When the species develop resistance to existing antibiotics, it 
becomes necessary to carry out research and development of new antibiotics as 
well as new testing procedures to identify strains that are resistant. The correlation 
between the increase in antibiotic resistance and the enormous cost to the patient 
and the health care system are growing problems and present major therapeutic 
challenges now and in the future.  
One of these challenges is that many governments imposed new regulations for the 
pharmaceutical industry to invest in antibiotic research, such as increased 
regulatory conditions and strict price controls. These regulations have partly 
prevented developments in antibiotic research (Franco, 2009).  
In the last three decades the development of such antibiotic resistance in bacteria 
has inflated the financial cost of development of new drugs which are effective 
against such infections. Linezolid and daptomycin are the only two new classes with 
antibiotics of novel mechanisms of action which have been introduced into the 
market. The rest of the new antibiotics are just chemical modifications of existing 
drugs as shown in Table 1.2 (Franco, 2009).      
 
C
ha
pt
er
 1
 
 
 
 
 
 
 
In
tro
du
ct
io
n 
25
 
 Ta
bl
e 
 1.
2 
D
ev
el
op
m
en
t o
f n
ew
 a
nt
ib
io
tic
s 
du
rin
g 
th
e 
la
st
 th
re
e 
de
ca
de
s.
 S
ou
rc
e:
 (F
ra
nc
o,
 2
00
9)
. 
A
nt
ib
io
tic
 a
ge
nt
 a
nd
 b
ra
nd
 
na
m
e 
 
A
nt
ib
io
tic
 c
la
ss
 
 
A
nt
im
ic
ro
bi
al
 a
ct
iv
ity
 
 
C
ou
nt
ry
 a
nd
 d
at
e 
of
 
ap
pr
ov
al
 
 
Q
ui
nu
pr
is
tin
 a
nd
 d
al
fo
pr
is
tin
 
(S
yn
er
ci
d®
) I
.V
.  
S
tre
pt
og
ra
m
in
s 
In
fe
ct
io
ns
 a
ss
oc
ia
te
d 
w
ith
 v
an
co
m
yc
in
 re
si
st
an
t 
E
nt
er
oc
oc
cu
s 
fa
ec
iu
m
 b
ac
te
re
m
ia
 
 
U
S
, S
ep
te
m
be
r 2
1,
 1
99
9 
D
al
ba
va
nc
in
, t
el
av
an
ci
n,
 
or
ita
va
nc
in
 
S
ec
on
d-
ge
ne
ra
tio
n 
gl
yc
op
ep
tid
es
  
B
ac
te
ric
id
al
 a
ct
iv
ity
 a
ga
in
st
 M
R
S
A
, V
R
S
A
, v
an
co
m
yc
in
-
re
si
st
an
t e
nt
er
oc
oc
cu
s 
an
d 
dr
ug
-re
si
st
an
t S
tre
pt
oc
oc
cu
s 
pn
eu
m
on
ia
e 
 
U
S
, p
ha
se
 II
, 2
00
9 
 D
ap
to
m
yc
in
 (C
ub
ic
in
®
) I
.V
. 
C
yc
lic
 li
po
pe
pt
id
e 
ne
w
 c
la
ss
 o
f 
an
tib
io
tic
 
B
ac
te
ric
id
al
 a
ct
iv
ity
 a
ga
in
st
 G
ra
m
 +
ve
 S
. a
ur
eu
s,
 M
R
S
A
, 
S
ta
ph
yl
oc
oc
cu
s 
ep
id
er
m
id
is
 in
cl
ud
in
g 
m
et
hi
ci
lli
n-
re
si
st
an
t S
. e
pi
de
rm
id
is
, v
an
co
m
yc
in
-re
si
st
an
t 
en
te
ro
co
cc
us
, p
en
ic
ill
in
-re
si
st
an
t S
. p
ne
um
on
ia
e 
an
d 
S
tre
pt
oc
oc
cu
s 
py
og
en
es
 
 U
S
, D
ec
em
be
r 9
, 2
00
3 
Ti
ge
cy
cl
in
e 
(T
yg
ac
il®
) I
.V
.  
G
ly
cy
lc
yc
lin
e 
si
m
ila
r 
to
 th
e 
te
tra
cy
cl
in
es
 
B
ac
te
rio
st
at
ic
 a
ct
iv
ity
 a
ga
in
st
 G
ra
m
+v
e,
 
G
ra
m
 -v
e 
an
d 
at
yp
ic
al
 a
na
er
ob
ic
 b
ac
te
ria
, a
nd
 a
nt
ib
io
tic
-
re
si
st
an
t, 
M
R
S
A
, v
an
co
m
yc
in
-re
si
st
an
t e
nt
er
oc
oc
cu
s,
 
pe
ni
ci
lli
n-
re
si
st
an
t S
. p
ne
um
on
ia
e 
 U
S
, J
un
e,
 2
00
5 
Li
ne
zo
lid
 (Z
yv
ox
®
) O
ra
l 
an
d 
pa
re
nt
er
al
 fo
rm
s 
O
xa
zo
lid
in
on
e 
 
B
ac
te
rio
st
at
ic
 a
ct
iv
ity
 a
ga
in
st
 e
nt
er
oc
oc
ci
 a
nd
 
st
ap
hy
lo
co
cc
i, 
ba
ct
er
ic
id
al
 a
ct
iv
ity
 a
ga
in
st
 m
an
y 
dr
ug
-
re
si
st
an
t s
tre
pt
oc
oc
ci
, S
. p
ne
um
on
ia
e 
an
d 
in
fe
ct
io
ns
 
ca
us
ed
 b
y 
an
ae
ro
bi
c 
ba
ct
er
ia
 
 U
S
, A
pr
il 
18
, 2
00
0 
Te
lit
hr
om
yc
in
 (K
et
ek
®
) 
E
ry
th
ro
m
yc
in
 
de
riv
at
iv
e 
Th
e 
FD
A
 a
nn
ou
nc
ed
 c
ha
ng
es
, i
nc
lu
di
ng
 th
e 
re
m
ov
al
 o
f 
tw
o 
of
 th
e 
th
re
e 
pr
ev
io
us
ly
 a
pp
ro
ve
d 
in
di
ca
tio
ns
 –
 a
cu
te
 
ba
ct
er
ia
l s
in
us
iti
s 
an
d 
ac
ut
e 
ba
ct
er
ia
l e
xa
ce
rb
at
io
ns
 o
f 
ch
ro
ni
c 
br
on
ch
iti
s.
 K
et
ek
 is
 n
ow
 in
di
ca
te
d 
fo
r t
he
 
tre
at
m
en
t o
f c
om
m
un
ity
-a
cq
ui
re
d 
pn
eu
m
on
ia
e 
(o
f m
ild
 to
 
m
od
er
at
e 
se
ve
rit
y)
 d
ue
 to
 S
tre
pt
oc
oc
cu
s 
pn
eu
m
on
ia
e,
 
(in
cl
ud
in
g 
m
ul
ti -
dr
ug
 re
si
st
an
t i
so
la
te
s)
, H
ae
m
op
hi
lu
s 
 in
fl 
ue
nz
ae
, M
ox
ar
el
la
 c
at
ar
rh
al
is
, C
hl
am
yd
op
hi
la
 
pn
eu
m
on
ia
e,
 o
r M
yc
op
la
sm
a 
pn
eu
m
on
ia
e 
U
S
, A
pr
il 
01
, 2
00
4 
  La
st
 p
ub
lis
he
d 
re
vi
si
on
: 
Fe
br
ua
ry
 1
2,
 2
00
7 
   
C
ha
pt
er
 1
 
 
 
 
 
 
 
In
tro
du
ct
io
n 
26
 
 A
nt
ib
io
tic
 a
ge
nt
 a
nd
 b
ra
nd
 
na
m
e 
 
A
nt
ib
io
tic
 c
la
ss
 
 
A
nt
im
ic
ro
bi
al
 a
ct
iv
ity
 
 
C
ou
nt
ry
 a
nd
 d
at
e 
of
 
ap
pr
ov
al
 
 
E
rta
pe
ne
m
 (I
nv
an
z®
)  
I.V
. a
nd
 
in
tra
m
us
cu
la
r 
C
ar
ba
pe
ne
m
  
A
ct
iv
ity
 a
ga
in
st
 G
ra
m
 +
ve
 a
nd
 G
ra
m
 -v
e 
ba
ct
er
ia
, b
ut
 
sh
ow
s 
on
ly
 li
m
ite
d 
ac
tiv
ity
 a
ga
in
st
 E
nt
er
oc
oc
cu
s 
as
pp
., 
P
se
ud
om
on
as
 a
er
ug
in
os
a 
an
d 
ot
he
r n
on
fe
rm
en
tin
g 
G
ra
m
 +
ve
 b
ac
te
ria
 
U
S
, N
ov
em
be
r 2
1,
 2
00
1 
D
or
ip
en
em
 (D
or
ib
ax
®
) I
.V
. 
C
ar
ba
pe
ne
m
  
B
ac
te
ric
id
al
 a
ct
iv
ity
, f
or
 th
e 
tre
at
m
en
t o
f c
om
pl
ic
at
ed
 
ur
in
ar
y 
tra
ct
 a
nd
 in
tra
-a
bd
om
in
al
 in
fe
ct
io
ns
 
U
S
, O
ct
ob
er
 1
2,
 2
00
7 
Fa
ro
pe
ne
m
 O
ra
l 
C
ar
ba
pe
ne
m
 
It 
w
as
 d
ev
el
op
ed
 fo
r t
he
 tr
ea
tm
en
t o
f c
om
m
un
ity
-
ac
qu
ire
d 
re
sp
ira
to
ry
 tr
ac
t i
nf
ec
tio
ns
 a
nd
 la
te
r f
or
 
un
co
m
pl
ic
at
ed
 s
ki
n 
an
d 
sk
in
 s
tru
ct
ur
e 
in
fe
ct
io
ns
. I
t w
as
 
sh
ow
n 
to
 b
e 
ac
tiv
e 
ag
ai
ns
t p
en
ic
ill
in
-re
si
st
an
t S
. 
pn
eu
m
on
ia
e 
an
d 
β-l
ac
ta
m
as
e-
pr
od
uc
in
g 
H
. i
nf
lu
en
za
e 
an
d 
M
. c
at
ar
rh
al
is
 
N
ot
 y
et
 F
D
A
 a
pp
ro
ve
d,
 2
00
8 
C
ef
to
bi
pr
ol
e 
(Z
ef
te
ra
®
) 
C
ep
ha
lo
sp
or
in
e 
B
ac
te
ric
id
al
 a
ct
iv
ity
 is
 m
ai
nl
y 
ac
tiv
e 
ag
ai
ns
t G
ra
m
 +
ve
 
pa
th
og
en
s.
 F
or
 th
e 
tre
at
m
en
t o
f c
om
pl
ic
at
ed
 s
ki
n 
an
d 
so
ft 
tis
su
e 
in
fe
ct
io
ns
 a
nd
 n
os
oc
om
ia
l p
ne
um
on
ia
 c
au
se
d 
by
 M
R
S
A
b,
 e
nt
er
oc
oc
ci
 a
nd
 S
. p
ne
um
on
ia
e 
 
U
S
, p
ha
se
 II
I, 
20
09
  
Ic
la
pr
im
  
D
ia
m
in
op
yr
im
id
in
e 
N
ew
 a
nt
ib
io
tic
 
It 
ha
s 
de
m
on
st
ra
te
d 
in
 v
itr
o 
ac
tiv
ity
 a
ga
in
st
 S
. a
ur
eu
s,
 
in
cl
ud
in
g 
M
R
S
A
b.
 Ic
la
pr
im
 w
as
 a
ls
o 
ac
tiv
e 
ag
ai
ns
t o
ne
 
st
ra
in
 o
f V
R
S
A
c 
U
S
, p
ha
se
 II
I, 
20
09
 
A
bb
re
vi
at
io
ns
: I
V
, i
nt
ra
ve
no
us
 p
re
se
nt
at
io
n;
 M
R
S
A
, m
et
hi
ci
lli
n-
re
si
st
an
t S
. a
ur
eu
s;
 V
R
S
A
, v
an
co
m
yc
in
-re
si
st
an
t S
. a
ur
eu
s.
 
  
Chapter 1      Introduction 
27 
 
1.6.2 In fungi 
Antifungal resistance has also been increasing and therefore there is an urgent 
need to develop new antifungal drugs. Moreover, some fungi could form biofilms 
which increases the resistance too. Candida species, which have the ability to form 
drug resistant biofilms, are a major factor in contributing to human disease. Different 
mechanisms of resistance are applied when the biofilm changes into a complex 
biofilm from an adherent phenotype. These mechanisms are extracellular matrix 
(ECM), efflux pump activity, persisters, cell density, overexpression of drug targets, 
stress responses, and the general physiology of the cell. The mechanisms of action 
of different classes of antifungal agents such as, azoles (AZL), polyenes (POL), and 
echinocandins (ECN) and their antifungal resistance, are summarised in the 
diagram below (Figure 1.10). First, it can be see that the layer of extracellular matrix 
(ECM) binds to the antifungal agents and shields the cells. ATP-binding cassette 
(ABC) and major facilitator superfamily (MFS) transporters in the membrane are 
efflux pumps for the antifungal agent. By changing the ergosterol biosynthesis 
pathway through mutation in genes such as; ERG, Cyp51, and FKS1 will change 
the drug target. Moreover, response to the antifungal agent stress can be altered by 
calcineurin, which is a Ca2+-calmodulin-activated serine/ threonine-specific protein 
phosphatase, that plays many critical stress roles in the fungal cell (Ramage et al., 
2012, Sardi et al., 2013).  
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Figure  1.10 Molecular mechanisms of fungal biofilm resistance. Source: (Ramage et al., 
2012). 
 
In the last 20 years other species such as Aspergillus spp have increased their 
resistance to the antifungal drugs, although the use of the antifungal drugs has also 
increased as well, which then partially results in the failure of the treatment. The 
extensive use of the antifungal drugs was clear in Denmark in using azoles, which is 
one of the major drug classes used against fungal infections. Their results doubled 
over the last decade (2002–2011) as summarised in Figure 1.11 (Hadrich et al., 
2012, Arendrup et al., 2013). 
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Figure  1.11 National antifungal consumption (1000 DDD) in the years 2000–11 in Denmark. 
The hospital use in percentage of the total use in the study period 2010–11 is indicated in 
parenthesis for each compound. Source: (Arendrup et al., 2013). 
 
1.7 Antimicrobial stewardship  
Meanwhile, existing antimicrobials need to be preserved by controlling their usage. 
Therefore, an approach addressed by the Department of Health, antimicrobial 
resistance strategy in the UK 2013–2018 under the name of “Antimicrobial 
stewardship” has been instigated. This approach has three goals; improve the 
therapy for individual patients, prevent misuse, and control the increase of 
resistance at patient and community level. Over the past two decades there has 
been notable progress in UK hospitals in developing and implementing antimicrobial 
stewardship. The collected data of this approach is summarised in Table 1.3 
(Department of Health, 2013a) 
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Table  1.3 Implementation of antimicrobial stewardship strategies in UK hospitals – progress 
over two decades. Source: (Department of Health, 2013a) 
Criteria  Percent of total hospitals using criteria  
Year 1994 2006 2012 (ongoing) 
Source BSAC Wickens & Jacklin 
ESGAP & ISC 
(unpublished) 
Sample  n=427 UK hospitals 
n=125 
English 
hospitals 
n=126 
UK hospitals 
Guidelines for antibiotic therapy 62% 90% 100% 
Guidelines for surgical 
prophylaxis 
51% 87% 99% 
Antibiotic formulary 79% 89% 99% 
Restricted list 61% 69% 93% 
Educational campaigns 52% 73% 100% 
Automatic stop policy 26% - 61% (stop/review) 
Antibiotic committee 17% 56% 85% 
Antibiotic audit 11% 78% 98% 
IV-to-oral switch guidance - 69% 92% 
Microbiology ward rounds 64% - 96% 
Stewardship ward rounds - 35% 86% 
Antimicrobial consumption 
surveillance (WHO defined daily 
doses) 
- 46% 69% 
Dedicated antimicrobial 
prescription chart 
1.5% <1% 40% 
Inflammatory marker testing 
(e.g. procalcitonin) 
- - 11% 
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1.8 The need to develop new drugs 
According to what has been mentioned in Section 1.6, there is a critical need to 
develop new drugs, but the investment available for such development is frequently 
lower than the required level. There are various reasons for this according to the 
annual Report of the Chief Medical Officer in UK, including the high cost for drugs 
that are effective against Gram -ve bacteria; type of drug which is used for short 
treatment courses, compared with drugs used for chronic conditions; reducing 
ineffective patent period and the investment for the current drug; and also there are 
challenges in the requirements for testing new drugs. The Chief Medical Officer for 
England; Professor Dame Sally Davies has described the dangers of the continuing 
increase of resistance to antibiotics, and listed it at the same level as “terrorism” on 
a list of threats to the community. Figure 1.12 illustrates that no new class of 
antibiotics have been developed since the late 80s (BBC, 2013). 
Therefore, researchers only had focused on the chemical modification of existing 
drugs to inhibit multi drug resistance in bacteria. Also it is possible to use existing 
drugs to inhibit virulence rather than inhibit growth directly (Imperi et al., 2013). As it 
will be describe in section 1.10, benzimidazole has been widely used in medicinal 
chemistry and researchers are actively seeking new uses and applications for it. 
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1.9 Benzimidazoles in medicinal chemistry 
1.9.1 The structure of benzimidazole 
Benzimidazole (1) is a heterocyclic compound in which the benzene and imidazole 
rings are fused together. The chemical structure of benzimidazole is shown in 
Figure 1.13 (Wagner, 1943). This bicyclic compound has two nitrogen atoms from 
the imidazole nucleus and it has numerous medical and biological activities such as 
antibacterial, antifungal, antiviral, anticonvulsant, antidepressant, analgesic, anti-
inflammatory and antidiabetic properties (Bansal and Silakari, 2012) (Figure 1.14).  
N
N
H
 
(1) 
Figure  1.13 The chemical structure of benzimidazole. 
 
 
Figure  1.14 Benzimidazole, a multifunctional nucleus. Source:(Bansal and Silakari, 2012) 
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1.9.2 Properties of benzimidazole 
Benzimidazole is a slightly beige coloured powder with a melting point of 172 oC and 
boiling point of 360 oC. It is sparingly soluble in water but readily soluble in ethanol. 
It is generally stable under normal temperature and pressure.  
Since benzimidazole consists of a phenyl ring fused to imidazole, it is expected to 
form hydrogen bonding due to the nitrogen atoms of the imidazole ring and the H-
bonding is illustrated in Figure 1.15.  
 
HN N N
H
NN
H
N
 
Figure  1.15 Hydrogen bonding network of benzimidazole 
 
The nitrogen atoms of the imidazole ring possess a lone pair of electrons which 
indicates that benzimidazole and its derivatives have a tendency to donate electron 
pairs, but such tendency depends upon the substitution on the compound. 
Therefore, benzimidazoles act as bases and their properties can be compared with 
nitrogens of pyridine and pyrrole rings (Figure 1.16). Moreover, because of the 
tautomerism in benzimidazoles two non-equivalent structures can be written, but 
only one compound is known, as the situation of 5(or 6)-methylbenzimidazole.   
 
N
H
N
N
pyridine
pyrrole
N
H
 
Figure  1.16 Pyridine and pyrrole type nitrogens of benzimidazole 
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1.9.3 Synthesis of benzimidazoles 
Benzimidazole (2) can be readily synthesised by heating o-phenylenendiamine with 
formic acid in absence of any catalyst as shown in Figure 1.17.  
N
H
NNH2
NH2
CH
O
HO
+ + 2 H2O
 
   (2) 
Figure  1.17 Synthesis of benzimidazole  
 
Numerous derivatives of benzimidazole can be formed by altering the carboxylic 
acid especially for the formation of 2-substituted benzimidazoles. There are several 
methods available for the preparation of benzimidazole derivatives (3) (Khan, 2007). 
Only a few examples have been selected to illustrate the recent developments. 
Bahrami et al. (2008) proposed a method for synthesis of 2-substituted 
benzimidazole as shown in Figure 1.18. This is a very convenient method and 
involves quick reaction times with high yields and quick and easy isolation of the 
benzimidazole derivatives along with good chemoselectivity (Bahrami et al., 2008). 
 
          (3) 
Figure  1.18 Synthesis of 2-substituted benzimidazole according to Bahrami et al., (2008) 
 
Another synthesis, which was proposed by Alinezhad et al., (2012), involves ZnO 
nanoparticles as catalysts for the reaction of 1,2-phenylenediamine with formic acid 
at 70 oC and under solvent-free conditions (Figure 1.19) (Alinezhad et al., 2012).  
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NH2
NH2
HCO2H
N
H
NZnO nanopracticles (2 mol%)
70 oC, solvent-f ree, 6-150 min.
R: H, CH3, OCH3, COOH, PHCO- yield: 90-98%
RR
          (4) 
Figure  1.19 Synthesis of benzimidazole according to Alinezhad et al. (2012a)  
            
 
Another excellent synthesis which has been proposed by Saha et al. (2009) 
involved a simple, efficient and ligand free reaction scheme for the synthesis of 
substituted benzimidazoles, 2-aminobenzimidazoles as well as benzothiazoles (5) 
(Saha et al., 2009). The reaction is catalysed by CuO nanoparticles in DMSO and 
this heterogeneous catalyst can be recovered without losing its activity (Figure 1.20) 
(Saha et al., 2009). 
 
N
NHR2
R1
BrR
N
N
R1
R
R2
5 mol% CuO nanoparticles
1.5-3 eq. KOH
DMSO, 110 oC, 3-24 h upto 97% yield
R= H, Br, Cl, Me, OMe
R1 = Me, Ph, morpholine,
pyrrolidine,piperazine
R2 = Ph, Me
 
   (5) 
Figure  1.20 Synthesis of 2-substituted benzimidazole according to Saha  et al. (2009)  
 
In recent developments ultrasonic irradiation has been reported by Zhang et al., 
(2012a), for the synthesis of 1,2-disubstitued benzimidazoles (6) and 2-substitued 
benzothiazoles (7), using rare-earth metal chlorides as a catalysts (Figure 1.21). 
This method has many advantages such as, economical catalysts, good yields, 
simple operation, solvent-free conditions, and ambient temperature (Zhang et al., 
2012a). 
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  (7) 
Figure  1.21 Synthesis of 1,2-substituted benzimidazole and benzothiazoles according to 
Zhang et al. (2012a)  
 
1.10 Benzimidazoles in Medicinal Chemistry 
As mentioned in section 1.10.1, benzimidazole and its derivatives are very important 
in terms of their medicinal applications.  Derivatives such as thiabendazole (8), 
cambendazole (9), parbendazole (10), mebendazole (11), albendazole (12), 
flubendazole (13) are very popular anti-helminth drugs used to cure people and 
animals of gastrointestinal worm infections (Cho and Lopes, (2011)) (Figure 1.22 
and 1.23). 
 
Figure  1.22 Endoscopic visualization of hookworms in the duodenum. Source: (Sudha and 
Christian, 2009) 
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N
H
N
N
S
N
H
N
N
S
N
H
O
O
 
 
Thiabendazole (8)   Cambendazole (9) 
 
N
H
N
Bu
H
N
O
OMe
N
H
N HN
O
OMe
Ph
O  
      
Parbendazole (10)   Mebendazole (11) 
 
 
 
   Albendazole (12)   Flubendazole (13) 
 
Figure  1.23 Examples of benzimidazole derivatives as anti-helminth drugs according to Cho 
and Lopes (2013)  
 
Two mechanisms have been proposed for the action of benzimidazoles as anti-
helminth drugs. Fumarate reductase is an important enzyme in helminths that helps 
in the oxidation of NADH to NAD. Benzimidazole derivatives are known to inhibit the 
activity of the enzyme and hence oxidative phosphorylation is uncoupled, which is 
an important event for ATP production (Prichard, 1970). The second mechanism 
involves binding of benzimidazoles with the protein tubulin resulting in reduced or no 
formation of microtubules. Due to reduced solubility of benzimidazoles in water, 
these are poorly adsorbed from the gut, which may act as a positive property of the 
drugs since primarily these drugs need to be concentrated in the intestinal tract for 
treating helminths. After consumption, these drugs undergo rapid metabolism in the 
liver and are excreted to the bile (Williams, 2008). Albendazole is quite unique as an 
anti-helminth due to the presence of a thio-ether group which helps in increasing 
sulfur oxidation. The metabolite formed by this drug is a highly potent anti-helminth. 
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Mebendazole reduction gives a metabolite with a secondary alcohol substituent 
which increases the solubility of the drug into water and makes the drug quite 
active. Mintezol, tresaderm and arbotect are the trade names for thiabendazole and 
are commonly used in veterinary medicine for management and treatment of 
enterobiasis, strongloidiasis, ascariasis, unicinariasis and trichuriasis. Therefore, 
thiabendazole and its derivatives are less commonly used than albendazole or 
mebendazole. It is known to inhibit fumurate reductase with possible interaction with 
endogenous quinone, however it is not well established whether metal ions are 
involved in the inhibition mechanism or not. It also acts as a chelating agent and is 
useful to bind with metal ions and hence, medicinally useful for treating metal 
poisoning such as lead poisoning and mercury poisoning. Thiabendazole is known 
to be toxic and may lead to Strevens-Johnson syndrome and causes hepatotoxicity 
and crystalluria (Prichard, 1970).  
A study (Kim et al., 2008) has shown that 2-aminobenzimidazole acts as a potent 
glucogen receptor antagonist which causes resistance to glucagon. The glucogen 
receptor is a 62 kDa protein that is activated by a hormone of glucagon which is 
secreted by the pancreas, and causes the liver to convert stored glycogen into 
glucose. The results also showed excellent selectivity over other human glucagon-
like peptide receptors and the human glucagon-like peptide 1 receptor which have a 
role in glucose-dependent insulin secretion. 
Another study showed that 5,6-dichlorobenzilidazole-1-β-D-ribofuranoside 
(commonly known as DRB) and its 2-substituted derivatives have excellent activity 
against cytomegalovirus in humans (Devivar et al., 1994). Some derivatives of 
benzimidazole such as 5,6-dinitrobenzimidazole are capable of replacing 5,6-
dimethylbenzimidazole found in vitamin B12 in Corynebacterium species (Gram +ve 
bacterial genus) and other derivatives acts as an inhibitor for photosynthesis by 
decoupling oxidative phosphorylation in mitochondria (Burton et al.,1965 cited in 
Maske) (Maske et al., 2012). 
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Since benzimidazole and its derivatives can act as excellent ligands due to an 
electron rich nitrogen atom present in the imidazole ring, the transition metal ions 
can form complexes with benzimidazoles and some have shown anti-cancer 
activities. Cu(II) complexes of 2-substituted benzimidazole have the ability to mimic 
copper, zinc superoxide dismutase (Cu, Zn-SOD) which is an antioxidant enzyme 
which helps cells to protect from the toxicity of superoxides by dismutation of 
oxygen and hydrogen peroxide through a series of biochemical reactions in 
biological systems. Due to the lower superoxide dismutase activity of tumour cells, 
as compared to the normal cells, Cu(II) complexes of 2-substituted benzimidazole 
can target tumour cells easily and have the ability to act as anticancer agents (Azam 
et al., 2009).  
Another very important and widely used benzimidazole derivative is omeprazole 
(14)(Figure 1.24) which acts as a proton pump inhibitor. It is widely used in 
treatment of dyspepsia, gastroesophageal reflux, laryngopharyngeal reflux and 
peptic ulcer disease. Due to its existence as a racemate (it exists in R as well as S 
configuration in a 1:1 ratio), it is converted to achiral products under acidic 
conditions in the stomach, which on reaction with cysteine residue of H+/K+ 
ATPase, inhibits the production of gastric acid. Omeprazole acts as a competitive 
inhibitor for certain enzymes that are associated with cytochrome P450 and hence 
is able to interact with other drugs that involve cytochrome P450 in metabolism. 
Examples include diazepam and warfarin. However, there are several side effects 
associated with its use such as headache, diarrhea, nausea, reduction in vitamin 
B12 and sleep deprivation. Its prolonged use may also cause inflammation of the 
kidney (tubulointerstitial nephritis) (Stedman and Barclay, 2000, Furuta, 2005, Ray 
et al., 2010, Madanick, 2011). 
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N
H
N
 
(14) 
Figure  1.24 Omeprazole 
 
1.10.1 Benzimidazole and derivatives as Antimicrobial  and other 
medicinal agents 
There have been some benzimidazole derivatives which have shown activity 
against Entamoeba indicating anti-protozoal efficacy of the drugs. 2-
Methoxycarbonylamino derivatives of benzimidazole have shown better 
antiprotozoal activities against some protozoan parasites such as Giardia lamblia 
and Entamoeba histolytica by inhibiting the tubulin polymerization and hence 
making these better antiprotozoal agents than metronidazole and albendazole 
(Valdez et al., 2002). Besides the above mentioned medicinal properties of 
benzimidazole and its derivatives, two groups of benzimidazole derivatives, namely 
5,6-dinitro and 2-trifluromethyl derivatives, are known for use as antihelminth drugs 
(Stefanska et al., 1999). Nitrogen and halogen substituted derivatives of 
benzimidazole and their analogues show potential chemotherapeutic activity against 
Stenotrophomonas maltophilia which is a Gram -ve opportunistic pathogen. Some 
analogues are highly effective against Trichomonas vaginalis which is an anaerobic, 
flagellated protozoan parasite, and are known to act in the same way as 
metronidazole behaves, via reduction of the nitro group through ferrodoxin.  
Benzimidazole D-ribonucleosides such as 2, 5, 6-trichloro-(1-β-D-ribofuranosyl) 
benzimidazole (TCRB) as well as its bromo homologue (BDCRB) (15)have been 
found to be potent and selective inhibitors of human cytomegalovirus (HCMV). 
These drugs inhibit the processing and maturation of viral DNA and cause 
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mutations in viral genes UL56 and UL89 and are better than the antiviral drugs used 
to date such as ganciclovir, cidoclovir and the pyrophosphate analogue foscarnet 
due to their improved oral bioavailability as well as fewer toxic side effects. These 
benzimidazole ribonucleoside derivatives, along with many additional analogues 
e.g. 1263W94 (16) and 275175X (17) (Figure 1.25) have been found to be more 
biologically stable and orally active (Williams et al., 2003). 
 
N
NCl
Cl
Br
O
OHHO
HO
N
NCl
Cl
Br
N
NCl
Cl
H
N
O
OHHO
OH O
OHHO
HO
BDCRB 1263W94 275175X
 (15)     (16)    (17) 
Figure  1.25 Analogues of benzimidazole ribonucleoside according to Williams et al. (2003)  
 
Helicobacter pylori is a well-known Gram -ve bacterial human pathogen that is 
responsible for type B gastritis of the stomach and can lead to duodenal ulcers and 
even gastric cancer. This species is typically treated with bismuth salts in 
combination with antibiotics. However, lansoprazole (18) (Figure 1.26), a novel 
benzimidazole, has proven itself a better antagonist against H. pylori with a notable 
and highly selective activity which is much superior to bismuth salts or bismuth-
antibiotic combinations. Lansoprazole acts as a proton pump inhibitor for stomach 
and hence useful for treatment of gastroduodenal diseases (Iwahi et al., 1991). 
 
N
H
N
S N
O
F
F F
O
 
(18) 
Figure  1.26 Lansoprazole  
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1.10.1.1 Benzimidazole derivatives possessing the amino group 
In SAR, the amino group found at position 2 of the benzimidazole ring (19) (Figure 
1.27) plays a significant role in the antibacterial activities of the benzimidazoles. 
However, the presence of some substituents are a disadvantage, when the methyl 
groups exist at positions 5 and 6, the antibacterial activity of the benzimidazoles are 
decreased, and even no activity was recorded for the methyl derivatives against 
Pseudomonas aeruginosa. However the activity against the Gram +ve strains, 
Bacillus cereus ATCC 10876, Staphylococcus aureus ATCC 25923 and Sarcina 
lutea ATCC 9341, were about 1.5 to four fold less potent (MIC value 500 or 750 
μg/ml) than the unsubstituted derivatives (Podunavac-Kuzmanovic and Cvetkovic, 
2007).   
 
N
N
NH2 X = F, Cl
R= H, CH3
R1= H, CH3
X
R
R1
 
(19) 
Figure  1.27 Structure of 2-amino benzimidazole derivatives synthesised by Podunavac-
Kuzmanovic and Cvetkovic (2007)  
 
When a series of derivatives related to 2-amino benzimidazole and 2-methyl 
benzimidazole were synthesised to evaluate their inhibitory activities against the 
yeast Candida albicans, antimicrobial activity was detected. The 2-amino derivatives 
(20) shown in Figure 1.28 increased the activity in contrast to the methyl group 
which decreased activity. The compound exhibited less antifungal activity than 
fluconazole and ketoconazole (comparator control drugs), with 15 mm inhibition 
zone diameter (Kus et al., 2001). 
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(20) 
Figure  1.28 Structure of methyl 5-fluoro-6-(4-methylpiperidin- 1-yl)-1H-benzimidazole-2-
carbamate according to Kus et al. (2001)  
 
1.10.1.2 Bezimidazole derivatives possessing the sulfide group 
Some of the derivatives of benzimidazole that possess sulfide groups show 
inhibitory activities against Helicobacter spp. with minimum bactericidal 
concentrations (MBCs) of 0.5 - 4 μg/mL (Kuhler et al., 2002).  
The derivatives of 4,6-dichloro(bromo)-2-(4-nitrobenzylthio)-1H-benzimidazole (21) 
as shown in Figure 1.29, displayed antibacterial activity against all selected Gram 
+ve bacteria; Staphylococcus aureus ATCC 6538P, Staphylococcus. aureus NCTC 
4163, Bacillus stearothermophilus ATCC 7953, Bacillus subtilis ATCC 6633 and 
Bacillus cereus ML 98 with MICs within the range of  0.78–50 μg/ml, and also were 
more potent than nitrofurantion (control drug) by 4x - 32x except against 
Enterococcus faecalis ATCC 29212, which they were, respectively, 2 and 4 times 
less potent against (Andrzejewska et al., 2004). 
N
H
N
S
NO2R
R1
R = R1 = Cl or Br  
(21) 
Figure  1.29 4,6-Dichloro(bromo)-2-(4-nitrobenzylthio)-1H-benzimidazole derivatives studied 
by Andrzejewska et al. (2004)  
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Several 2-[benzimidazol-2-yl-sulfanyl]acetyl amidino]thiazole derivatives, when 
tested against Micrococcus luteus, Bacillus cereus, Staphylococcus aureus, Proteus 
vulgaris, Salmonella typhimurium, Escherichia coli, Candida albicans and Candida 
globrata, showed significant levels of activity (MICs within the range of 3.9-250 
μg/mL) (Kaplancikli et al., 2004). 
Some other analogues of omeprazole also showed some eukaryotic efflux pump 
inhibitor properties, and when combined with the norfloxacin, the MIC of the drug 
decreased by 4-16 times. It was also concluded that the compound (22) (Figure 
1.30), was more effective than omeprazole, and particularly in restoring the 
bactericidal activity of norfloxacin over a prolonged period (Vidaillac et al., 2007). 
 
(22) 
Figure 1.30 7-Chloro-4-(((5-methoxy-1H-benzo[d]imidazol-2-yl)sulfinyl)methyl)pyrrolo[1,2-
a]quinoxaline according to Vidaillac et al. (2007) 
 
1.10.1.3 Benzimidazole possessing N-alkyl and N-acyl derivatives 
The results of a study by Das et al. (2005) found that the N-linked benzimidazole 
(23,24) as shown in Figure 1.31, showed antibacterial activities (MIC values within 
the range of MICs 16- ≥32 μg/ml), comparable to C-linked benzimidazole, against 
selected strains; Mycobacterium smegmatis MTCC 006; S. aureus ATCC 29213 
(MSSA); S. aureus ATCC 49951, S. aureus ATCC 33591 (MRSA); Enterococcus. 
faecalis ATCC 29212; Enterococcus. faecalis NCTC 12201 Enterococcus. faecium 
NCTC 12202 (VREfm) (Das et al., 2005). 
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CN
H
CN
R= H, CH3  
  (23)      (24) 
Figure  1.31 Structure of 1,2 disubstituted benzimidazole derivatives according to Das et al. 
(2005) (Das et al., 2005) 
 
In order to investigate the antimicrobial activities further, some of the N-alkyl and N-
acyl derivatives (25) (Figure 1.32) were tested against some fungal strains and the 
research concluded that the presence of the isopropyl group at position-1 helped in 
enhancing sufficient amount of antifungal activity against Aspergillus niger, 
Aspergillus flavus, Alternaria alternata and Fusarium oxysporum (zone of inhibition 
within the range of 40-50 mm). A significant amount of antibacterial activity against 
Bacillus mecarium, Bacillus japonecum and Pseudomonas fluorescence was shown 
by the butyl (zone of inhibition within the range of 14-18 mm) and cinnamate 
derivatives (zone of inhibition within the range of 10-18 mm) (Pawar et al., 2004). 
 
R=(CH3)2CH
R=CH3(CH2)2CH2
R=C6H5CH=CHCON
N
R
N
S
 
(25) 
Figure  1.32 Structure of thiazolyl-benzimidazole derivatives according to Pawar et al. (2004)  
 
Two compounds of series 4-(5,6-dichloro-1H-benzimidazole-2-yl)-N-substituted 
benzimidazole derivatives (26) (Figure 1.33) possessed antibacterial activity with 
MIC values of just 3.12 μg/mL against S. aureus, methicillin-resistant S. aureus and 
methicillin-resistant S. epidermidis (Ozden et al., 2004). 
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N
N OCl
Cl
Cl
NH
N
H CH3
R
R= H, CH3  
(26) 
Figure  1.33 Structure of 4-(5,6-dichloro-1H-benzimidazole-2-yl)-N-substituted 
benzamidazole derivatives according to Ozden et al. (2004)  
 
A series of 1,2,4-triazalo[ 2,3-a] benzimidazoles (27) displayed antibacterial as well 
as the antifungal activities. Their activity improved with an increase in the bulkiness 
of the introduced alkyl groups to position-1 and 2. The most active derivatives are 
shown in Figure 1.34 ( 1 zone of inhibition 6-18 mm) (Mohamed et al., 2006).  
N
N
N
R
N
SR1
R R1
allyl CH3
C2H5 C2H5
allyl C2H5
C2H5 allyl
allyl allyl  
(27) 
Figure  1.34 Structure of 1,2,4-triazalo[ 2,3-a] benzimidazole derivatives synthesised by 
Mohamed et al. (2006)   
 
Some 2-(6-flurochroman-2yl)-1-alkyl/ acyl/ aroyl 1H-benzimidazoles (28) as shown 
in Figure 1.35, have displayed promising antibacterial activity against Salmonella 
typhimurium (MICs within the range of MIC 200 to > 1000) (Kumar et al., 2006).  
(28)
N
N O
R
F
R= CH3, C2H5, C3H7, C4H9, -CO-O-C2H5,
-CO-O-tert -Butyl, -CO-Phenyl, -SO2-CF3, -
SO2-Phenyl, -SO2-C6H4-Me-p, -Benzyl,
p-Fluorobenzyl, p-Bromobenzyl, p-
Methylbenzyl, p-ter t-Butylbenzyl  
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Figure  1.35 Structure of 2-(6-flurochroman-2yl)-1-alkyl/ acyl/ aroyl 1H-benzimidazoles 
studied by Kumar et al. (2006)  
1.10.1.4 Benzimidazole complexes 
According to a recent study by some US researchers, clay which contained iron 
showed antibacterial activity against E. coli. They believed that Fe2+ ions 
overwhelmed the bacteria's outer membranes and oxidised inside the cells to 
produce lethal hydroxyl (OH) radicals. This indicates that the complexes of iron 
metal were capable of inhibiting the bacteria (Cartwright, 2011). In addition, silver 
ion has been known as an antimicrobial agent from ancient times, and have been 
used for treatment infections of burns, open wounds, and chronic ulcers (Atiyeh et 
al., 2007). Likewise benzimidazole itself has a broad spectrum of biological activity. 
Therefore, a complex of silver ions with benzimidazole could be useful as an 
antimicrobial agent. Silver in the metallic state is not active, but if present in an 
aqueous environment, it will then be as an ion which can then demonstrate activity 
against microbes (Cooper, 2004). Silver ions interact with a wide range of 
components of bacterial and fungal cells, resulting in inhibition of the microbial cells 
at very low concentrations. They do not possess a single mode of action; they can 
inactivate the vital enzymes by reacting with the thiol group, or prevent DNA 
replication by interaction with DNA. However, silver ions as metal with ligand 
contain sulfur will form a new and small molecule that causes changes on the cell 
structure (Matsumura et al., 2003).   
There are also reports on the synthesis and antimicrobial activity of some other 
transition metal complexes of benzimidazoles.(29) For example, some novel 
benzimidazole complexes of silver were synthesised and found to be effective 
against a series of bacteria and fungi. The compounds exhibited good activity 
against the selected bacteria for the chloro derivatives; Staphylococcus aureus 
ATCC 29213, Enterococcus faecalis ATCC 29212, Escherichia coli ATCC 25922 
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and Pseudomonas aeruginosa ATCC 27853, (MIC ≤100 μg/ml), while the bromo 
derivatives were most active against the selected fungi; Candida albicans and 
Candida tropicalis (MIC12.5- 25 μg/ml) (Figure 1.36) (Özdemir et al., 2010). For this 
reason, one of the aims of this project was to synthesise silver complexes of 
benzimidazole to explore the activity of these complexes against selected 
microorganisms. 
N
N
R1
R2
R
R R1 R2
-CH2-CH2-O-C2H5 AgCl Ph-CH-Ph
3,4,5-tri-methoxyphenyl AgCl Ph-CH-Ph
-CH2-CH2-1,3-dioxane AgBr 2,4,6-tri-methyl-phenyl
-CH2-CH2-1,3-dioxane AgBr -CH2-CH2-O-CH3  
(29) 
Figure  1.36 Structure of benzimidazol-2-ylidene carbene complexes of Ag(I) screened by 
Özdemir et al. (2010)  
 
Many studies have also shown that the presence of metals connected with 
benzimidazole increase the activity of these compounds against a number of 
microorganisms. The copper complex (30) (Figure 1.37) was found to be active 
against S. aureus (with zone of inhibition of 19 mm), E. coli (with zone of inhibition 
of 17 mm) and A. niger (with zone of inhibition of 19 mm), and that can be due to 
the effect of the copper ion on the normal cell processes (Arjmand et al., 2005). 
 
(30) 
Figure  1.37 Structure of Benzimidazole derived Cu(II) complex studied by Arjmand et al. 
(2005)  
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ZnL2Cl2 are complexes of zinc(II)chloride with 1-benzylbenzimidazole derivatives (L) 
(see Figure 1.27). Their biological activity showed that the Zn(II) complexes were 
more effective than the starting ligands against all the bacteria tested with the 
following results; Bacillus cereus ATCC 10876 (MIC 125- ≥500 μg/ml), 
Staphylococcus aureus ATCC 25923 (MIC 60- 250 μg/ml) and Sarcina lutea ATCC 
9341 (MIC 60-250 μg/ml) and one gram negative isolate: Pseudomonas aeruginosa 
ATCC 27853 (MIC 125-250μg/ml) (Podunavac-Kuzmanovic and Cvetkovic, 2007). 
 
 
A series of Co(II) and Zn(II) complexes of benzimidazole (bz) were tested against 
various bacteria. The complex [Zn(bz)2Cl2] 0.5 H2O displayed antibacterial activity 
against Micrococcus luteus ATCC 9341 with zone of inhibition 10.4 mm (MIC value 
1.6 μg/ml), whereas complex[Co(bz)2Br2] showed no inhibition. Also, both 
complexes showed antibacterial activity against E. coli ATCC 6538P with zone of 
inhibition of 10 and 11.1 mm (MICs value 1.6 and 3.9μg/ml), respectively (Lopez-
Sandoval et al., 2008). 
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1.11 Programme of study 
1.11.1 Design of an antimicrobial inhibitor 
As mentioned in Section 1.4, the mechanisms of action of antibiotics include the 
following; inhibition of cell wall synthesis, protein synthesis, synthesis of nucleic 
acids, the metabolic pathways and cell membrane functions (Hooper and 
Rubinstein, 2003, Lorian, 2005, Greenwood et al., 2007, Pelczar et al., 2009, 
Bauman, 2010, Karaiskos et al., 2013, Rogers et al., 2013). The mode of action of 
antifungal agents (Section 1.5) include the following: fungal ergosterol synthesis 
inhibitors, squalene epoxidase inhibitors, ergosterol disruptors, glucan synthesis 
inhibitors, chitin synthesis inhibitors, nucleic acid synthesis inhibitors, protein 
synthesis inhibitors, and microtubules synthesis inhibitors (Kathiravan et al., 2012). 
If further compounds were found to selectively block one of these targets, it could 
have potential as a chemotherapeutic drug.  
It has been reported that the basic antimicrobial activity of the benzimidazoles is 
due to the presence of an amino group at position 2 of the benzimidazole ring 
(Podunavac-Kuzmanovic et al., 1999). Disruption of the growth of bacteria through 
treatment with compounds with substitution of 2-alkylamine (Figure 1.38) could 
provide a new approach to antimicrobial inhibitors 
N
H
NR
Substitution at
5-position
Methylation at
1-position
Substitution at
2-position
R1
R : H, CH3, OCH3, Cl, Br, F, CN, NO2
R1 : CH2NH2, (CH3)CHNH2, CH2OH,COOH, CH2Cl, CH2SH  
Figure  1.38 1,2 and 5 benzimidazole derivatives available for this project 
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The biological activity of (1H-benzo[d]imidazol-2-yl)methanol FAS22, as mentioned 
in Table 2.4 (Section 2.4.3), was previously studied. However, its antimicrobial 
activity was not investigated. Furthermore, the oxidation of 2-
methanolbenzimidazole derivatives produces 2-carboxylic acid benzimidazole 
derivatives, which will decrease the pH, and may enhance the inhibition activity 
against different microorganisms, according to a study done by Talley et al. (2008), 
which found that the carboxylic analogue (1H-benzo[d]imidazole-2-carboxylic acid), 
inhibited the D-amino acid oxidase (Barden et al., (2008)). Therefore this series of 
compounds are of interest for this study. 
It has been found that the N-linked-benzimidazole showed antibacterial activities 
comparable to C-linked-benzimidazole (Das et al., 2005). Thus, the alkylation of 5-
substituted bezimidazole, and 2-methanolbenzimidazole derivatives could produce 
compounds which have antimicrobial activity (Figure 1.38).  
It has also been found that the antibacterial activities of the chlorinated compounds 
are greater than the non-chlorinated compounds (Nandi et al., 1984). According to 
this, the chlorine atom in 2-chloromethylbenzimidazole and its derivatives could 
enhance the antimicrobial activity of benzimidazole (Figure 1.38).  
According to some literature which showed promising results for the silver ion, the 
silver complexes could be enhaced the biological activity of the benzimidazole as a 
ligand (Özdemir et al., 2010). 
Review of the literature therefore suggests that there is scope for the design of 
benzimidazole derivatives with antimicrobial activity, by including a number of 
different functional groups. 
 
1.11.2 Aims and objectives 
The focus of this project was to synthesise derivatives of benzimidazole with a 
degree of antimicrobial activity. A detailed study of the structure-activity relationship 
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of these derivatives will inform the design of more potent compounds. The activity 
will then be investigated against a range of pathogens to see if the compound has 
an enhanced spectrum of activity, relative to that of related structures. Efforts will 
then be made to enhance the activity by further chemical modification.  
The objectives for the project included:  
? Literature review of use of benzimidazole derivatives in medicinal chemistry 
and antimicrobial chemotherapy; 
? Design, synthesis and characterisation (m.p., IR, 1H and 13C NMR, mass 
spectrometry, and elemental analysis), of a series of benzimidazole 
derivatives with varying functional groups at positions 1, 2 and 5 (Figure 
1.39-42); 
? Synthesis of some silver complexes as well. 
? Developing the optimum method for the biological screening of the new 
compounds. 
? Biological evaluation of the compounds against a bacterial reference 
collection that include 15 strains of Staphylococcus Spp. (inc  2 x S. aureus, 
8 x MRSA, 2 x EMRSA, 2 x S. epidermidis and 1 x S. haemolyticus). 5 
strains of E. coli, 3, 4 strains of Ps. aeruginosa, 1 strain of Serratia 
marcescens, and 1 strain of Burkholderia cepacia. 
? Biological evaluation of the compounds against a fungal reference collection 
that include 4 unicellular fungi (4 x Candida), 6 filamentous fungi, (1x 
Absidia), (2 x Aspergillus), (1 x Mucor), (1 x Penicillium ), (1 x 
Syncephalastrum).  
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Figure  1.39 Group 1 target; benzimidazole derivatives  
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Figure  1.40 Group 2 target; 2-methanol benzimidazole derivatives 
 
 
Figure  1.41 Group 3 target; silver benzimidazole complexes 
 
 
 
Figure  1.42 Group 4 target; N-bromoalkyl-benzimidazole derivatives 
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2 MATERIALS AND METHODS 
 
The following section is an index of all compounds synthesised during this project, 
with full analysis data. 
2.1 Index of compounds synthesised and purified 
2-Aminomethylbenzimidazole dihydrochloride (FAS1) ........................................................................... 62 
(5-Methyl-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS2) .............................................. 62 
(5-Chloro-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS4) ............................................... 63 
(5-Bromo-1H-benzimidazole-2-yl)methanamine (FAS5) ......................................................................... 64 
(5-Fluoro-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS6)................................................ 64 
5-Nitro-2-aminomethylbenzimidazole dihydrochloride (FAS7) ............................................................... 65 
(S)-1-(1H-Benzimidazole-2-yl)ethanamine dihydrochloride (FAS8) ......................................................... 66 
(S)-1-(5-methyl-1H-benzimidazole-2-yl)ethanamine dihydrochloride (FAS9) ......................................... 66 
(S)-1-(5-Chloro-1H-benzimidazole-2-yl)ethanamine dihydrochloride (FAS11) ........................................ 67 
(S)-1-(5-Bromo-1H-benzimidazole-2-yl)ethanamine (FAS12) .................................................................. 67 
(S)-1-(5-Fuoro-1H-benzimidazole-2-yl)ethanamine (FAS13) ................................................................... 68 
(S)-1-(5-Nitro-1H-benzimidazole-2yl)ethanamine (FAS14) ...................................................................... 68 
1H-Benzimidazole (FAS15)....................................................................................................................... 69 
5-Methylbenzimidazole (FAS16) .............................................................................................................. 69 
5-Methoxy-1H-benzo[d]imidazole (FAS17) ............................................................................................. 70 
5-Chloro-1H-benzo[d]imidazole (FAS18) ................................................................................................. 70 
5-Bromo-1H-benzo[d]imidazole (FAS19) ................................................................................................. 71 
5-Fluoro-1H-benzo[d]imidazole (FAS20) ................................................................................................. 71 
5-Nitro-1H-benzo[d]imidazole (FAS21) ................................................................................................... 72 
1H-Benzo[d]imidazole-5-cyano (FAS51) .................................................................................................. 72 
1-Methyl-5-nitro-1H-benzo[d]imidazole (FAS58) .................................................................................... 73 
(1H-benzimidazol-2-yl)-methanol (FAS22) .............................................................................................. 73 
((5-Methyl-1H-benzimidazole-2-yl)-methanol) (FAS23) .......................................................................... 74 
((5-Methyl-1H-benzimidazole-2-yl)-methanol) (FAS24) .......................................................................... 75 
5-Chloro-1H-benzimidazol-2-yl)-methanol (FAS25)................................................................................. 75 
(5-Bromo-1H-benzimidazole-2-yl)methanol (FAS26) .............................................................................. 76 
(5-Fluoro-1H-benzimidazol-2-yl)-methanol (FAS27) ................................................................................ 76 
(5-Nitro-1(3)H-benzimidazol-2yl)-methanol (FAS28)............................................................................... 77 
2-(Hydroxymethyl)-1H-benzo[d]imidazole-5-cyano (FAS52) ................................................................... 78 
2-Carboxylic acid benzimidazole (FAS29) ................................................................................................ 78 
5-Methyl-1H-benzimidazole-2-carboxylic acid (FAS30) ........................................................................... 79 
5-Methoxy-1H-benzimidazole-2-carboxylic acid (FAS31) ........................................................................ 80 
5-Chloro-1H-benzimidazole-2-carboxylic acid (FAS32) ............................................................................ 80 
5-Bromo-1H-benzimidazole-2-carboxylic acid (FAS33) ........................................................................... 81 
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5-Fluoro-1H-benzimidazole-2-carboxylic acid (FAS34) ............................................................................ 81 
5-Nitro-1H-benzimidazole-2-carboxylic acid (FAS35) .............................................................................. 82 
(N-Methyl-1H-benzimidazole-2-yl)-methanol (FAS36) ............................................................................ 83 
(N-Methyl-5-methyl-1H-benzimidazole-2-yl)-methanol (FAS37) ............................................................ 83 
(N-Methyl-5-chloro-1H-benzimidazole-2-yl)-methanol (FAS38) ............................................................. 84 
(N-Methyl-5-bromo1H-benzimidazole-2-yl)-methanol (FAS40) .............................................................. 85 
(N-Methyl-5-fluoro 1H-benzimidazole-2-yl)-methanol (FAS41) .............................................................. 86 
(N-Methyl-5-methoxy-1H-benzimidazole-2-yl)-methanol (FAS42).......................................................... 86 
(N-Methyl-5-nitro-1H-benzimidazole-2-yl)-methanol (FAS50) ................................................................ 87 
N-methyl -5-chloro-2-methoxymethyl-1H-benzimidazole (FAS39) ......................................................... 88 
2-Chloromethylbenzimidazole (FAS43) ................................................................................................... 89 
2-(Chloromethyl)-5-methyl-1H-benzimidazole (FAS44) .......................................................................... 89 
2-(Chloromethyl)-5-methoxy-1H-benzimidazole (FAS45) ....................................................................... 90 
2-(Chloromethyl)-5-chloro-1H-benzimidazole (FAS46) ........................................................................... 90 
2-(Chloromethyl)-5-bromo-1H-benzimidazole (FAS47) ........................................................................... 91 
2-(Chloromethyl)-5-flouro-1H-benzimidazole (FAS48) ............................................................................ 92 
2-(Chloromethyl)-5-nitro-1H-benzimidazole (FAS49) .............................................................................. 92 
2-(Chloromethyl)-5-cyano-1H-benzimidazole (FAS53) ............................................................................ 93 
2-Ethyl-1H-benzo[d]imidazole (FAS54) .................................................................................................... 93 
2-Ethyl-5-nitro-1H-benzo[d]imidazole (FAS55) ....................................................................................... 94 
(1H-Benzo[d]imidazol-2-yl)methanethiol (FAS56) ................................................................................... 95 
(5-Nitro-1H-benzo[d]imidazol-2-yl)methanethiol (FAS57) ...................................................................... 95 
5-Nitro-1H-benzo[d]imidazole 3-oxide (FAS59) ....................................................................................... 96 
6-Chlorobenzo[d]oxazol-2(3H)-one (FAS61) ............................................................................................ 97 
6-Nitrobenzo[d]oxazol-2(3H)-one (FAS62) .............................................................................................. 97 
6-Chlorobenzo[d]oxazole (FAS63) ........................................................................................................... 98 
Benzo[d]thiazol-2-ylmethanol (FAS65) .................................................................................................... 98 
1-(2-Bromoethyl)-2-(chloromethyl)-1H-benzo[d]imidazole (FAS67) ....................................................... 99 
1-(10-bromodecyl)-2-(chloromethyl)-1H-benzo[d]imidazole (FAS68) ..................................................... 100 
Silver complex of 1H-benzo[d]imidazole-2-carboxylic acid (FAS69) ........................................................ 101 
Silver complex of 5-bromo-1H-benzo[d]imidazole (FAS70) ..................................................................... 101 
Silver complex of 1H-benzo[d]imidazole-2-carboxylic acid (FAS71) ........................................................ 102 
Silver complex of bis(5-methyl- 1H-benzo[d]imidazole-2-carboxylic acid) (FAS72) ................................ 102 
Silver complex of bis(5-bromo-1H-benzo[d]imidazole) (FAS73) .............................................................. 103 
Silver complex of bis(5-nitro- 1H-benzo[d]imidazole) (FAS74) ................................................................ 103 
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2.2 Materials for synthesis 
2.2.1 Reagents 
All reagents were purchased from Sigma Aldrich, Alfa Aesar, Goss Scientific or 
Merck unless otherwise stated. All solvents were purchased from Fisher and were 
of technical grade with the exception of dichloromethane and acetone, which were 
HPLC grade. All purchased reagents were used without further purification unless 
stated otherwise.  
2.2.2 Purification of Solvents 
All solvents were used without further purification except dichloromethane, which 
was distilled from anhydrous calcium chloride and stored over 4 Å molecular sieves 
(Sigma Aldrich, UK). Dimethylformamide was stored over 3 Å molecular sieves. 
Ethanol and chloroform were stored over 4 Å molecular sieves overnight before use. 
Triethylamine was heated under reflux and distilled from calcium chloride before 
storing over potassium hydroxide. Diethyl ether was stored over sodium wire. 
2.2.3 Instrumentation   
2.2.3.1 Nuclear magnetic spectroscopy (NMR) 
1H and 13C NMR spectra were recorded using a Bruker DPX400 spectrometer. 
Coupling constants are given in Hertz (Hz). Deuterated solvents were obtained from 
Goss Scientific Instruments. Deuterated chloroform was stored over 4 Å molecular 
sieves. D6-DMSO and D2O were stored in silica gel desiccators. For 1H NMR 
experiments, typically the sample (~20 mg) was dissolved in the appropriate 
deuterated solvent (0.7 ml). For 13C NMR experiments, typically the sample (~40 
mg) was dissolved in the appropriate deuterated solvent (0.7 ml). 
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2.2.3.2 Infrared spectra (IR) 
IR of solid samples were recorded from KBr discs using 5 mg of dry sample and 35 
mg of dry KBr. Spectra were recorded on a Nicolet 140 FTIR spectrophotometer in 
the range 4000- 400 cm-1. 
2.2.3.3 Mass spectrometry (MS) 
Spectra were acquired by electron impact using an AEI MS902 mass spectrometer 
operated by Andrew Healey in the analytical centre of the University of Bradford. 
2.2.3.4 Melting points (m.p.) 
These were determined using an electronic melting point apparatus (Gallenkamp, 
Germany) and are uncorrected.  
2.2.3.5 Elemental analysis  
Elementalnalysis was carried out by the CHN microanalysis service using 2 mg of 
the sample, (MEDAC LTD, Analytical and chemical consultancy services, Chobham, 
Surrey, UK). 
2.2.4 Chromatography 
2.2.4.1 Thin layer chromatography (TLC) 
TLC was performed on silica gel plates (60 F254, Plastic sheets from MERCK) with 
UV indicator. Developed plates were visualised under UV light (366 nm).  
2.2.4.2 Column chromatography  
Column chromatography was performed using Silica gel, high-purity grade, pore 
size 60 Å, 70-230 mesh (Material Harvest, UK). 
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2.3 Procedures for synthesis 
2.3.1 General procedure for the synthesis of 2-substituted 
benzimidazoles 
 
The general method for the synthesis of benzimidazoles was based on the Phillips 
procedure (Phillips, 1928). The appropriate acid (1 equivalent) was added to a 
magnetically stirred solution of a 1,2-phenylenediamine (1 equivalent) and aqueous 
hydrochloric acid (typically 5.5 M). The mixture was heated under reflux until the 
1,2-phenylenediamine was no longer detectable by NMR or until consumption of the 
starting materials had ceased. The characteristically bright blue reaction mixture 
was cooled to room temperature. The mixture was allowed to stand for several 
weeks until the desired 2-substituted benzimidazole precipitated out in its 
dihydrochloride salt form. The resulting solid was washed with acetone (3 x 20 ml) 
and recrystallised from water. Alternatively the reaction mixture was concentrated to 
one third under reduced pressure and cooled to produce the desired benzimidazole 
as a dihydrochloride salt. The free base was obtained by neutralisation of the 
reaction mixture with triethylamine or excess ammonia solution followed by 
extraction with ethyl acetate. The extract was evaporated to dryness and the solid 
residue was recrystallised from an appropriate solvent. 
2.3.2 General Procedure for the synthesis of N-Methylbenzimidazoles 
General method for the synthesis of N-methylbenzimidazoles was based on the 
Harisha procedure (Harisha et al., 2009). A solution of 5-substituted-(1H-
benzimidazole-2-yl)-methanol (0.01 mol) and anhydrous potassium carbonate (0.01 
mol) in dry acetone (35 ml) was stirred for 30 min. Then, iodomethane (0.01 mol) 
was added to the mixture and the mixture was then stirred for 24 hours at room 
temperature. The reaction mixture was concentrated to 25% and then poured into 
ice-cold water. The solid was filtered and washed with 50% HCl to neutralize excess 
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potassium carbonate. Then, the solid was washed with cold water (100 ml) and with 
aqueous ethanol. The desired product was then dried and recrystallized from an 
appropriate solvent.   
2.3.3 General Procedure for the synthesis of N-bromoalkyl-2-
(chloromethyl)-1H-benzo[d]imidazole  
General method for the synthesis of these derivatives was based on Meyers 
procedure (Meyers et al., 2005). 2-Chloromethylbenzimidazole derivatives (10 
mmol) were combined with an excess of potassium hydroxide (13 mmol), and 
dissolved in ethanol (20 ml). An ethanol solution of dibromoalkane derivatives (1,4-
1,6-1,8-1,10-1,12) (15 mmol) was added dropwise to the 2-
chloromethylbenzimidazole solution, and the combined mixture was heated under 
reflux for 48 hrs. Water (50 ml) was added to the mixture, and then the product 
extracted with CHCl3 (2 X 100 ml), then the organic phase was collected and dried 
over MgSO4. The solvent was removed, and the remaining solid was purified by 
column chromatography (silica gel, 2:8 hexane/ ethyl acetate) yielding a light yellow 
solid. 
2.3.4 General Procedure for the synthesis of silver complexes of 
benzimidazole  
The general method for the synthesis of the silver complexes of benzimidazoles 
was based on the Podunavac-Kuzmanovic procedure (Podunavac-Kuzmanovic et 
al., 2004). A solution of AgNO3 (1 equivalent) in ethanol (5 ml) was added to a 
solution of 5-subistituted-1H-benzo[d]imidazole-2-carboxylic acid FAS29-30,33,35 
(1 or 2 equivalent) in ethanol (5 ml) to form 1:1 and 1:2 M:L complexs. The reaction 
mixture was stirred at 50 ºC for 2 hrs. The resulting precipitate was filtered off, 
washed with diethyl ether, followed by warm ethanol. The formed complex was kept 
under dry conditions.  
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2.3.5 Synthesis of 2- aminomethylbenzimidazole derivatives 
 2-Aminomethylbenzimidazole dihydrochloride (FAS1) 
 
The compound FAS1 was prepared according to general procedure 2.3.1, using 
1,2-phenylenediamine (10.80 g, 0.10 mol) and glycine (12.65 g, 0.15 mol) dissolved 
in hydrochloric acid (70 ml, 5.5 M). The mixture was heated under reflux for 300 
hours. The reaction mixture was then cooled to room temperature and left to 
evaporate slowly over several days. The resulting green crystals were washed with 
acetone. 2-Aminomethylbenzimidazole dihydrochloride was obtained as a grey 
powder (19.56 g; 89%), m.p. 270-272 ºC (lit., 268-270 ºC) (Cescon and Day, 1962). 
δH (400 MHz; DMSO-d6) 7.85 (2H, dd, 3J  6.00, 4J 3.20, 4-H, 7-H), 7.53 (2H, dd, 3J  
6.40, 4J 3.20, 5-H, 6-H), 4.59 (2H, s, CH2), 9.287 (2H, br, s, NH, NH2,); δC (400 MHz; 
DMSO-d6) 150.16 (C-2), 132.20 (C-3a, C-7a), 125.47 (C-5, C-6), 114.48 (C-4, C-7), 
38.78 (C-1’); υmax /cm-1 (KBr) 3481 (N-H), 3053 (C-H, sp2), 2850 (C-H, sp3), 1485 
and 1424 (C-H, bend). 
 
 (5-Methyl-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS2) 
 
(5-Methyl-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS2) was 
prepared according to general procedure 2.3.1, using 4-methyl-1,2-
phenylenediamine (12.22 g, 0.1 mol), and glycine (11.26 g, 0.1 mol) dissolved in 
hydrochloric acid (70 ml, 5.5 M). The mixture was heated under reflux for 170 hours. 
(5-Methyl-1H-benzimidazole-2-yl)methanamine dihydrochloride was isolated as a 
blue solid (12.05 g, 52% ) after standing the reaction mixture for several weeks, 
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m.p. 208-210 °C(lit., 208-210 ºC)(Donkor, 2007). δH (DMSO-d6) 9.34 (2H, br, s, 
NH2), 8.37 (1H, br, s, NH), 7.38 (1H, d, 3J 8.40, 7-H), 7.65 (1H, s, 4-H), 7.73 (1H, d, 
3J 8.40, 6-H), 4.58 (2H, s, C-1’), 2.48 (3H, s, CH3); δC (DMSO-d6) 168.1 (C-2), 146.2 
(C-3a), 138.6 (C-7a), 133.3 (C-6),128.4 (C-5), 126.4 (C-4), 113.8 (C-7), 34.2 (C-1’), 
20.9 (CH3); υmax /cm-1 (KBr) 3420 (N-H), 2994 (C-H, sp2), 2863 (C-H, sp3). 
 
 (5-Chloro-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS4) 
 
(5-Chloro-1H-benzimidazole-2-yl)methanamine (FAS4) was prepared according to 
general procedure 2.3.1, using 4-chloro-1,2-phenylenediamine (3.50 g, 0.025 mol) 
and glycine (2.25 g, 0.03 mol) dissolved in hydrochloric acid (14 ml, 5.5 M). The 
mixture was heated under reflux for 216 hours. The reaction mixture was filtered to 
remove a black solid which had formed during the reaction. The filtrate was left to 
evaporate slowly whereupon (5-chloro-1H-benzimidazole-2-yl)methanamine 
dihydrochloride (2.51 g, 39%) was recovered as a brown solid, m.p. 252-254 °C (lit., 
251-252 ºC)(Donkor, 2007). δH (DMSO-d6) 8.99 (2H, br, s, NH2), 6.52 (1H, br, s, 
NH), 7.49 (1H, d, 4J 5.6, 4-H), 8.17 (1H, d, 3J 9.2, 7-H), 7.83 (1H, dd, 3J 8.80, 4J 
2.40, 6-H), 4.54 (2H, s, 1’-H); δC (DMSO-d6) 156.6 (C-2), 140.15 (C-3a), 137.51 (C-
7a), 130.2 (C-5), 133.62 (C-6), 130.50 (C-7), 128.18 (C-4), 35.32 (C-1’); υmax /cm-1 
(KBr) 3500 (N-H), 3040 (C-H, sp2), 2836 (C-H, sp3), 1113 C-Cl. 
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(5-Bromo-1H-benzimidazole-2-yl)methanamine (FAS5) 
 
 
(5-Bromo-1H-benzimidazole-2-yl)methanamine (FAS5) was prepared using general 
procedure 2.3.1, using 4-bromo-1,2-phenylenediamine (3.74 g, 0.02 mol) and 
glycine (2.25 g, 0.03 mol) dissolved in hydrochloric acid (14 ml, 5.5 M). The reaction 
was heated under reflux for 216 hours and then was left to evaporate slowly until 5-
bromo-1H-benzimidazole-2-yl)methanamine which was isolated as brownish orange 
precipitate (1 g, 22%), m.p. 258-260 °C (lit., 256-258 ºC) (Gillard.et al.,2004). δH 
(DMSO-d6) 9.093 (2H, br, s, NH2), 8.815 (1H, br, s, NH), 7.36 (1H, d, 4J 4.8, 4-H), 
8.11 (1H, d, 3J 8.8, 7-H), 7.77 (1H, dd, 3J 9.20, 4J 1.60, 6-H), 4.38 (2H, s, 1’-H); δC 
(DMSO-d6) 168.98 (C-2), 149.58 (C-3a, C-7a), 129.41 (C-6),  126.55 (C-4), 122.51 
(C-7), 106.86 (C-5), 36.30 (C-1’); υmax /cm-1 (KBr) 3233 (N-H), 3056 (C-H, sp2), 2852 
(C-H, sp3), 1074 C-Br. MS (EI): m/z 226 (M+., 100%) 228 (M+2, 100%). 
 
   
(5-Fluoro-1H-benzimidazole-2-yl)methanamine dihydrochloride (FAS6) 
 
(5-Fluoro-1H-benzimidazole-2-yl)methanamine (FAS6) was prepared using general 
procedure 2.3.1, using 4-fluoro-1,2-phenylenediamine (1.50 g, 0.012 mol) and 
glycine (1.13 g, 0.015 mol) dissolved in hydrochloric acid (60 ml, 5.5 M). The 
reaction was heated under reflux for 216 hours. The resulting bright blue reaction 
mixture was left to crystallise at room temperature. After one week green crystals of 
(5-fluoro-1H-benzimidazole-2-yl)methanamine dihydrochloride (0.56 g, 16%) were 
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recovered, m.p. 262-264 °C (lit., 258-262 ºC)(Donkor, 2007).. δH (DMSO-d6) 12.64 
(2H, br, s, NH2), 9.21 (1H, br, s, NH), 7.69 (1H, dd, 3J 8.80, 4J 2.40,  7-H), 7.82 (1H, 
dd, 3J 8.80, 4J 4.80, 4-H), 7.34 (1H, td, 3J 9.40, 4J, 2.40, 6-H), 4.51 (2H, s, CH2). δC 
(DMSO-d6) 164.30 (C-5), 149.10 (C-2), 134.4 (C-3a), 129.70 (C-7a), 115.3 (C-7), 
113.2 (C-6), 106.3 (C-4), 34.5 (C-1’); υmax /cm-1 (KBr) 3314 (N-H), 2928 (C-H, sp2), 
2858 (C-H, sp3), 1139 (C-F). 
   
5-Nitro-2-aminomethylbenzimidazole dihydrochloride (FAS7) 
 
5-Nitro-2-aminomethylbenzimidazole dihydrochloride (FAS7) was prepared 
according to general procedure 2.3.1, using 4-nitro-1,2-phenylenediamine (7.65g; 
0.05 mol) and glycine (9.13 g; 0.125 mol) dissolved in hydrochloric acid (35 ml, 5.5 
M). The mixture was heated under reflux temperature for 300 hours. The bright 
orange reaction mixture was evaporated to dryness and (5-Nitro-1H-benzimidazole-
2-yl)-methylamine) (FAS7) was isolated as a bright orange solid (2.83 g, 21%); m.p. 
254- 256 ºC (lit., 248-251 ºC)(Donkor, 2007). δH (DMSO-d6) 10.51 (1H, br, s, NH), 
9.04 (2H, s, NH2), 8.43 (2H, d, 3J 10.00, 6-H & H-7), 8.10 (1H, s, 4-H), 4.41 (2H, s, 
CH2); δC (DMSO-d6) 152.81 (C-2), 143.9 (C-7a), 140.96 (C-5), 137.61 (C-3a), 
118.23 (C-6), 115.14 (C-7), 111.64 (C-4), 36.16 (CH2NH2); υmax /cm-1 (KBr); 3401 (N-
H), 2966 (C-H, sp2), 2851 (C-H, sp3), 1509 and 1350 (N-O); MS (EI): m/z 192 (M+., 
100%) 163 (M-CH2NH2). 
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2.3.6 Synthesis of 2-ethanaminebenzimidazole derivatives  
 
(S)-1-(1H-Benzimidazole-2-yl)ethanamine dihydrochloride (FAS8) 
 
(S)-1-(1H-Benzimidazole-2-yl)-ethylamine dihydrochloride (FAS8) was prepared 
according to general procedure 2.3.1 using 1,2-phenylenediamine (11.00 g, 0.102 
mol) and S-alanine (16.00 g, 0.18 mol) in hydrochloric acid (70 ml; 5.5 M). The 
mixture was heated under reflux for 144 hours after which time a further portion of 
1,2-phenylenediamine (5.00 g, 0.046 mol) was added and the mixture was heated 
under reflux for a further 120 hours. (S)-1-(1H-benzimidazole-2-yl)ethanamine was 
obtained as a blue solid (15.98 g, 67%), m.p. 138-140 °C (lit., 133-138 ºC) (Cescon 
and Day, 1962). δH (DMSO-d6) 7.82 (2H, dd, 3J  6.00, 4J 3.20, 4-H, 7-H), 7.52 (2H, 
dd, 3J  6.40, 4J 3.20, 5-H, 6-H), 4.83 (1H, d, 3J  6.80, CH), 1.83 (3H, d, 3J  6.80, CH3),  
9.37 (2H, br, s, NH, NH2,). δC (DMSO-d6) 146.91 (C-2), 131.67 (C-3a, C-7a), 125.67 
(C-5, C-6), 131.67 (C-4, C-7), 17.07 (C-1’), 40.44 (CH3). υmax /cm-1 (KBr) 3420(N-H), 
3033 (C-H, sp2), 2873 (C-H, sp3), 1617 and 1476 (C=C). 
 
(S)-1-(5-methyl-1H-benzimidazole-2-yl)ethanamine dihydrochloride (FAS9) 
 
(S)-1-(5-methyl-1H-benzimidazole-2-yl)ethanamine dihydrochloride (FAS9), was 
prepared according to general procedure 2.3.1 using 4-methyl-1,2-
phenylenediamine (6.10 g, 50.00 mmol) and L-alanine (5.34 g, 60.00 mmol) in 
hydrochloric acid (60 ml; 5.5 M). (S)-1-(5-methyl-1H-benzimidazole-2-yl)ethanamine 
dihydrochloride (6.00 g, 68%) was obtained  as a green solid, m.p. 212-214 °C (lit., 
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212-213 ºC) (Donkor, 2007). δH (DMSO) 7.71 (1H, d, 3J 8.00, 7-H), 7.62 (1H, s, 4-
H), 7.36 (1H, d, 3J 8.00, 6-H), 4.97 (1H, q, 3J 8.00, CH, (1’-H), 2.48 (3H, s, 5a-H), 
1.83 (3H, d, 3J 8.00, 2’-H); 9.41 (2H, br, s, NH, NH2,);  δC (DMSO-d6) 149.51 (C-2), 
135.63 (C-3a), 132.02 (C-7a), 130.01 (C-5), 127.18 (C-6), 114.05 (C-4), 113.70 (C-
7), 43.21 (C-1’), 21.11 (C-5a), 17.01 (C-2’); υmax /cm-1 (KBr) 3411 (N-H), 2979 (C-H, 
sp2), 2874 (C-H, sp3), 1625 and 1487 (C=N). 
 
(S)-1-(5-Chloro-1H-benzimidazole-2-yl)ethanamine dihydrochloride (FAS11) 
 
(S)-1-(5-Chloro-1H-benzimidazole-2-yl)ethanamine (FAS11) was prepared 
according to general procedure 2.3.1 , using 4-chloro-1,2-phenylenediamine (0.17 
g, 1.2 mmol), S-alanine (0.11 g, 1.23 mmol) and hydrochloric acid (20 ml, 5.5 M). 
The mixture was heated under reflux for 288 hours. The resulting dark brown 
solution was evaporated to dryness. (S)-1-(5-Chloro-1H-benzimidazole-2-
yl)ethanamine dihydrochloride was obtained as a dark brown solid (0.13 g. 41%); 
m.p. 154-156 °C (lit., 152-154 ºC)(Donkor, 2007). δH (DMSO-d6) 8.85 (1H, br, s, 
NH), 8.35 (2H, s, NH2),  7.83-7.54 (2H, m, 4-H, 7-H), 7.25 (1H, m, 6-H), 4.55 (1H, 
br, s, 1’-H), 1.39 (3H, m, 2’-H). δC (DMSO-d6) 153.03 (C-2), 135.76 (C-3a), 127.12 
(C-7a), 123.61 (C-5), 120.74 (C-6), 117.75 (C-7), 115.24 (C-4), 47.8 (C-1’), 16.11. 
   
(S)-1-(5-Bromo-1H-benzimidazole-2-yl)ethanamine (FAS12) 
 
(S)-1-(5-bromo-1H-benzimidazole-2-yl)ethanamine (FAS12) was prepared 
according to general procedure 2.3.1 using 4-bromo-1,2-phenylenediamine (0.22 g, 
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1.2 mmol), S-alanine (0.11 g, 1.23 mmol) and hydrochloric acid (20 ml, 5.5 M). The 
mixture was heated under reflux for 288 hours. The resulting dark brown solution 
was evaporated to dryness. (S)-1-(5-bromo-1H-benzimidazole-2-yl)ethanamine was 
obtained as a dark brown solid (0.07 g. 19%); m.p. 158-160 °C (lit., 160-162 ºC) 
(Gillard.et al.,2004) δH (DMSO-d6) 8.13 (1H, t, 3J 9.20, 7-H), 7.78 (1H, d, 3J 9.20, 6-
H), 7.33 (1H, d, 4J 4.40, 4-H), 4.73 (1H, m, 1’-H), 1.39 (3H, d, 3J 6.80, 2’). υmax /cm-1 
(KBr) 3401 (N-H), 3044 (C-H, sp2), 2847 (C-H, sp3), 1621 and 1471 (C=N). MS (EI): 
m/z 240 (M+., 100%) 242 (M+2, 100%). 
 
(S)-1-(5-Fuoro-1H-benzimidazole-2-yl)ethanamine (FAS13) 
 
(S)-1-(5-Fluoro-1H-benzimidazole-2-yl)ethanamine (FAS13) was prepared 
according to procedure 2.3.1, using 4-fluoro-1,2-phenylenediamine (0.15 g, 1.2 
mmol), S-alanine (0.11 g, 1.23 mmol) and hydrochloric acid (20 ml, 5.5 M). The 
mixture was heated under reflux for 288 hours. The resulting green solution was 
evaporated to dryness. (S)-1-(5-Fluoro-1H-benzimidazole-2-yl)ethanamine (FAS13) 
was obtained as a dark brown solid ( 0.1 g, 33%). m.p. 260-262°C (lit., 262-264 
ºC)(Donkor, 2007). δH (DMSO-d6) 8.18 (1H, d, 3J 8.80, 7-H), 7.62 (1H, s, 4-H), 7.54 
(1H, d, 3J 8.00, 6-H), 4.87 (1H, m, 1’-H), 1.39 (3H, d, 3J 7.20, 2’) (lit., 1.57 (3H, d) 
4.39 (1H, q) 5.10 (3H, bs) 7.08.about.7.52 (3H, m)) (Shibata et al., (1998)).  
. 
 (S)-1-(5-Nitro-1H-benzimidazole-2yl)ethanamine (FAS14) 
 
(S)-1-(5-Nitro-1H-benzimidazole-2yl)ethanamine (FAS14) was prepared according 
to general procedure 2.3.1 using 4-nitro-1,2-phenylenediamine (3.06 g, 20 mmol) 
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and S-alanine (2.00 g, 22.5 mmol) in hydrochloric acid (60 ml; 5.5 M). The mixture 
was heated under reflux for 336 hours. The reaction mixture was evaporated to 
dryness and dissolved in minimum ammonia solution. Water was added and the 
product was extracted with ethyl acetate. (S)-1-(5-Nitro-1H-benzimidazole-
2yl)ethanamine (FAS14) containing unreacted 4-nitro-1,2-phenylenediamine (50% 
as determined by NMR) was recovered. δH (DMSO-d6) 8.48 (1H, d, 4J 2.00, 4-H), 
8.10 (1H, dd, 3J 8.00, 4J 2.00 6-H), 7.74 (1H, d, 3J 8.80, 7-H),  3.48 (1H, br, s, 1’-H), 
1.77 (3H, s, 2’-H).  
 
2.3.7 Synthesis of 5-substituted-benzimidazole derivatives   
1H-Benzimidazole (FAS15) 
 
1H-benzimidazole (FAS 15) was prepared according to general procedure 2.3.1. 
1,2-phenylenediamine (3.78 g, 35 mmol) was dissolved in formic acid (2.30 g, 50 
mmol) and the mixture heated under reflux for 1 hour. 1H-benzimidazole (FAS15) 
was obtained as a cream powder (3.08 g, 74%). m.p. 170-172 °C (lit.,170-172 °C) 
(Hojati et al., 2011). δH (DMSO-d6) 8.27 (1H, s, 2-H ) ,7.63 (1H, dd, 3J 6.90, 4J 3.20, 
7-H & H-4), 7.20 (1H, dd, 3J 6.90, 4J 3.20, 5-H & H-6). δC (DMSO-d6) 141.93 (C-2), 
138.09 (C-3a & C-7a), 121.71 (C-4 & C7), 115.30 (C-5 & C-6); υmax /cm-1 (KBr) 3468 
(N-H), 3062 (C-H, sp2). 
 
5-Methylbenzimidazole (FAS16) 
 
5-Methylbenzimidazole (FAS 16) was prepared according to procedure 2.3.1. 4-
mehyl-1,2-phenylenediamine (4.20 g, 35 mmol) was dissolved in formic acid (2.30 
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g, 50 mmol) and the mixture heated under reflux for 1 hour. 5-Methylbenzimidazole 
(FAS16) was obtained as a cream powder (4.06 g, 87%). m.p. 112-114 °C, (lit., 112-
114 °C) (Mohammadpoor-Baltork et al., 2007). δH (DMSO-d6) 8.18 (1H, s, 2-H ) , 
7.50 (1H, d, 3J 8.00, 7-H), 7.40 (1H, s, 4-H), 7.01 (1H, d, 3J 8.00, 6-H),  2.41 (3H, s, 
CH3); δC (DMSO-d6) 141.55 (C-2), 130.93 (C-3a & C-7a), 123.15 (C-5), 116.06 (C-
6), 113.44 (C-4 & C-7), 21.06 (C-5a); υmax /cm-1 (KBr) 3429 (N-H),  3073 (C-H, sp2), 
2805 (C-H, sp3). 
 
5-Methoxy-1H-benzo[d]imidazole (FAS17) 
 
5-Methoxybenzimidazole (FAS 17) was prepared according to procedure 2.3.1. 4-
Mehoxy-1,2-phenylenediamine (1.20 g, 8.75 mmol) was dissolved in formic acid 
(0.57 g, 12.5 mmol) and the mixture heated under reflux for 1 hour. 5-
Methyoxybenzimidazole (FAS17) was obtained as a cream powder (1.10 g, 85 %). 
m.p. 116-118 °C,(lit., 117-120 °C) (Tanaka et al., 1981). δH (DMSO-d6) 8.09 (1H, s, 
2-H ) , 7.53 (1H, d, 3J 8.00, 7-H), 7.07 (1H, s, 4-H), 6.91 (1H, d, 3J 8.00, 6-H),  3.79 
(3H, s, CH3); δC (DMSO-d6) 141.55 (C-2), 130.93 (C-3a & C-7a), 156.1 (C-5), 113.06 
(C-6), 97.6 (C-4) 116.44 ( C-7), 55.30 (C-5a). 
 
5-Chloro-1H-benzo[d]imidazole (FAS18) 
 
5-Chlorobenzimidazole (FAS 18) was prepared according to procedure 2.3.1. 4-
chloro-1,2-phenylenediamine (2 g, 14 mmol) was dissolved in formic acid (10 ml) 
and the mixture heated under reflux for 3 hours. 5-Chlorobenzimidazole (FAS18) 
was obtained as a brown crystals (2.15 g, 100%). m.p. 123-125 °C (lit., 124-126 °C) 
Chapter 2    Materials and Methods 
71 
 
(Liu et al., 2011). δH (DMSO-d6) 8.32 (1H, s, 2-H ), 7.60 (1H, d, 3J 8.40, 7-H), 7.66 
(1H, d, 4J 2.00, 4-H), 7.20 (1H, dd, 3J 8.80, 4J 2.00, 6-H). δC (DMSO-d6) 143.40 (C-
2), 139.16 (C-3a) 136.48 (C-7a), 126.19 (C-5), 122.02 (C-6), 115.14 (C-7)  116.34 
(C-4); υmax /cm-1 (KBr) 3429 (N-H),  3103 (C-H, sp2), 1057 (C-Cl). 
 
5-Bromo-1H-benzo[d]imidazole (FAS19) 
 
5-Bromobenzimidazole (FAS 19) was prepared according to procedure 2.3.1. 4-
chloro-1,2-phenylenediamine (2.61 g, 14 mmol) was dissolved in formic acid (10 ml) 
and the mixture heated under reflux for 2 hours. 5-Bromobenzimidazole (FAS19) 
was obtained as brown crystals (2.69 g, 98%). m.p. 130-133 °C (lit., 130-131°C) 
(Evans and et al., 1978). δH (DMSO-d6) 8.27 (1H, s, 2-H ), 7.56 (1H, d, 3J 8.40, 7-H), 
7.81 (1H, d, 4J 2.00, 4-H), 7.32 (1H, dd, 3J 8.40, 4J 2.00, 6-H). δC (DMSO-d6) 143.29 
(C-2), 139.92 (C-3a) 136.89 (C-7a), 124.54 (C-6), 118.17 (C-5), 113.95 (C-7)  
116.81 (C-4); υmax /cm-1 (KBr) 3437 (N-H),  3087 (C-H, sp2), 1046 C-Br. 
   
  5-Fluoro-1H-benzo[d]imidazole (FAS20) 
 
5-Flourobenzimidazole (FAS 20) was prepared according to procedure 2.3.1. 4-
Fluoro-1,2-phenylenediamine (0.5g, 4 mmol) was dissolved in formic acid (10 ml) 
and the mixture heated under reflux for 3 hours. 5-Flourobenzimidazole (FAS20) 
was obtained as beige powder (0.49 g, 90 %). m.p. 130-132 °C (lit., 132 °C) (Fisher 
and Joullie, 1958, Rao and Kondal Reddy, 1979). δH (DMSO-d6) 9.05 (1H, s, 2-H ) , 
7.56 (1H, d, 3J 8.80, 4J 2.40, 7-H), 7.25 (1H, d, 4J 2.00, 4-H), 7.75 (1H, dd, 3J 8.40, 
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4J 4.80, 6-H); δC (DMSO-d6) 142.26 (C-2), 134.22 (C-3a) 130.52 (C-7a), 158.12 (C-
5), 115.94 (C-7), 112.51 (C-67), 101.00 (C-4).  
 
5-Nitro-1H-benzo[d]imidazole (FAS21) 
 
5-Nitrobenzimidazole (FAS 21) was prepared according to procedure 2.3.1. 4-Nitro-
1,2-phenylenediamine (3.06 g, 20 mmol) was dissolved in formic acid (5 ml) and the 
mixture heated under reflux for 8 hours. 5-Nitrobenzimidazole (FAS21) was 
obtained as a cream powder (3.28 g, 100%). m.p. 203-205 °C (lit., 204-205 °C) (Liu 
et al., 2011). δH (DMSO-d6) 8.54 (1H, s, 2-H ) , 7.74 (1H, d, 3J 9.2, 7-H), 8.49 (1H, d, 
4J 2.00, 4-H), 8.07 (1H, dd, 3J 8.80, 4J 2.00, 6-H). δC (DMSO-d6) 142.47 (C-2), 
138.63 (C-3a) 141.75 (C-7a), 146.82 (C-5), 114.63 (C-7), 117.38 (C-6)  112.70 (C-
4); υmax /cm-1 (KBr) 3104 (C-H, sp2), 1514 and 1345 (N-O). 
 
1H-Benzo[d]imidazole-5-cyano (FAS51) 
 
5-Cyano-1H-benzimidazole (FAS 51) was prepared according to procedure 2.3.1. of 
4-Cyano-1,2-phenylenediamine (2.66 g, 20 mmol) was dissolved in formic acid (5 
ml) and the mixture heated under reflux for 24 hours. 5-Cyanobenzimidazole 
(FAS51) was obtained as a cream powder (1.26 g, 44%). m.p. 230-232 °C (lit., 230-
233 °C)(Elshihawy, 2008). δH (DMSO-d6) 8.48 (1H, s, 2-H ), 7.75 (1H, d, 3J 8.00, 7-
H), 8.16 (1H, s, 4-H), 7.58 (1H, d, 3J 8.00, 6-H), 12.97 (1H, br, s, NH); δC (DMSO-d6) 
145.21 (C-2), 142.02 (C-3a &C-7a), 103.78 (C-5), 119.75 (C-7), 125.26 (C-6) 
123.40 (C-4) 123.21 (CN). 
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 1-Methyl-5-nitro-1H-benzo[d]imidazole (FAS58) 
 
N-Methyl-5-nitrobenzimidazole (FAS 58) was prepared according to general 
procedure 2.3.2.  5-Nitro-1H-benzo[d]imidazole (FAS 21) (1.63 g, 0.01 mol) was 
added to sodium hydroxide (0.01 mol, 0.4 g) in dry acetone (10ml) and stirred for 30 
min. Then, Iodomethane (0.01 mmol, 1.41 g) was added to the mixture and stirring 
was continued for 24 hours. The reaction mixture was concentrated to a quarter and 
then poured into ice-cold water. The solid was filtered and washed with 50% HCl to 
neutralize the excess potassium carbonate. The solid was washed with cold water 
(10 ml) and with aqueous ethanol (50%). The desire product (FAS58) was then 
dried and purified by column chromatography (2:8 cyclohexane/ethyl acetate) to 
give the desired product to give a beige precipitate (0.02 g, 25 %). m.p. 212-214 °C 
(lit., 211-215 ºC)(Piersanti et al., 2007). δH (DMSO) 7.78 (1H, d, 3J 8.00, 7-H), 8.58 
(1H, d, 4J 4.00, 4-H), 8.16 (1H, d, 3J 8.00, 6-H), 8.51 (1H, q, 3J 8.00, 4J4.00, 2-H ), 
3.93 (3H, d, 3J 16.00 CH3). δC (DMSO-d6) 142.68(C-2), 142.61 (C-3a) 142.39 (C-7a), 
148.73 (C-5), 119.52 (C-6), 117.79 (C-4), 110.85 (C-7), 31.18 (CH3). 
 
2.3.8 Synthesis of 2-hydroxymethylbenzimidazole derivatives  
 (1H-benzimidazol-2-yl)-methanol (FAS22) 
 
2-Hydroxymethylbenzimidazole (FAS22) was prepared according to general 
procedure 2.3.1. 1,2-Phenylenediamine (10.80 g, 0.10 mol) and glycolic acid 50% 
(30 ml) were dissolved in hydrochloric acid (70 ml; 5.5 M) and the mixture heated 
under reflux for 3 hours. The reaction mixture was neutralised with ammonia 
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solution and the cream precipitate was recrystallised from water. 2-
Hydroxymethylbenzimidazole (14.15 g; 96%) was obtained as pure brown crystals. 
m.p. 172-174 °C (lit. 170-172 °C) (Lahlou et al., 2003). δH (DMSO-d6) 7.50 (2H, br,s, 
4-H, 7-H), 7.14 (2H, dd, 3J 6.00, 4J  3.20, 5-H, 6-H), 5.73 (1H, t, 3J 5.56, OH,), 4.71 
(2H, d, 3J 5.12, CH2), 12.40 (1H, br, s, NH). δC (400 MHz; DMSO-d6) 155.02 (C-2), 
121.27 (C-3a, C-7a), 118.14 (C-5, C-5), 111.12 (C-4, C-7), 57.51 (C-1’); υmax /cm-1 
(KBr) 3259 (O-H), 3060 (C-H, sp2), 2856 (C-H, sp3), 1440 and 1345 (C-H, bend). 
 
  ((5-Methyl-1H-benzimidazole-2-yl)-methanol) (FAS23) 
 
(5-Methyl-1H-benzimidazole-2-yl)-methanol (FAS23) was prepared according to 
procedure 2.3.1. 4-Methyl-1,2-phenylenediamine (12.22 g; 0.1 mol) and glycolic 
acid (11.40 g, 0.15 mmol) in hydrochloric acid (50 ml, 5.5 M) were heated under 
reflux with for 3 hours. The reaction mixture was cooled to room temperature and 
ammonia solution was added and the mixture cooled in ice until a bright brown 
precipitate formed. The resulting solid was recrystallised from aqueous ethanol to 
give (5-methyl-1H-benzimidazole-2-yl)-methanol as a pale creamy powdery solid 
(16.2g; 100%). m.p. 194-196 ºC (lit. 203 ºC) (Dellweg et al., 1956). δH (DMSO-d6) 
7.38 (1H, d, 3J 8.40, 7-H), 7.29 (1H, s, 4-H), 6.97 (1H, d, 3J 8.40, 6-H), 4.69 (2H, s, 
CH2), 2.39 (3H, s, CH3), NH not observed; δC (DMSO-d6) 154.73 (C-2), 137.96 (C-
3a), 136.6 (C-7a), 130.4 (C-6),122.9 (C-5), 114.64 (C-4), 114.13 (C-7), 57.52 (C-1’), 
21.20 (CH3); υmax /cm-1 (KBr) 3481 (O-H), 3314 (NH) 3050 (C-H, sp2), 2850 (C-H, 
sp3). 
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  ((5-Methyl-1H-benzimidazole-2-yl)-methanol) (FAS24) 
 
(5-Methoxy-1H-benzimidazole-2-yl)-methanol (FAS24) was prepared according to 
procedure 2.3.1. 4-Methoxy-1, 2-phenylenediamine (0.7 g, 5 mmol) was heated 
under reflux temperature with glycolic acid (0.4 g, 5.25 mmol) in hydrochloric acid 
(15 ml, 5.5 M) for 6 hours. The reaction mixture was cooled to room temperature 
and ammonia solution was added and the mixture cooled in ice until a bright brown 
precipitate formed. The resulting solid was recrystallised from aqueous ethanol to 
give 5-methoxy-1H-benzimidazole-2-yl)-methanol as a bright brown solid (0.89 g; 
100%). m.p. 182-184 ºC. δH (DMSO-d6) 7.37 (1H, d, 3J 8.72, 7-H), 6.99 (1H, d, 4J 
2.36, 4-H), 6.76 (1H, dd, 3J 8.64, 4J 2.48, 6-H), 4.75 (2H, s, CH2), 3.75 (3H, s, 
OCH3), 5.65 (1H, br, s, OH), 12.20 (1H, br, s, NH). δC (DMSO-d6) 115.74 (C-2), 
155.20 (C-3a,C-7a), 97.27 (C-5), 110.56 (C-4, C-6), 154.50 (C-7), 57.68 (C-1’), 
55.35 (OCH3); MS (EI): m/z 177 (M-1, 100%), 162 (M-OH, 10% ). υmax /cm-1 (KBr) 
3392 (O-H), 3110 (C-H, sp2), 3038 (C-H, sp3), 1459 and 1378 (C-H, bend); MS (EI): 
m/z 178 (M+., 100%). Found; C, 60.47 %; H, 5.30 %; N, 15.92 %, requires; C, 60.66 
%; H, 5.66 %; N, 15.72 %. 
   
5-Chloro-1H-benzimidazol-2-yl)-methanol (FAS25) 
 
5-Chloro-1H-benzimidazole-2-yl) methanol (FAS25) was prepared according to 
procedure 2.3.1. using 4-chloro-1,2-phenylenediamine (2.12 g, 14.84 mmol), 
glycolic acid (1.30 g, 17 mmol) and hydrochloric acid (40 ml, 5.5 M). The solution 
was heated under reflux for 8 hours. 5-Chloro-1H-benzimidazole-2-yl)methanol was 
recovered as brownish red coloured crystals (2.58 g, 95%). m.p. 200- 202 °C (lit., 
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202 °C) (Lahlou et al., 2003). δH (DMSO-d6) 7.54 (1H, d, 4J 1.88, 4-H), 7.49 (1H, d, 
3J 8.52, 7-H), 7.16 (1H, dd, 3J, 8.00, 4J 2.00, 6-H), 5.80 (1H, br, s, OH), 4.70 (2H, s, 
CH2), 12.50 (1H, br, s, NH); δC (DMSO-d6) 114.75 (C-2), 121.52 (C-3a, C-7a), 
156.67 (C-5), 125.64 (C-7), 156.67 (C-4, C6), 57.60 (C-1’); υmax /cm-1 (KBr) 3441 (O-
H), 3136 (C-H, sp2), 3041 (C-H, sp3), 1441 and 1362 (C-H, bend), 1044 (C-Cl). 
  
(5-Bromo-1H-benzimidazole-2-yl)methanol (FAS26)  
 
(5-Bromo-1H-benzimidazole-2-yl) methanol (FAS26) was synthesised according to 
general procedure 2.3.1 using 4-bromo1,2-phenylenediamine (0.65 g, 3.5 mmol) 
and glycolic acid (0.305 g, 4 mmol) dissolved in hydrochloric acid (10 ml, 5.5 M). 
The mixture was heated under reflux for 8 hours. The product was obtained as an 
orange precipitate (0.67 g, 85%) m.p. 208- 210 °C (lit., 208 °C)(Khan  et al., 
1972).δH (DMSO-d6) 7.67 (1H, d, 4J 1.80, 4-H), 7.45 (1H, d, 3J 8.48, 7-H), 7.27 (1H, 
dd, 3J, 8.52, 4J 1.96, 6-H), 5.75 (1H, br, s, OH), 4.70 (2H, s, CH2), 12.50 (1H, br, s, 
NH). δC (DMSO-d6) 121.40 (C-2), 117.58 (C-3a), 116.19 (C-7a), 156.20 (C-5), 
113.46 (C-7), 124.13 (C-4, C6), 57.58 (C-1’); υmax /cm-1 (KBr) 3376 (O-H), 3130 (C-
H, sp2), 3089 (C-H, sp3), 1445 and 1320(C-H, bend), 1081 (C-Br); MS (EI): m/z 227 
(M+., 100%), 229 (M+2, 100% ). 
 
 (5-Fluoro-1H-benzimidazol-2-yl)-methanol (FAS27)  
 
(5-Fluoro-1H-benzimidazol-2-yl)methanol (FAS27) was synthesised according to 
general procedure 2.3.1 using 4-fluoro-1,2-phenylenediamine (1.26 g, 10 mmol) and 
glycolic acid (0.80 g, 10.5 mmol) dissolved in hydrochloric acid (30 ml, 5.5 M). The 
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mixture was heated under reflux for 8 hours. The brown crude product was 
decolourised using activated charcoal and recrystallised from ethanol to give 5-
fluoro-1H-benzimidazol-2-yl)methanol as brown crystals (1.15 g, 70%) . m.p. 182-
184 °C (lit., 182 °C) (Wagner and et al., 1972). δH (DMSO-d6) 7.49 (1H, dd, 3J 8.72, 
4J 4.96, 7-H), 7.28 (1H, dd, 3J 9.56, 4J 2.48 4-H), 6.99 (1H, m, 3J 9.32, 6-H), 4.70 
(2H, s, 1’-H), NH, OH not observed; δC (DMSO-d6) 159.38 (C-2), 156.79 (C-5), 
138.9 (C-3a), 134.9 (C-7a), 115.25 (C-7), 109.30 (C-6), 100.87 (C-4), 57.59 (C-1’); 
υmax /cm-1 (KBr) 3256 (C-H, sp2), 3079 (C-H, sp3), 1455 and 1355 (C-H, bend), 1076 
(C-F). 
 
(5-Nitro-1(3)H-benzimidazol-2yl)-methanol (FAS28) 
 
5-Nitro-2-hydroxymethylbenzimidazole (FAS28) was prepared according to 
procedure 2.3.1 4-nitro-1,2-phenylenediamine (8.00 g; 52 mmol) and glycolic acid 
50% in water (30 ml) were dissolved in hydrochloric acid (70 ml; 5.5 M) and the 
mixture heated under reflux for 48 hours. The reaction mixture was neutralised with 
ammonia solution and the brown pale yellow precipitate was recrystallised from 
water to give 5-nitro-2-hydroxymethylbenzimidazole as a yellow powder (5.65 g, 
56%). m.p. 198-200 ºC (lit., 198-200 °C)(Donkor, 2007). δH (DMSO-d6) 8.39 (1H, d, 
4-H, 4J 2.22), 8.08 (1H, dd, 3J 8.86, 4J 2.2, 6-H), 7.66 (1H, d, 3J 8.88, 7-H), NH not 
observed, 4.76 (2H, s, CH2), 3.74 (1H, s, OH); δC (DMSO-d6) 160.3 (C-2), 144.1 (C-
7a), 138.9 (C-5), 134.7 (C-3a), 119.8 (C-6), 115.2 (C-7), 111.5 (C-4), 56.9 (C-1’); 
υmax /cm-1 (KBr) 3586 (O-H), 3488 (N-H), 3121 (C-H, sp2), 2850 (C-H, sp3), 1507 and 
1353 (N-O). 
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2-(Hydroxymethyl)-1H-benzo[d]imidazole-5-cyano (FAS52) 
 
(5-Cyano-1H-benzimidazole-2-yl)-methanol (FAS52) was prepared according to 
procedure 2.3.1. 4-Cyano-1, 2-phenylenediamine (0.66 g, 5 mmol) was heated 
under reflux temperature with glycolic acid (0.4 g, 5.25 mmol) in hydrochloric acid 
(15 ml, 5.5 M) for 1 hour. The reaction mixture was cooled to room temperature and 
ammonia solution was added and the mixture cooled in ice until a bright orange 
precipitate formed. The resulting solid was recrystallised from aqueous ethanol to 5-
cyano-1H-benzimidazole-2-yl)-methanol as a bright orange solid (0.49g; 57%). m.p. 
170-172 ºC; (lit. 172-173 ºC) (Rangarajan et al., 2000). δH (DMSO-d6) 7.64 (1H, d, 3J 
8.00, 7-H), 8.00 (1H, s, 4-H), 7.52 (1H, d, 3J 8.00, 6-H), 4.73 (2H, s, CH2), NH & OH 
not observed; δC (DMSO-d6) 142.27 (C-2), 136.44 (C-3a,C-7a), 102.98 (C-5), 
120.16(C-4), 128.88 (C-6), 108.55 (C-7), 57.60 (C-1’), 118.16 (CN). 
 
2.3.9 Synthesis of 2-carboxylic acid benzimidazole derivatives 
 
2-Carboxylic acid benzimidazole (FAS29) 
 
2-Hydroxymethylbenzimidazole (FAS22) (2.96 g, 20 mmol) was dissolved in water 
warm (150 ml). Potassium permanganate (4.80 g, 30 mmol) in water (150 ml) was 
added slowly and the solution stirred until the purple potassium permanganate 
colour had been discharged. The potassium oxide was filtered off to leave a slightly 
pale brown solution. The filtrate was concentrated by two thirds and the solution 
acidified with concentrated hydrochloric acid. The resulting white precipitate was 
recrystallised from aqueous ethanol to give 2-carboxylic acid benzimidazole 
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(FAS29) as fine white crystals (1.76 g, 44%). m.p. 170-172 °C (lit. 168-169 °C) 
(Prostakov et al., 1990). δH (DMSO-d6)  10.61 (1H, s, NH), 8.30 (1H, s, OH), 7.67 
(1H, m, 3J 6.16, 4J 3.20, 4-H), 7.63 (1H, m, 3J 6.02, 4J 3.20, 7-H), 7.38 (1H, m, 3J 
6.12, 4J 3.20, 6-H), 7.22 (1H, m, 3J 6.02, 4J 3.08, 5-H); δC (DMSO-d6) 159.14 (C=O), 
144.59 (C-2), 141.86 (C-3a), 137.79 (C-7a), 136.49 (C-5), 124.22 (C-6), 121.81 (C-
4), 115.59 (C-7). υmax /cm-1 (KBr) 3539 (O-H), 3032 (C-H, sp2), 1647 (C=O), 1342 
(C-O). 
   
5-Methyl-1H-benzimidazole-2-carboxylic acid (FAS30) 
 
((5-Methyl-1 H-benzimidazole-2-yl)-methanol) (FAS23) (0.81 g, 5 mmol) was 
dissolved in acetone (35 ml). Potassium permanganate (0.95 g, 6 mmol) in water 
(160 ml) was added slowly and the solution stirred until the purple potassium 
permanganate colour had been discharged. The potassium oxide was filtered off to 
leave a clear solution. The solution was evaporated to dryness and the resulting 
solid dissolved in the minimum amount of water. The solution was acidified with 
concentrated hydrochloric acid and the resulting white precipitate recrystallised from 
aqueous ethanol to give 5-methyl-1H-benzimidazole-2-carboxylic acid (FAS30) as a 
white solid (0.88 g, 83%). m.p.140-142 °C, (lit., 140 °C) (Kempe et al., 1989). δH 
(DMSO-d6) 8.20 (2H, br, s, OH, NH), 7.55 (1H, d, 3J 8.36, 7-H), 7.49 (1H, 3J 8.20, 6-
H), 7.43 (1H, s, 4-H), 2.42 (3H, s, CH3); δC (DMSO-d6) 158.68 (C=O), 143.01 (C-2), 
136.44 (C-3a), 134.37 (C-7a), 131.10 (C-5), 124.53 (C-6), 115.5 (C-4), 114.6 (C-7), 
21.21 (CH3); υmax /cm-1 (KBr) 3488 (O-H), 3024 (C-H, sp2), 2861 (C-H, sp3), 1624 
(C=O), 1300 (C-O). 
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5-Methoxy-1H-benzimidazole-2-carboxylic acid (FAS31) 
 
((5-Methoxy-1 H-benzimidazole-2-yl)-methanol) (FAS24) (0.89 g, 5 mmol) was 
dissolved in acetone (35 ml). Potassium permanganate (0.95 g, 6 mmol) in water 
(160 ml) was added slowly and the solution stirred until the purple potassium 
permanganate colour had been discharged. The potassium oxide was filtered off to 
leave a clear solution. The solution was evaporated to dryness and the resulting 
solid dissolved in minimum water. The solution was acidified with concentrated 
hydrochloric acid and the resulting cream solid recrystallised from aqueous ethanol 
to give 5-methyl-1H-benzimidazole-2-carboxylic acid (FAS31) as a white solid (0.96 
g, 84%). m.p.150-152°C (lit., 152-154 ºC) (Thakurdesai et al., 2007). δH (DMSO-d6) 
7.50 (3H, br, s, H-4, H-6 & H-7s), 3.65 (3H, s, OCH3); δC (DMSO-d6) 157.33 (C=O), 
143.46 (C-2), 139.89 (C-3a), 132.67 (C-7a), 124.16 (C-5), 117.75 (C-6), 115.18 (C-
4), 96.32 (C-7), 55.63 (OCH3); υmax /cm-1 (KBr) 3130 (O-H), 3110 (C-H, sp2) 1641 
(C=O), 1300 (C-O) 1401 (C=N). 
 
5-Chloro-1H-benzimidazole-2-carboxylic acid (FAS32) 
 
Synthesis of 5-chloro-1H-benzimidazole-2-carboxylic acid (FAS32) was prepared, 
using 5-chloro-1H-benzimidazole-2-yl)methanol (FAS25) (0.365 g, 2.0 mmol) was 
dissolved in acetone (20 ml) and potassium permanganate was dissolved in water 
(20 ml). The crude product was recrystallised from water. 5-Chloro-1H-
benzimidazole-2-carboxylic acid (FAS32) (0.11 g, 24 %) was recovered as a creamy 
white powder. m.p. 158-160 °C (lit., 159-160ºC) (Thakurdesai et al., 2007). δH 
(DMSO-d6) 8.75 (1H, br, s, OH), 7.73 (1H, d, 4J 1.80, 4-H), 7.70 (1H, d, 3J 8.00, 7-
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H), 7.38 (1H, dd, 3J 8.00, 4J 1.80, 6-H). δC (DMSO-d6) 160.01 (C=O), 143.53 (C-2), 
141.36 (C-3a), 139.80 (C-7a), 130.01 (C-5), 124.52 (C-6), 117.56 (C-7), 115.59 (C-
4). υmax /cm-1 (KBr) 3499 (O-H), 3096 (C-H, sp2), 1741 (C=O), 1331 (C-O), 1063 (C-
Cl). 
 
5-Bromo-1H-benzimidazole-2-carboxylic acid (FAS33) 
 
Synthesis of 5-bromo-1H-benzimidazole-2-carboxylic acid hydrochloride (FAS33) 
was prepared using 5-bromo-1H-benzimidazole-2-yl)-methanol (FAS26) (0.23 g, 1.0 
mmol) dissolved in acetone (10 ml) and potassium permanganate (0379, 2.4 mmol) 
dissolve in water (10 ml). The crude product was recrystallised from water. 5-
Bromo-1H-benzimidazole-2-carboxylic acid (FAS33) (0.10 g, 37 %) was recovered 
as a creamy white powder. m.p. 162-164 °C. δH (DMSO-d6) 10.80 (1H, s, NH), 8.44 
(1H, s, OH), 7.84 (1H, d, 4J 3.20, 4-H), 7.62 (1H, d, 3J 8.80, 7-H), 7.47 (1H, dd, 3J 
6.80, 4J 5.40, 6-H). δC (DMSO-d6) 160.1 (C=O), 144.30 (C-2), 139.80 (C-3a), 137.80 
(C-7a), 127.30 (C-5), 124.80 (C-6), 119.70 (C-7), 116.30 (C-4); υmax /cm-1 (KBr) 3062 
(C-H, sp2), 1744 (C=O), 1046 (C-Br); (lit., ESI+ 241) (ISHII et al., (2010)). 
 
5-Fluoro-1H-benzimidazole-2-carboxylic acid (FAS34) 
 
5-Fluoro-1H-benzimidazole-2-carboxylic acid (FAS34) was synthesised using 5-
fluoro-1H-benzimidazole-2-yl)methanol (FAS 27) (0.10 g, 0.60 mmol) dissolved in 
acetone (20 ml) and potassium permanganate (0.10 g, 0.63 mmol) dissolved in 
water (10 ml). 5-Fluoro-1H-benzimidazole-2-carboxylic acid (FAS34) (0.05 g, 38%) 
was recovered as bright white crystals. m.p. (166-168 °C). δH (DMSO-d6) 12.14 (1H, 
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br, s, OH), 7.80 (1H, 3J 8.00, 4J 3.20, 7-H), 7.53 (1H, d, 3J 8.00, 4-H), 7.32 (1H, t, 3J 
8.00, 6-H); δC (DMSO-d6) 165.43 (C=O), 159.68 (C-5), 142.78 (C-2), 141.80 (C-3a), 
132.30 (C-7a), 112.02 (C-7), 113.90 (C-6), 104.20 (C-4); υmax /cm-1 (KBr) 3433 (O-
H), 3108 (C-H, sp2), 1748 (C=O), 1335 (C-O), 1199 (C-F) ; (lit., ESI+ 181) (ISHII et 
al., (2010)). 
  
5-Nitro-1H-benzimidazole-2-carboxylic acid (FAS35) 
 
2-Hydroxymethyl-5-nitrobenzimidazole (FAS 28) (0.96 g, 5 mmol) was dissolved in 
acetone (35 ml). Potassium permanganate (0.95 g, 6 mmol) in water (160 ml) was 
added slowly and the solution stirred until the potassium permanganate colour had 
been discharged. The solution was filtered to leave a pale yellow solution which 
then was acidified with concentrated hydrochloric acid and the volume reduced until 
a precipitate formed. The resulting yellow precipitate was recrystallised from 
aqueous ethanol to give 5-Nitro-1H-benzimidazole-2-carboxylic acid (FAS35) as a 
yellow powder (0.67 g, 55%), m.p. (198-200 °C) (lit., 198-200 ºC)(Donkor, 2007). δH 
(DMSO-d6) 8.52 (1H, s, br , 4-H), 8.10 (1H, s, br, 6-H), 7.77 (1H, s, br, 7-H), 2.50 
(1H, s, OH), 13.10 (1H, s, NH). δC (DMSO-d6) 159.80 (C=O), 143.64 (C-7a), 142.37 
(C-5), 142.64 (C-2), 136.90 (C-3a), 116.39 (C-6), 113.24 (C-7), 111.34 (C-4). υmax 
/cm-1 (KBr) 3550 (O-H), 3117 (C-H, sp2), 1629 (C=O), 1343 (C-O), 1509 and 1393 
(N-O). 
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2.3.10 Synthesis of N-methyl-2-methanolbenzimidazole derivatives 
(N-Methyl-1H-benzimidazole-2-yl)-methanol (FAS36) 
N
N
OH
CH3  
N-Methyl-2-methanolbenzimidazole (FAS36) was prepared according to general 
procedure 2.3.2.  A solution of (1H-benzimidazole-2-yl)-methanol (FAS22) (1.48 g, 
0.01 mol), and sodium hydroxide (0.40 g, 0.01 mol) was stirred in dry acetone (30 
ml) for 30 min. Then, iodomethane (0.01 mol, 1.41g) was added to the mixture and 
continued stirring for 24 hours. The reaction mixture was concentrated to a quarter 
and then poured into ice-cold water. The solid was filtered and washed with 50% 
HCl to neutralize the excess sodium hydroxide and washed the solid with cold water 
(100 ml) and with aqueous ethanol. The desired product (FAS36) was then dried 
and recrystallized from ethanol to give white crystals (0.7 g, 43%). m.p. (128-130 
°C) (lit., 125-130ºC) (Bednyagina and Postovskii, 1960). δH (DMSO-d6) 7.60 (1H, d, 
3J 8.00, 7-H), 7.53 (1H, d, 3J 8.00, 4-H), 7.25 (1H, dt, 3J 7.80, 4J 1.20, 5-H), 7.19 
(1H, dt, 3J 8.00, 4J 1.20, 6-H),  5.63 (1H, t, 3J 5.60, OH,), 4.72 (2H, d, 3J 5.20, CH2), 
3.83 (3H, s, CH3); δC (DMSO-d6) 155.02 (C-4, C-7), 121.27 (C-5, C-6), 118.14 (C-3a, 
C-7a), 111.12 (C-2), 57.51 (C-1’); υmax /cm-1 (KBr) 3441 (O-H), 3139 (C-H, sp2), 2837 
(C-H, sp3), 1482and 1334 (C-H, bend); MS (EI): m/z 162 (M+., 100%). 
   
(N-Methyl-5-methyl-1H-benzimidazole-2-yl)-methanol (FAS37) 
 
N-Methyl-2-methanol-5-methylbenzimidazole (FAS37) was prepared according to 
general procedure 2.3.2.  A solution of 5-methyl-(1H-benzimidazole-2-yl)-methanol 
(FAS23) (1.62 g, 0.01 mol), and sodium hydroxide (0.40 g, 0.01 mol) were stirred in 
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dry acetone (30 ml) was stirred for 30 min. Then, iodomethane (1.41g, 0.01 mol) 
was added to the mixture and the mixture was stirred for 24 hours. The reaction 
mixture was concentrated to a quarter and then poured into ice-cold water. The 
solid was filtered and washed with 50% HCl to neutralize the excess potassium 
carbonate. Then, wash the solid with cold water (100 ml) and then aqueous ethanol. 
The product was purified by column chromatography (9:1 chloroform/ethanol) to 
give the desired product (FAS37) as a brown powder (0.82 g, 46%). m.p. (122-124 
°C). δH (DMSO-d6) 7.46 (1H, d, 3J 8.00, 7-H), 7.31 (1H, s, 4-H), 7.39 (1H, dd, 3J 
9.80, 4J 2.80, 6-H), 5.59 (1H, s, OH,), 4.67 (2H, s, CH2), 3.79 (3H, s, N-CH3), 2.40 
(3H, s, CH3); δC (DMSO-d6) 153.8 (C-2), 142.06 (C-3a), 136.24 (C-7a), 131.34 (C-
6),123.44 (C-5), 118.63 (C-4), 109.64 (C-7), 55.40 (C-1’), 21.39 (CH3), 29.76 (CH3); 
υmax /cm-1 (KBr) 3154 (C-H, sp2), 2853 (C-H, sp3). MS (EI): m/z 176 (M+., 100%). 
 
 (N-Methyl-5-chloro-1H-benzimidazole-2-yl)-methanol (FAS38) 
 
N-Methyl-2-methanol-5-chlorobenzimidazole (FAS38) was prepared according to 
general procedure 2.3.2. A solution of 5-chloro-(1H-benzimidazole-2-yl)-methanol 
(FAS25) (1.50 g, 8.20 mmol), and sodium hydroxide (0.33 g, 8.2 mmol) were stirred 
in dry acetone (30 ml) for 30 min. Then, iodomethane (1.41g, 8.20 mmol) was 
added and the mixture was stirred for 24 hours. The reaction mixture was 
concentrated to a quarter and then poured into ice-cold water. The solid was filtered 
and washed with 50% HCl to neutralize the excess potassium carbonate. The solid 
was washed with cold water (100 ml) and aqueous ethanol. The product was 
purified by column chromatography (9:1 chloroform/ethanol) to give the desired 
product (FAS38) as bright orange crystals (0.14 g, 9 %). m.p. (136-138 °C). δH 
(DMSO-d6) 7.64 (1H, s, 4-H), 7.58 (1H, d, 3J 8.00, 4J 2.80 7-H), 7.19 (1H, d, 3J, 8.00, 
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6-H), 5.64 (1H, br, s, OH), 4.71 (2H, s, CH2), 3.82 (3H, s, N-CH3); δC (DMSO-d6) 
155.57 (C-2), 142.51 (C-3a), 136.78 (C-7a), 126.66 (C-5), 122.19(C6), 120.09 (C-7), 
111.40 (C-4) 56.31 (C-1’) 30.03 (N-CH3); υmax /cm-1 (KBr) 3154 (C-H, sp2), 2853 (C-
H, sp3), 1439 and 1334 (C-H, bend), 1134 (C-Cl). MS (EI): m/z 197 (M+., 100%),199 
(M+2, 40% ). Found; C, 54.65 %; H, 4.64 %; N, 14.12 %, requires; C, 54.97 %; H, 
4.61 %; N, 14.25 %. 
 
 (N-Methyl-5-bromo1H-benzimidazole-2-yl)-methanol (FAS40) 
 
N-Methyl-2-methanol 5-bromobenzimidazole (FAS 40) was prepared according to 
general procedure 2.3.2.  A solution of 5-bromo-(1H-benzimidazole-2-yl)-methanol 
(FAS26) (0.60 g, 2.60 mmol), and sodium hydroxide (0.10 g, 2.60 mmol) were 
stirred in dry acetone (10 ml) for 30 min. Then, iodomethane (0.37 g, 2.60 mmol) 
was added and the mixture was stirred for 24 hours. The reaction mixture was 
concentrated to a quarter and then poured into ice-cold water. The solid was filtered 
and washed with 50% HCl to neutralize the excess potassium carbonate. The solid 
was washed with cold water (100 ml) and with aqueous ethanol. The product was 
purified by column chromatography (9:1 chloroform/ethanol) to give the desired 
product (FAS40) as a bright yellow crystals (0.10 g, 16 %). m.p. (158-160 °C). δH 
(DMSO-d6) 7.88 (1H, s, 4-H), 7.58 (1H, d, 3J 8.00,7-H), 7.43 (1H, dd, 3J 8.00, 4J 1.60 
6-H), 5.68 (1H, br, s, OH), 4.75 (2H, s, CH2), 3.86 (3H, s, N-CH3); δC (DMSO-d6) 
155.42 (C-2), 143.10 (C-3a), 137.27 (C-7a), 124.74 (C-5), 121.66 (C6), 120.55 (C-
7), 111.90 (C-4) 56.27 (C-1’) 30.03 (N-CH3); υmax /cm-1 (KBr) 3122 (C-H, sp2), 2851 
(C-H, sp3), 1479 and 1348 (C-H, bend), 1105 (C-Br); MS (EI): m/z 241 (M+., 100%), 
243 (M+2, 100% ). 
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 (N-Methyl-5-fluoro 1H-benzimidazole-2-yl)-methanol (FAS41) 
N
N
OH
CH3
F
 
N-Methyl-2-methanol-5-flourobenzimidazole (FAS41) was prepared according to 
general procedure 2.3.2. A solution of (5-fluoro-1H-benzimidazole-2-yl) methanol 
(FAS27) (0.42g, 2.5 mmol), and sodium hydroxide (0.1 g, 2.5 mmol) were stirred in 
dry acetone (8 ml) for 30 min. Then, iodomethane (0.35 g, 2.5 mmol) was added 
and the mixture was stirred for 24 hours. The reaction mixture was concentrated to 
a quarter and then poured into ice-cold water. The solid was filtered and washed 
with 50% HCl to neutralize the excess potassium carbonate. The solid was washed 
with cold water (25 ml) and aqueous ethanol. The desired product (FAS41) was 
dried and recrystallized from ethanol to give white pale cream crystals (0.24 g, 
53%). m.p. 132-134 °C. δH (DMSO-d6) 7.60 (1H, d, 3J 8.00, 7-H), 7.53 (1H, d, 3J 
8.00, 4-H), 7.25 (1H, dt, 3J 7.80, 4J 1.20, 5-H), 7.19 (1H, dt, 3J 8.00, 4J 1.20, 6-H),  
5.63 (1H, t, 3J 5.60, OH,), 4.73 (2H, d, 3J 4.80, CH2), 3.83 (3H, s, CH3); δC (400 MHz; 
DMSO-d6) 155.02 (C-4, C-7), 121.27 (C-5, C-6), 118.14 (C-3a, C-7a), 111.12 (C-2), 
57.51 (C-1’); υmax /cm-1 (KBr) 3170 (C-H, sp2), 2865 (C-H, sp3), 1434 and 1343 (C-H, 
bend), 1137 (C-F). MS (EI): m/z 181 (M +1, 100%), 182 (M+ 2, 15%), 163 (M-OH, 
15%). 
 
 (N-Methyl-5-methoxy-1H-benzimidazole-2-yl)-methanol (FAS42) 
 
N-Methyl-2-methanol-5-methoxybenzimidazole (FAS 42) was prepared according to 
general procedure 2.3.2. A solution of (5-methoxy-1 H-benzimidazole-2-yl)-
methanol (FAS24) (0.06g, 0.43 mmol), and sodium hydroxide (0.017 g, 0.43 mmol) 
were stirred in dry acetone (1 ml) for 30 min. Then, iodomethane (0.06 g, 0.43 
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mmol) was added and the mixture was stirred for 24 hours. The reaction mixture 
was concentrated to a quarter and then poured into ice-cold water. The solid was 
filtered and washed with 50% HCl to neutralize the excess potassium carbonate. 
The solid was washed with cold water (10 ml) and aqueous ethanol. The product 
was purified by column chromatography (9:1 chloroform/ethanol) to give the desired 
product (FAS42) as a dark green precipitate (0.02 g, 25 %). m.p. 182-184 °C (lit., 
183 ºC) (Khristich et al., 1982). δH (DMSO) 7.93 (1H, d, 3J 9.20, 7-H), 7.58 (1H, d, 4J 
2.40, 4-H), 7.30 (1H, dd, 3J 8.00, 4J 2.40, 6-H), 5.01 (2H, d, 3J 10.40, CH2), 4.05 
(3H, s, OCH3), 3.90 (3H, s, CH3); δC (DMSO-d6) 126.27 (C-2), 158.30 (C-3a,C-7a), 
96.52 (C-5), 113.86 (C-4, C-6), 152.32 (C-7), 56.08 (C-1’), 51.43 (OCH3), 31.77 
(CH3); υmax /cm-1 (KBr) 3411 (OH) 3000 (C-H, sp2), 2834 (C-H, sp3), 1425 and 1356 
(C-H, bend), 1105 (C-Br); MS (EI): m/z 193 (M + 1, 100%), 177 (M-CH3). Found; C, 
48.09 %; H, 4.45 %; N, 10.61 %, requires; C, 48.69 %; H, 6.13 %; N, 11.36 %. 
 
  (N-Methyl-5-nitro-1H-benzimidazole-2-yl)-methanol (FAS50) 
 
N-Methyl-2-methanol-5-nitrobenzimidazole (FAS50) was prepared according to 
general procedure 2.3.2.  A solution of 5-nitro-(1H-benzimidazole-2-yl)-methanol 
(FAS28) (0.86 g, 4.50 mmol), and sodium hydroxide (0.18 g, 4.50 mmol) were 
stirred in dry acetone (20 ml) for 30 min. Then, iodomethane (0.64 g, 4.50 mmol) 
was added and the mixture was stirred for 24 hours. The reaction mixture was 
concentrated to a quarter and then poured into ice-cold water. The solid was filtered 
and washed with 50% HCl to neutralize the excess potassium carbonate. The solid 
was washed with cold water (100 ml) and aqueous ethanol. The product was 
purified by column chromatography (9:1 chloroform/ethanol) to give the desired 
product (FAS50) as an yellow crystals (0.18 g, 19 %). m.p. (160-162 °C) (lit., 167-
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168 ºC) (Khristich et al., 1982). δH (DMSO-d6) 7.47 (1H, d, 4J 1.60  4-H), 7.77 (1H, d, 
3J 8.00,7-H), 7.16 (1H, dd, 3J 8.00, 4J 1.60 6-H), 5.76 (1H, br, s, OH), 4.78 (2H, s, 
CH2), 3.91 (3H, s, N-CH3); δC (DMSO-d6) 153.31 (C-2), 142.52 (C-3a), 140.89 (C-
7a), 140.49 (C-5), 117.80 (C6), 115.06 (C-7), 110.58 (C-4) 56.36 (C-1’) 30.45 (N-
CH3). υmax /cm-1 (KBr) 3104 (C-H, sp2), 2853 (C-H, sp3), 1436 and 1347 (C-H, bend), 
1531 and 1339 (N-O).  
 
N-methyl -5-chloro-2-methoxymethyl-1H-benzimidazole (FAS39) 
 
N-Methyl-5-chloro-2-methoxymethybenzimidazole (FAS39) was prepared according 
to general procedure 2.3.2. A solution of 5-chloro-1H-benzimidazole-2-yl)-methanol 
(FAS25) (0.91 g, 0.005 mol), and sodium hydroxide (0.2 g, 0.005 mol) were stirred 
in dry acetone (15 ml) for 30 min. Then, iodomethane (0.71 g, 0.005 mol) was 
added and the mixture was stirred for 24 hours. The reaction mixture was 
concentrated to a quarter and then poured into ice-cold water. The solid was filtered 
and washed with 50% HCl to neutralize the excess potassium carbonate. The solid 
was washed with cold water (50 ml) and aqueous ethanol. The desired product 
(FAS39) was dried and recrystallized from ethanol to give a cream crystals (0.46 g, 
46 %). m.p. (138-140 °C). δH (DMSO-d6) 8.01 (1H, d, 3J 8.80, 7-H), 7.89 (1H, d, 4J 
2.00, 4-H), 7.64 (1H, dd, 3J 8.80, 4J 2.00, 6-H), 5.06 (2H, s,  CH2), 3.53 (3H, s, CH3) , 
4.03 (3H, s, OCH3); δC (DMSO-d6) 114.38 (C-2), 125.85 (C-3a, C-7a), 130.08 (C-5), 
131.42 (C-7), 144.28 (C-6), 152.19 (C-4),  64.42 (C-1’), 59.34 (OCH3), 32.36 (CH3); 
υmax /cm-1 (KBr) 3451 (OH) 3027 (C-H, sp2), 2851 (C-H, sp3), 1425 and 1338 (C-H, 
bend), 1123 (C-Cl); MS (EI): m/z 211 (M+., 100%), 213 (M+2, 40% ); Found; C, 
37.61 %; H, 4.09 %; N, 7.62 %, requires; C, 37.53 %; H, 4.41 %; N, 8.75 %. 
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2.3.11 Synthesis of 2- Chloromethylbenzimidazole derivatives 
2-Chloromethylbenzimidazole (FAS43) 
 
Thionyl chloride (2.5 ml) was added dropwise to finely ground 2-
hydroxymethylbenzimidazole (FAS22) (2.5 g, 0.0167 mol). The orange solution was 
heated under reflux for 3 hours. The reaction was allowed to cool to room 
temperature before any excess thionyl chloride was destroyed by the addition of 
methanol in small portions. The methanol was removed in vacuo and the resulting 
orange/red solid dissolved in dichloromethane (25 ml) and water (25 ml). The 
aqueous phase was separated and evaporated to dryness. The creamy white solid 
was recrystallised from water to give yellow crystals (FAS43) (2.00 g; 72%). m.p. 
142-144 ºC (lit, 140-141 ºC) (Prostakov et al., 1990). δH (DMSO) 7.81 (2H, dd, 3J 
6.00, 4J 3.20 4-H, 7-H), 7.54 (2H, dd, 3 J 6.00, 4J 3.20, 5-H, 6-H), 5.28 (1H, s, CH2); 
δC (DMSO-d6) 148.29 (C-2), 130.74 (C-3a, C-7a), 125.84 (C-5, C-6), 114.03(C-4, C-
7), 33.79 (C-1’); υmax /cm-1 (KBr) 3088 (C-H, sp2), 2851 (C-H, sp3), 1253 (CH2-Cl). 
  
2-(Chloromethyl)-5-methyl-1H-benzimidazole (FAS44) 
 
5-Methyl-1 H-benzimidazole-2-yl)-methanol) (FAS23) (5 g, 25 mmol) was dissolved 
in thionyl chloride (30 ml). 2-(Chloromethyl)-5-methyl-1H-benzimidazole (FA 44) 
(2.75g, 61%) was recovered as yellow powder. m.p. 128-130 °C; (lit., 127-132 
°C)(Wilson and Hunt, 1983). δH (DMSO-d6) 7.66 (1H, d, 3J 7.60, 7-H), 7.57 (1H, s, 4-
H), 7.34 (1H, d, 3J 7.60, 6-H), 5.25 (2H, s, CH2), 2.44 (3H, s, CH3); δC (DMSO-d6) 
153.95 (C-2), 147.64 (C-3a), 135.83 (C-7a), 130.95 (C-6),128.76 (C-5), 127.33 (C-
Chapter 2    Materials and Methods 
90 
 
4), 113.47 (C-7), 33.76 (C-1’), 21.11 (CH3); υmax /cm-1 (KBr) 3420 (NH) 3089 (C-H, 
sp2), 2846 (C-H, sp3), 1275 (CH2-Cl). 
 
2-(Chloromethyl)-5-methoxy-1H-benzimidazole (FAS45) 
 
Thionyl chloride (27.5 mmol, 2 ml) was added slowly to a solution of 5-methoxy-1H-
benzimidazole-2-yl)-methanol) (FAS24) (0.58 g, 3.31 mmol) in dichloromethane (10 
ml) at 10 ºC, the mixture was stirred until no presence of the starting material. The 
solvent was then evaporated, and the residue was triturated with DCM, and suction 
filtered, then was washed with dichloromethane and ether. 5-Methoxy-2-
(chloromethyl)-5-methyl-1H-benzimidazole (FAS45)(0.58 g, 89%) was recovered as 
a green powder. m.p. 200-202 °C. δH (DMSO-d6) 7.72 (1H, d, 3J 9.20, 7-H), 7.25 
(1H, d, 4J 2.00, 4-H), 7.16 (1H, d, 3J 9.00, 4J 2.40  6-H), 5.22 (2H, s, CH2), 3.85 (3H, 
s, OCH3). δC (DMSO-d6) 157.44 (C-2), 146.77 (C-3a), 131.50 (C-7a), 124.76 (C-
6),115.64 (C-5), 114.54 (C-4), 95.47 (C-7), 35.15 (C-1’), 33.26 (OCH3). υmax /cm-1 
(KBr) 3401 (NH) 3093 (C-H, sp2), 2850 (C-H, sp3), 1272 (CH2-Cl). MS (EI): m/z 197 
(M+., 100%), 199 (M+2, 40% ). Found; C, 45.78%; H, 4.08 %; N, 11.83 %, requires; 
C, 46.37 %; H, 4.32 %; N, 12.02 %. 
 
2-(Chloromethyl)-5-chloro-1H-benzimidazole (FAS46) 
 
Thionyl chloride (27.5 mmol, 5 ml) was added slowly to a solution of 5-chloro-1 H-
benzimidazole-2-yl)-methanol) (FAS25) (1.51 g, 8.27 mmol) in dichloromethane (25 
ml) at 10 ºC, the mixture was stirred until no presence of the starting material. The 
solvent was evaporated and then the residue was triturated with dichloromethane, 
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suction filtered, washed with dichloromethane and ether. 2-(Chloromethyl)-5-chloro-
1H-benzimidazole (FAS46) (1.32 g, 80%) was recovered as a light brown powder. 
m.p. 210-212 °C (lit., 213-214°C ) (King et al., 1949). δH (DMSO-d6) 7.78 (1H, d, 3J 
8.40, 7-H), 7.85 (1H, d, 4J 1.60, 4-H), 7.49 (1H, d, 3J 8.80, 4J 2.00  6-H), 5.16 (2H, s, 
CH2); δC (DMSO-d6) 156.12 (C-2), 150.21 (C-3a), 134.09 (C-7a), 129.72 (C-
6),125.91 (C-5), 116.11 (C-4), 114.42 (C-7), 35.11 (C-1’); υmax /cm-1 (KBr) 3420 (NH) 
3075 (C-H, sp2), 2790 (C-H, sp3), 1199 (CH2-Cl). MS (EI): m/z 201 (M+., 100%), 203 
(M+2, 70%). 
 
2-(Chloromethyl)-5-bromo-1H-benzimidazole (FAS47) 
 
Thionyl chloride (68.75 mmol, 5 ml) was added slowly to a solution of 5-bromo-1H-
benzimidazole-2-yl)-methanol) (FAS26) (1.51 g, 8.27 mmol) in dichloromethane (25 
ml) at 10 ºC, the mixture was stirred until no presence of the starting material. The 
solvent was then evaporated and the residue was triturated with dichloromethane, 
suction filtered, washed with dichloromethane and ether. 2-(Chloromethyl)-5-bromo-
1H-benzimidazole (FAS47) (2.03 g , 92 %) was recovered as a brown pale orange 
powder. m.p. 248-250 °C; (lit., 249-250 °C)(Dandegaonker and Shastri, 1965). δH 
(DMSO-d6) 7.73 (1H, d, 3J 8.80, 7-H), 7.99 (1H, d, 4J 0.80, 4-H), 7.61 (1H, d, 3J 
8.80, 4J 1.20  6-H), 5.17 (2H, s, CH2). δC (DMSO-d6) 150.16 (C-2), 134.37 (C-3a), 
132.15 (C-7a), 129.47 (C-6),125.54 (C-5), 117.30 (C-4), 116.09 (C-7), 35.00 (C-1’); 
υmax /cm-1 (KBr) 3436 (NH) 3070 (C-H, sp2), 2867 (C-H, sp3), 1208 (CH2-Cl); MS (EI): 
m/z 245 (M+., 80%), 247 (M+2, 100%), 249(M+4, 20%); Found; C, 34.95%; H, 2.61 
%; N, 9.84 %, requires; C, 34.08 %; H, 2.50 %; N, 9.94 %. 
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2-(Chloromethyl)-5-flouro-1H-benzimidazole (FAS48) 
 
Thionyl chloride (27.5 mmol, 2 ml) was added slowly to a solution of 5-flouro-1H-
benzimidazole-2-yl)-methanol) (FAS27) (0.55 g, 3.31 mmol) in dichloromethane (10 
ml) at 10 ºC, the mixture was stirred until no presence of the starting material. The 
solvent was then evaporated, and the residue was triturated with dichloromethane, 
suction filtered, washed with dichloromethane and ether. 2-(Chloromethyl)-5-flouro-
1H-benzimidazole (FAS48) (0.49 g, 80%) was recovered as a brown powder. m.p. 
212-214. δH (DMSO-d6) 7.82 (1H, d, 3J 8.80, 7-H), 7.67 (1H, d, 4J 2.00, 4-H), 7.38 
(1H, d, 3J 8.80, 4J 2.00 6-H), 5.18 (2H, s, CH2) (lit., 4.87 (2H, s, CH2), 7.05 (1H, td, 3J 
9.00, 4J 3.00) 7.27 (1H, dd, 3J 9.00, 4J 3.00), 7.51-7.55 (1H, m)) (Cowart et al., 
2004); δC (DMSO-d6) 158.63 (C-2), 149.99 (C-3a), 132.97 (C-7a), 129.33.14 (C-
6),116.14 (C-5), 114.17 (C-4), 101.11 (C-7), 35.00 (C-1’); υmax /cm-1 (KBr) 3434 (NH) 
3083 (C-H, sp2), 2797 (C-H, sp3), 1219 (CH2-Cl);  MS (EI): m/z 185 (M+., 100%), 187 
(M+2, 30%). 
 
2-(Chloromethyl)-5-nitro-1H-benzimidazole (FAS49) 
 
Thionyl chloride (275 mmol, 20 ml) was added slowly to a solution of 5-nitro-1 H-
benzimidazole-2-yl)-methanol) (FAS28) (6.38 g, 33.1 mmol) in dichloromethane 
(100 ml) at 10 ºC, the mixture was stirred until no presence of the starting material. 
The solvent was then evaporated, and the residue was triturated with 
dichloromethane, suction filtered, washed with dichloromethane and ether. 2-
(Chloromethyl)-5-nitro-1H-benzimidazole (FAS49) (6.14 g, 88%) was recovered as 
an orange crystals. m.p. 170-172 °C (lit., 174 °C)(Labas et al., 2011). δH (DMSO-d6) 
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7.74 (1H, d, 3J 8.80, 7-H), 7.48 (1H, d, 4J 2.00, 4-H), 8.11 (1H, d, 3J 7.52, 4J 2.20  6-
H), 5.01 (2H, s, CH2). δC (DMSO-d6) 142.63 (C-2 &C-3a &C-7a), 118.10 (C-6 & C-5 
& C-4 & C-7), 37.82 (C-1’). υmax /cm-1 (KBr) 3503 (NH) 3090 (C-H, sp2), 2854 (C-H, 
sp3), 1313 (CH2-Cl). MS (EI): m/z 212 (M+., 100%), 214 (M+2, 30%). 
 
2-(Chloromethyl)-5-cyano-1H-benzimidazole (FAS53) 
 
Thionyl chloride (27.5 mmol, 2 ml) was added slowly to a solution of 5-cyano-1 H-
benzimidazole-2-yl)-methanol) (FAS52) (0.57 g, 3.31 mmol) in dichloromethane (10 
ml) at 10 ºC, the mixture was stirred until no presence of the starting material. The 
solvent was then evaporated then the residue was triturated with dichloromethane, 
suction filtered, washed with dichloromethane and ether. 2-(Chloromethyl)-5-cyano-
1H-benzimidazole (FAS53) (0.36 g, 57 %) was recovered as a beige powder, m.p. 
230-232 °C (lit., 230-232 °C)(Elshihawy, 2008). δH (DMSO-d6) 7.52 (1H, d, 3J 8.40, 
7-H), 7.99 (1H, s, 4-H), 7.64 (1H, d, 3J 8.00, 6-H), 4.66 (2H, s, CH2); δC (DMSO-d6) 
142.63 (C-2), 140.99 (C-3a), 130.97 (C-7a), 120.33.14 (C-6),115.14 (CN)  , 113.78 
(C-4), 112.11 (C-7), 110.20 (C-5), 57.00 (C-1’). 
 
2.3.12 Synthesis of 2-ethylbenzimidazole derivatives 
 
2-Ethyl-1H-benzo[d]imidazole (FAS54) 
 
1,2-Phenylenediamine (2.16 g, 20 mmol) was dissolved in hydrochloric acid (20 ml, 
5.5 M). Propionic acid (1.48 g, 20 mmol) was then added and the mixture heated 
under reflux for 24 hours. The reaction mixture was cooled in ice before the 
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ammonia solution was added. 2-Ethyl-1H-benzimidazole (FAS54) was recovered as 
creamy powder (1.75 g, 60 %). m.p. 164-166 °C (lit., 164-165 °C) (Aridoss and 
Laali, 2011). δH (DMSO-d6) 7.47 (2H dd, 3J 8.00, 4J  2.40, 4-H, 7-H), 7.11 (2H, dd, 3J 
8.00, 4J  2.20, 5-H, 6-H), 1.33 (3H, t, 3J 6.00, CH3,), 2.84 (2H, q, 3J 6.00, CH2), 12.24 
(1H, br, s, NH); δC (400 MHz; DMSO-d6) (156.13) (C-2), 120.99 (C-5, C-6), 138.68 
(C-3a, C-7a), 114.16 (C-4, C-7), 21.95 (C-1’) 12.18 (CH3). 
 
2-Ethyl-5-nitro-1H-benzo[d]imidazole (FAS55) 
 
4-Nitro-1,2-phenylenediamine (3.06 g, 20 mmol) was dissolved in hydrochloric acid 
(20 ml, 5.5 M). Propionic acid (1.48 g, 20 mmol) was then added and the mixture 
was heated under reflux for 24 hours. The reaction mixture was cooled in ice before 
the ammonia solution was added. The resulting dark brown oil was dissolved in 
ethanol and treated with decolourising using charcoal. 2-Ethyl-5-nitro-1H-
benzimidazole (FAS55) was recovered as yellow crystals (1.50 g, 40%). m.p. 175-
177 °C (lit., 178-179 °C) (Willitzer et al., 1978). δH (DMSO-d6) 8.33 (1H, s, 4-H), 8.01 
(1H, d, 3J 8.80, 4J  2.20 6-H), 7.59 (1H, d, 3J 8.80, 7-H), 2.89 (2H, q, 3J 6.00, CH2), 
1.33 (3H, t, 3J 5.70, CH3), 12.85 (1H, br, s, NH); δC (DMSO-d6) 161.06 (C-2), 142.01 
(C-7a), 139.26 (C-5), 117.06 (C-3a), 114.21 (C-6), 110.98 (C-7), 107.39 (C-4), 
22.05 (C-1’), 11.67 (CH3). 
 
  
Chapter 2    Materials and Methods 
95 
 
2.3.13 Synthesis of 2-methanethiolbenzimidazole derivatives 
 (1H-Benzo[d]imidazol-2-yl)methanethiol (FAS56) 
 
(1H-Benzo[d]imidazol-2-yl)methanethiol (FAS56) was prepared according to general 
procedure 2.3.1. 1,2-Phenylenediamine (10.80 g, 0.10 mol) and 2-mercaptoacetic 
acid (50%) were dissolved in hydrochloric acid (70 ml, 5.5 M) and the mixture was 
heated under reflux for 60 hours. The reaction mixture was neutralised with 
ammonia solution to give a precipitate. The crude product was recrystallised from 
water. (1H-Benzo[d]imidazol-2-yl)methanethiol (FAS56) was obtained as olive 
coloured crystals(13.46 g; 82 %). m.p. 170-172 °C (lit. 173 °C) (Gowda et al., 2011). 
δH (DMSO-d6) 7.54 (2H, s, 4-H, 7-H), 7.16 (2H, s, 5-H, 6-H), 4.21 (2H, s, CH2), 12.72 
(1H, br, s, NH), SH not observed. δC (DMSO-d6) 114.50 (C-4, C-7), 118.51 (C-5, C-
6), 121.76 (C-3a, C-7a), 150.59 (C-2), 35.72 (C-1’); ). MS (EI): m/z 165 (M+1, 
100%). Found; C, 41.88 %; H, 3.56 %; N, 11.23 %; requires; C, 40.52 %; H, 4.25 %; 
N, 11.81 %. 
  
 (5-Nitro-1H-benzo[d]imidazol-2-yl)methanethiol (FAS57) 
 
5-Nitro-2-methanethiolbenzimidazole (FAS57) was prepared according to procedure 
2.3.1., 4-Nitro-1,2-phenylenediamine (7.65 g, 50 mmol) and 2-mercaptoacetic acid 
(50%) were dissolved in hydrochloric acid (70 ml, 5.5 M) and the mixture was 
heated under reflux for 70 hours. The reaction mixture was neutralised with 
ammonia solution and give 5-nitro-2- methanethiolbenzimidazole (FAS57) as bright 
orange crystals (5.00 g, 48%). m.p. 195-197 ºC (lit., 195 ºC) (Gowda et al., 2011). 
δH (DMSO-d6) 8.41 (1H, d, 4-H, 4J 2.22), 8.09 (1H, d, 3J 8.40, 4J 2.2, 6-H), 7.69 (1H, 
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d, 3J 8.40, 7-H), 4.27 (2H, s, CH2), 3.60 (1H, s, SH), 13.14 (1H, br, s, NH). δC 
(DMSO-d6) 155.31 (C-2), 142.47 (C-7a), 139.99 (C-5), 135.50 (C-3a), 117.69 (C-6), 
114.34 (C-7), 111.93 (C-4), 35.39 (C-1’). 
 
2.3.14 Synthesis of 1-oxidebenzimidazole derivatives 
5-Nitro-1H-benzo[d]imidazole 3-oxide (FAS59) 
 
5-Nitro-1H-benzo[d]imidazole 3-oxide (FAS59) was prepared by using 5-nitro -1H-
benzo[d]imidazole (FAS 21) (1.63 g, 10 mmol), which was reacted with hydrogen 
peroxide (30% v/v). 5-Nitro-3-oxido-1H-benzo[d]imidazole (FAS59) was obtained as 
a cream powder (0.95 g, 49%). m.p. 200-202 °C(lit., 201-203 °C)(Elshihawy, 2008) . 
δH (DMSO-d6) 8.55 (1H, s, 2-H) , 7.77 (1H, d, 3J 8.00, 7-H), 8.51 (1H, s, 4-H), 8.12 
(1H, d, 3J 8.00, 6-H), 13.90 (1H, s, NH). δC (DMSO-d6) 146.68 (C-2), 142.60 (C-7a)  
138.51(C-3a), 133.12 (C-5), 117.55 (C-4), 115.28 (C-6) 112.30 ( C-7). 
 
5-Nitro-2-oxo-1,2-dihydro-1H-benzo[d]imidazol-3-oxide (FAS60) 
 
5-Nitro-2-oxo-1,2-dihydro-1H-benzo[d]imidazol-3-oxide (FAS60) was prepared by 
using 5-nitro-1H-benzo[d]imidazol-2(3H)-one (1.79 g, 10 mmol), which was reacted 
with hydrogen peroxide (30% v/v). 5-Nitro-2-oxo-1,2-dihydro-1H-benzo[d]imidazol-3-
oxide (FAS60) was obtained as a yellow powder (0.98 g, 50 %). m.p. 298-300 °C 
(lit., 296-298 °C)(Elshihawy, 2008). δH (DMSO-d6) 7.09 (1H, d, 3J 8.00, 7-H), 7.69 
(1H, d, 3J 2.00, 4-H), 7.92 (1H, dd, 3J 8.00, 4J 2.00 6-H),  11.19 (1H, s, NH). δC 
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(DMSO-d6) 155.42 (C-2), 141.60 (C-7a)  135.66 (C-3a), 129.6 (C-5), 117.71 (C-4), 
108.01 (C-6) 103.58 ( C-7). 
 
2.3.15 Synthesis of benzoxazole derivatives 
6-Chlorobenzo[d]oxazol-2(3H)-one (FAS61) 
 
6-Chlorobenzo[d]oxazol-2(3H)-one (FAS61) was prepared by mixing 5-chloro-2-
hydroxyaniline (1.43 g, 10 mmol) with phosgene (4.95 g, 50 mmol) and the mixture 
reacted at 180 °C under reflux for 2 hours. 6-Chlorobenzo[d]oxazol-2(3H)-one was 
obtained as peach coloured crystals (1.27 g, 75 %). m.p. 154-156 °C (lit., 155-157 
°C)(Elshihawy, 2008). δH (DMSO-d6) 7.24 (1H, d, 3J 8.00, 7-H), 7.11 (1H, s, 4-H), 
6.82 (1H, dd, 3J 8.00, 4J 2.00 6-H),  8.15 (1H, s, NH); δC (DMSO-d6) 154.26 (C-2), 
143.41 (C-7a)  136.94 (C-3a), 129.10 (C-5), 116.70 (C-4), 113.05 (C-6) 106.93 ( C-
7); MS (EI): m/z 169.5 (M+, 100%). 
    
6-Nitrobenzo[d]oxazol-2(3H)-one (FAS62) 
 
6-Nitrobenzo[d]oxazol-2(3H)-one (FAS 62) was prepared by mixing 5-nitro-2-
hydroxyaniline (1.54 g, 10 mmol) with urea (3.00 g, 50 mmol), and the mixture 
reacted at 180 °C under reflux for 2 hours. 6-Nitrobenzo[d]oxazol-2(3H)-one 
(FAS62) was obtained as a cream powder (1.29 g, 72%). m.p. 240-242 °C (lit., 238-
241 °C) (Abdelaal et al., 1992). δH (DMSO-d6) 7.25 (1H, d, 3J 8.00, 7-H), 8.14 (1H, d, 
4J 2.00,  4-H), 8.09 (1H, dd, 3J 8.00, 4J 2.00 6-H), 12.38 (1H, s, NH); δC (DMSO-d6) 
154.16 (C-2), 142.73 (C-7a)  142.01 (C-3a), 136.76 (C-5), 120.75 (C-4), 109.33 (C-
6) 105.39 ( C-7). 
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6-Chlorobenzo[d]oxazole (FAS63) 
 
6-Chlorobenzo[d]oxazole (FAS 63) was prepared according to procedure 2.3.1. 5-
Chloro-2-hydroxyaniline (2.00 g, 14 mmol) was dissolved in formic acid (10 ml) and 
the mixture was heated under reflux for 3 hours. 6-Chlorobenzo[d]oxazole (FAS63) 
was obtained as a brown powder (1.93 g, 90%). m.p. 58-60 °C (lit., 61-62 °C)(Wertz 
et al., 2011)δH (DMSO-d6) 6.85 (1H, d, 3J 8.00, 7-H), 8.31 (1H, s, 4-H), 6.95 (1H, dd, 
3J 8.00, 4J 2.00 6-H),  9.72 (1H, s, 2-H); δC (DMSO-d6) 160.29 (C-2), 145.38 (C-7a)  
127.20 (C-3a), 123.28 (C-5), 122.15 (C-4), 119.73 (C-6) 115.89 ( C-7). 
 
2.3.16 Synthesis of benzothiozole derivative 
Benzo[d]thiazol-2-ylmethanol (FAS65) 
 
2-Aminothiophenol (12.5 g, 0.10 mol) was added to glycolic acid (99%) (11.40 g, 
0.15 mol) in the absence of a solvent. Then it was heated under reflux for 5 hours. 
After the reaction mixture was cooled to room temperature, ethanol (30 ml) was 
added with water (100 ml). The product was recrystallised from aqueous ethanol. 2-
Hydroxymethylbenothiazole (FAS65) was isolated as bright green needles (15.0 g, 
91%). m.p.100-102 °C (lit., 100-102 °C) (Asselin et al., 2010). δH (DMSO) 8.11 (1H, 
d, 3J 8.00, 4J 2.00, 4-H), 7.93 (1H, d, 3J 8.00, 7-H), 7.44 (2H, m, 3J 8.00, 4J 2.00, 5-H, 
6-H), 6.26 (1H, t, 3J 6.00, OH), 4.88 (2H, d, 3J 6.00, CH2); δC (400 MHz; DMSO-d6) 
153.05 (C-3a) 122.27 (C-4) 122.19 (C-7), 125.94 (C-5), 124.63 (C-6), 134.17 (C-
7a), 175.55 (C-2), 61.25 (C-1’); MS (EI): m/z 165 (M+., 100%); Found; C, 58.24 %; 
H, 4.60 %; N, 8.47 %; requires; C, 58.16 %; H, 4.27 %; N, 8.48 %. 
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2.3.17 Synthesis of N-bromoalkyl-2-chloromethylbenzimidazole 
derivatives 
1-(2-Bromoethyl)-2-(chloromethyl)-1H-benzo[d]imidazole (FAS67) 
 
2-Chloromethylbenzimidazole (FAS43) (1.66 g, 10mmol) was combined with an 
excess of potassium hydroxide (0.73 g, 13 mmol), and dissolved in ethanol (20 ml). 
An ethanol solution of 1,2-dibromoethane (2.79 g, 15 mmol) was added dropwise to 
the 2-chloromethyl-1H-benzimidazole (FAS43) solution, and the combined mixture 
was refluxed for 48 hrs. Water (50 ml) was added to the mixture, and then was 
extract the product with CHCl3 (2 X 100 ml), then collected the organic phase and 
dried it over MgSO4. The solvent was removed, and the remaining solid was purified 
by column chromatography (2:8 hexane/ ethyl acetate) to obtained a bright yellow 
solid (FAS67) (0.28 g, 10%). m.p. 108-110 ºC  δH (DMSO) 7.52 (2H, dd, 3J 5.80, 4J 
3.22 4-H, 7-H), 7.17 (2H, dd, 3 J 5.90, 4J 3.10, 5-H, 6-H), 4.66 (1H, s, CH2Cl), 4.04 
(1H, t, 3 J 7.16, CH2Br), 3.55 (1H, t, 3 J 7.00, CH2N). 
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1-(10-bromodecyl)-2-(chloromethyl)-1H-benzo[d]imidazole (FAS68) 
 
2-Chloromethylbenzimidazole (FAS 43) (0.83 g, 5 mmol) was combined with an 
excess of potassium carbonate (2.76 g, 20 mmol), and was dissolved in ethanol (20 
ml). An ethanol solution of 1,10-dibromodecane (1.80 g, 6 mmol) was added 
dropwise to the the 2-chloromethyl-1H-benzimidazole (FAS43) solution, and the 
combined mixture was heated under reflux for 48 hours. Water (50 ml) was added 
to the mixture, and then was extracted the product with CHCl3 (2 X 100 ml), then 
collected the organic phase and dried it over MgSO4. The solvent was removed, and 
the remaining solid was purified by column chromatography (9:1 chloroform/ 
ethanol) to obtained a bright yellow solid chloroform/ ethanol) to obtained a bright 
yellow solid (FAS68) (0.05 g, 3%). m.p. 154-156 ºC. δH (DMSO) 7.65 (2H, dd, 3J 
8.40, 4J 4.40 4-H, 7-H), 7.21 (2H, dd, 3 J 8.00, 4J 4.20, 5-H, 6-H), 4.72 (1H, s, 
CH2Cl), 3.50 (1H, t, 3 J 6.80, CH2Br), 4.23 (1H, t, 3 J 7.60, CH2N), 1.28 (12H, m, 3’-
H,4’-H,5’-H,6’-H,7’-H and 8’-H), 1.78 (4H, p, 2’-H & 9’-H). ). MS (EI): m/z 307 (M-Br, 
100%).  
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2.3.18 Synthesis of silver complexs of 2-carboxylic acid-benzimidazole 
derivatives 
Silver complex of 1H-benzo[d]imidazole-2-carboxylic acid (FAS69) 
 
A solution of AgNO3 (0.5 g, 3 mmol) in ethanol (5 ml), was added to a solution of 
1H-benzo[d]imidazole-2-carboxylic acid (FAS29) (0.49 g, 3mmol) in ethanol (5 ml) 
to form 1:1 M:L complex. The reaction mixture stirred at 50 ºC, for 2 hrs. The 
resulting precipitate was filtered off, washed with diethyl ether, followed by warm 
ethanol. The formed complex (FAS69) was kept under dry conditions. The complex 
was obtained as white solid (0.52 g, 63 %), m.p. >300ºC. υmax /cm-1 (KBr) 3224 (O-
H), 1631 (C=O), 1339 (C-O). δH (DMSO-d6) 7.70 (2H, s, 4-H, 7-H), 7.35 (2H, s, 6-H, 
5-H).Elemental analysis based on the structure above, found; C, 33.93 %; H, 2.00 
%; N, 10.98 %; requires; C, 34.40 %; H, 2.32 %; N, 10.03 %. 
  
Silver complex of 5-bromo-1H-benzo[d]imidazole (FAS70) 
 
A solution of AgNO3 (0.5 g, 3 mmol) in ethanol (5 ml), was added to a solution of 5-
bromo-1H-benzo[d]imidazole (FAS19) (0.72 g, 3mmol) in ethanol (5 ml) to form 1:1 
M:L complex. The reaction mixture was stirred at 50 ºC, for 2 hrs. The resulting 
precipitate was filtered off, washed with diethyl ether, followed by warm ethanol. The 
formed complex was kept under dry condition, to obtained the product as yellow 
solid (FAS70) (0.20 g, 20%). m.p. 258-260 ºC. υmax /cm-1 (KBr) 3464 (N-H), 1046 C-
Br. δH (DMSO-d6) 8.66 (1H, s, 2-H), 8.01 (1H, s, 4-H), 7.50 (1H, dd, 3J 8.00, 4J  2.20, 
6-H), 7.47 (1H, d, 3J 8.00, 7-H). Elemental analysis based on the structure above, 
found; C, 26.75 %; H, 1.53 %; N, 10.19 %; requires; C, 27.75 %; H, 1.65 %; N, 9.19 
%. 
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Silver complex of 1H-benzo[d]imidazole (FAS71) 
 
A solution of AgNO3 (0.5 g, 3 mmol) in ethanol (5 ml), was added to a solution of 5-
nitro-1H-benzo[d]imidazole (FAS21) (0.62 g, 3mmol) in ethanol (5 ml) to form 1:1 
M:L complex. The reaction mixture was stirred at 50 ºC, for 2 hours. The resulting 
precipitate was filtered off, washed with diethyl ether, followed by warm ethanol. The 
formed complex (FAS71) was kept under dry condition. The complex formed as 
yellow solid (FAS 71) (0.3 g, 33%). m.p. >300 ºC. υmax /cm-1 (KBr) 3432 (NH), 3103 
(C-H, sp2), 1520 and 1341 (N-O). δH (DMSO-d6) 8.71 (1H, s, 2-H), 8.65 (1H, s, 4-H), 
8.19 (1H, dd, 3J 8.00, 4J  2.20, 6-H), 7.84 (1H, d, 3J 8.00, 7-H). Elemental analysis 
based on the structure above, found; C, 27.22 %; H, 1.56 %; N, 13.86 %; requires; 
C, 27.43 %; H, 1.64 %; N, 13.71 %. 
 
Silver complex of bis(5-methyl- 1H-benzo[d]imidazole-2-carboxylic acid) (FAS72) 
 
A solution of AgNO3 (0.18 g, 1.07 mmol) in ethanol (5 ml), was added to a solution 
of 5-methyl-1H-benzo[d]imidazole-2-carboxylic acid (FAS30) (0.38 g, 2.15 mmol) in 
ethanol (5 ml) to formed 1:2 M:L complex. The reaction mixture was stirred at 50 ºC, 
for 2 hours. The resulting precipitate was filtered off, washed with diethyl ether, 
followed by warm ethanol. The formed complex (FAS72) was kept under dry 
condition. υmax /cm-1 (KBr) 3406 (N-H), 3052 (C-H, sp2), 1624 (C=O), 1336 (C-O). 
The complex formed as pink solid (FAS 72) (0.33 g, 31%). m.p. 288-290ºC. δH 
(DMSO-d6) 8.20 (2H, br, s, OH, NH), 7.52 (1H, s, br, 7-H), 7.45 (1H, s, br, 6-H), 7.19 
(1H, s, br,  4-H), 2.45 (3H, s, CH3). Elemental analysis based on the structure 
above, found; C, 43.61 %; H, 3.17 %; N, 11.43 %; requires; C, 43.62 %; H, 3.25 %; 
N, 11.30 %. 
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Silver complex of bis(5-bromo-1H-benzo[d]imidazole) (FAS73) 
 
A solution of AgNO3 (0.13 g, 0.8 mmol) in ethanol (5 ml), was added to a solution of 
5-bromo-1H-benzo[d]imidazole (FAS19) (0.38 g, 1.6 mmol) in ethanol (5 ml) to 
formed 1:2 M:L complex. The reaction mixture was stirred at 50 ºC, for 2 hours. The 
resulting precipitate was filtered off, washed with diethyl ether, followed by warm 
ethanol. The formed complex (FAS73) was kept under dry condition. υmax /cm-1 (KBr) 
3468 (N-H),  3052 (C-H, sp2), 1045 C-Br, 1585 and 1345 (N-O). The complex 
formed as yellow solid ( FAS73)(0.29 g, 33%). m.p.138-140 ºC. δH (DMSO-d6) 8.64 
(1H, s, 2-H),  8.00 (1H, s, 4-H), 7.70 (1H, d, 3J 8.00, 7-H), 7.48 (1H, dd, 3J 8.00, 4J 
2.40, 6-H). Elemental analysis based on the structure above, found; C, 29.58 %; H, 
1.81 %; N, 11.76 %; requires; C, 29.92 %; H, 1.43 %; N, 12.46 %. 
 
Silver complex of bis(5-nitro- 1H-benzo[d]imidazole) (FAS74) 
 
A solution of AgNO3 (0.16 g, 0.97 mmol) in ethanol (5 ml), was added to a solution 
of 5-nitro-1H-benzo[d]imidazole (FAS21) (0.40 g, 1.95 mmol) in ethanol (5 ml) to 
formed 1:2 M:L complex. The reaction mixture was stirred at 50 ºC, for 2 hours. The 
resulting precipitate was filtered off, washed with diethyl ether, followed by warm 
ethanol. The formed complex (FAS74) was kept under dry condition. υmax /cm-1 (KBr) 
3468 (NH), 3105 (C-H, sp2), 1514 and 1350 (N-O). The complex formed as yellow 
solid (FAS 74) (0.37 g, 39 %). m.p. >300 ºC. δH (DMSO-d6) 8.80 (1H, s, 2-H), 8.72 
(1H, s, br, 4-H), 8.21 (1H, dd, 3J 8.00, 4J 2.40, 6-H), 7.89 (1H, d, 3J 8.20, 7-H). 
Elemental analysis based on the structure above, found; C, 33.55 %; H, 2.05 %; N, 
18.91 %; requires; C, 33.89 %; H, 2.03 %; N, 19.76 %. 
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2.4 Materials and methods for microbiological evaluation 
2.4.1 Screening for Antibacterial activity  
2.4.1.1 Materials 
Tryptone Soya Agar (CM0131, Oxid Ltd., Basingstoke, UK) 
Iso-sensitest agar (CM0471, Oxid Ltd., Basingstoke, UK) 
Dimethylsulphoxide (DMSO), Sigma-Aldrich D5879 
Whatman grade AA discs, 6 mm diameter ( Fisher Scientific). 
 
2.4.1.2 Bacterial strains used in this project 
All reference and clinical strains were obtained from Dr Anna Snelling, University of 
Bradford. Details are given in Table 2.1. Overall, 15 strains of Staphylococcus Spp. 
(inc  2 x S. aureus, 8 x MRSA, 2 x EMRSA, 2 x S. epidermidis and 1 x S. 
haemolyticus), 5 strains of E. coli, 4 strains of Ps. aeruginosa, 1 strain of Serratia 
marcescens, and 1 strain of Burkholderia cepacia were used (Table 2.1). 
 
2.4.1.3 Culture media and incubation conditions  
Culture media was prepared and treated according to manufacturer’s guidelines and 
sterlised by autoclaving at 121°C for 15 minutes at 15 lbs/sq inch pressure. The 
strains were routinely grown on Tryptone Soya Agar or Iso-Sensitest agar, 
incubated at 37 ˚C in air for 16-18 hrs. Stock culture plate were stored at 4 ˚C. 
2.4.1.4 Ciprofloxacin 
The control drug used for the antibacteria screening was ciprofloxacin. The drug 
was purchased as discs: 5μg from Oxid Ltd (Basingstoke, UK) (CIP 5μg) (CT0425B) 
(Figure 2.1). 
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Figure  2.1 Structure of ciprofloxacin 
2.4.1.5 Disc diffusion tests  
Disc diffusion assays for antimicrobial susceptibility testing were carried out in-line 
with the standard method first described by Bauer (1966), to assess if the 
compounds had any antibacterial activities. Bacterial suspensions were prepared 
from fresh, overnight, agar cultures in sterile distilled water, and adjusted to a 0.5 
McFarland turbidity standard (Remel). These were used to seed Iso-sensitest agar 
plates evenly using a sterile swab (Bauer R. W. et al., 1966). 
For test compounds, each was measured to 10 mg/ ml in DMSO, and different 
amounts of each (typically 10, 100 and 200 μg) were loaded from the working stock 
solution onto 6 mm diameter sterile Whatmann discs (Fisher Scientific, UK) and 
allowed to dry. The loaded discs were placed on the surface of the agar lawns with 
the help of a needle and forceps. Each test plate comprised of 5 discs, three 
impregnated discs, one control (Ciprofloxacin 5 μg), and one negative control 
(impregnated with 20 μl of 100 % DMSO). The plates were incubated at 37˚C for 24 
hours. At the end of incubation, the plates were examined for zone of inhibition. 
Diameters of inhibition zones were measured (in mm) and recorded.  If any activity 
was observed, the test was repeated on a separate day, using a fresh culture. 
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2.4.1.6 Agar dilution method for determining Minimum Inhibitory 
Concentration (MICs) 
The MIC of the synthesised compounds was determined by the agar dilution 
technique using Iso-sensitest agar. Agar dilution was on the range of: 0.5, 1, 2, 4, 8, 
16, 32, 64, 128, 256, and 512 μg/ml. Iso-sensitest agar was prepared in 19 ml 
aliquots, using sufficient base powder for 20 ml. Once it had cooled to 
approximately 50˚C, appropriate amount of the test compound were added in a 
volume of 1 ml. 
 The 19 ml aliquots in universal bottles were double steamed instead of autoclaving; 
to ensure that there was no loss of the volume of water in them. The lids were 
tightend, and the bottles were then steamed for 2 hours; left to cool and set, then on 
the following day steamed again for another 2 hours to kill any vegetative cells that 
had germinated from spores. Eventually, the agar was ready to be used for MIC 
tests. A few extra universals were prepared to make the control plates (Iso-sensitest 
aga only). One of them was inoculated at the start and one at the end of a run; to 
ensure there is no splash over or cross contamination and that the strains grow.  
Strains were challenged against a series of doubling dilutions of the test compounds 
(from 512 through to 0.5 μg/ml) details are given in Table 2.2. A bacterial 
suspension was prepared in bijoux bottles in sterile water with the turbidity 
equivalent to a 0.5 McFarland standard. Then, 0.5 ml of each suspension was 
transferred to a seprate, sterile well of 32-well multipoint inoculator base. 
Microorganisms were seeded on to the freshly prepared MIC agar plates using a 
multi-point inoculator (Denley). The device has a 37 pin head.  
After briefly allowing the innocula to dry, the plates were incubated overnight at 37 
˚C and the MIC was defined as the lowest concentration of compound that inhibited 
bacterial growth completely, as indicated by the absence of any visible growth in the 
inoculation spot on the agar surface.  
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2.4.2 Screening for antifungal activity 
2.4.2.1 Materials  
Peptone Primatone® 
RL, Sigma-Aldrich P4963  
Agar powder, Sigma-Aldrich 05040 
Malt extract, Sigma-Aldrich 70167 
D-(+)-Glucose monohydrate, Sigma-Aldrich 49159 
Dimethylsulphoxide (DMSO) ReagentPlus®, ≥99.5% , Sigma-Aldrich D5879 
Amphotericin B solubilised, Sigma-Aldrich A9528 
 
2.4.2.2 Fungal strains used in this project 
The strains were obtained from the Regional Center for Mycology and 
Biotechnology (RCMB), Al-Azhar University, Cairo, Egypt and this part of the 
practical work was done there as well. Reference isolates for the antifungal 
screening; included representatives of unicellular fungi; namely, Candida albicans 
RCMB 05035, Candida krusei RCMB 05051, Candida parapsilosis RCMB 05065, 
Candida tropicalis RCMB 05049, and filamentous fungi; namely, Absidia 
corymbifera RCMB 09635, Aspergillus clavatus RCMB 2593, Aspergillus fumigatus 
RCMB 02564, Mucor circinelloides RCMB 07328, Mucor circinelloides RCMB 
07328, Absidia corymbifera RCMB 09635, Penicillium marneffei RCMB 01267, 
Syncephalastrum racemosum RCMB 05922 (Table 2.3).  
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Table  2.3. Details of fungal strains used in this project 
Fungal species / strain Type   
Aspergillus fumigatus RCMB 02564 filamentous 
Aspergillus clavatus RCMB 02593 filamentous 
Mucor circinelloides RCMB 07328 filamentous 
Absidia corymbifera RCMB 09635 filamentous 
Penicillium marneffei RCMB 01267 filamentous 
Syncephalastrum racemosum RCMB 05922 filamentous 
Candida albicans RCMB  05035 unicellular 
Candida tropicalis RCMB  05049 unicellular 
Candida  krusei RCMB  05051 unicellular 
Candida parapsilosis RCMB  05065 unicellular 
RCMB: Regional Center for Mycology and Biotechnology, Cairo, Egypt. 
 
2.4.2.3 Culture media and incubation conditions 
For culturing, maintenance of axenic strains and antifungal screening, Malt Extract 
Agar (Malt extracts, 20 g; Peptone, 1 g; Glucose, 20 g; Agar, 25 g per litre) was 
used. The medium was prepared by dissolving the solid ingredients in one litre of 
cold distilled water, and then heating to 60-70 °C with stirring. It was sterilized by 
autoclaving at 121°C for 15 minutes at 15 lbs/sq inch pressure and when cool, 
poured into sterile glass Petri-dishes. For maintenance of stock cultures, it was 
poured into slants, autoclaved, and then tilted whilst the agar set to provide a slope 
for growth of stock cultures. A cork borer was used to remove a piece of mycelia 
growth from an older plate, and transplant it onto the fresh agar. A liquid Malt 
Extract (broth) medium was prepared by using the same ingredients without the 
agar. 
 
2.4.2.4 Amphotericin B 
Amphotericin B was the control drug compartor used in the antifungal screening, 
see Figure 2.2. A stock solution was prepared in DMSO at 2.5 mg/ml and filters 
sterilized. 
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Figure  2.2 .Structure of amphotericin B 
 
2.4.2.5 Screening for antifungal activity by the well diffusion method  
Antimicrobial activity was determined by the well diffusion method according to 
National Committee for Clinical Laboratory Standards (NCCLS) methodology 
(National Committee for Clinical Laboratory Standards, 1993). Petri plates 
containing 20 ml of Malt extract Agar were seeded with 2-3 day old cultures of 
fungal inoculums (suspensions of spores in sterile water). Wells (6 mm in diameter) 
were cut by cork borer into the agar, and 50 μl of diluted compound in DMSO was 
added at a concentration of 5 mg/ml (250 μg per well) and incubated at 37?C 
(unicellular strains) or 28?C (filamentous strains) for 3-7 days depending on growth 
rate of each strain. The antifungal activity was determined based on measurement 
of the diameter of the inhibition zone formed around each well. 
 
2.4.2.6 Determination of Minimum Inhibitory Concentration Test (MIC) 
of compounds against fungi  
The chemical compounds were diluted in DMSO, and then serial doubling dilutions 
1:1, with a sterile diluent (typically appropriate broth) was inoculated in each well of 
a microtiter tray (96 well). After the compounds was diluted, a volume of the 
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standardized inoculum equal to the volume of the diluted antimicrobial agent was 
added to each well, bringing the microbial concentration to approximately 5 X 105 
cells per milliliter. The trays were incubated at an appropriate temperature (28?C or 
37?C) for the test species for a pre-set period. After incubation, the series of dilution 
wells was observed for microbial growth, usually indicated by turbidity and/or a 
pellet of fungi in the bottom of the well. The last well in the dilution series that didn’t 
demonstrate growth corresponds with the minimum inhibitory concentration (MIC) of 
the test compound. 
 
2.4.3 The series of compounds screened for Antimicrobial activity  
The compounds were synthesised, purified and used for antimicrobial screening 
assays; after first being divided into 13 main series as shown below according to 
their structures (Table 2.4).  
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3 Synthesis 
 
3.1 Introduction 
The Introduction (Section 1.10) highlighted the need for new chemotherapeutic 
drugs to treat microbial infections. It is possible to design a wide range of potential 
microbial inhibitors by replacing the hydrogen at various positions of the 
benzimidazole ring with different functional groups. However the most accessible 
derivatives are those with substituents at the 1-, 2- and 5-positions. Retrosynthetic 
analysis of a 2,5-disubstituted benzimidazole identified 2 fragments which explains 
why these particular substituted benzimidazoles are easy to prepare (Figure 3.1). 
The substitution at the 1-position occurs readily after the ring has formed. 
R NH2
NH2
N
H
N
N
R1
N
H
R
R1
HO
O
2-position
5-position
1-position
+
 
Figure  3.1 Retrosynthetic analysis of benzimidazole 
Benzimidazole is synthesised from the reaction of a 1,2-phenylenediamine and a 
carboxylic acid. It is through this route that the structural diversity arises on both 
sides of the fused bicyclic ring, i.e., the imidazole and benzene rings (Figure 3.1). 
The use of different substituted 1,2-phenylenediamines creates variation on the 
benzene ring whereas substitution on the imidazole side chain can be achieved 
through the use of various carboxylic acids. It is also possible to create structural 
diversity in the desired potential inhibitors, through the modification on the side 
chain of benzimidazole. The reaction between various carboxylic acids with a 
variety of 1,2-phenylenediamine derivatives would ultimately lead to numerous 
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benzimidazoles as potential microbial inhibitors. In this project, the design of these 
inhibitors focused on 5-substituted benzimidazoles (Section 3.3.1.) followed by 
synthesis of 2,5-disubstiututed analogues based on 1H-benzimidazole-2-
yl)methanol derivatives (Section 3.3.2), (1H-benzimidazole-2-yl)alkylamines  
derivatives (Section 3.4), (1H-benzimidazole-2-yl)-ethyl derivatives (Section 3.5), 
(1H-benzimidazole-2-yl)-methanthiol derivatives (Section 3.6), (1H-benzothiozole-2-
yl)-methanol (Section 3.7), N-alkylbromo-(1H-benzimidazole-2-yl)-chloromethyl 
(Section 3.8), 1(3)-oxide-benzimidazole derivatives (Section 3.9), benzoxazole 
derivatives (Section 3.10) and silver complexes (Section 3.11). 
 
3.2 Characterisation of products 
3.2.1 1H NMR spectroscopy 
The aromatic region of the 1H NMR spectra of benzimidazoles contained 
characteristic splitting and coupling constants. In all the benzimidazoles 
unsubstituted in the fused benzene ring, peaks corresponding to the 4-H, 7-H and a 
signal for 5-H, 6-H were observed. In benzimidazoles unsubstituted in the 2-
position, a singlet is also observed for 2-H. These peaks all appeared in the 
aromatic region of the spectrum. The 2-H peak will be absent in benzimidazoles 
with groups in the 2-position and will exhibit signals corresponding to the side chain. 
Simple splitting for a 5-substituted benzimidazole would be peaks arising from 4-H 
and two doublets arising from 6-H and 7-H. However, 4-H appears as a doublet, 6-H 
as a doublet of doublets and 7-H as a doublet. This occurs due to the coupling of 4-
H and 6-H protons. Coupling of the aromatic benzimidazole proton occurs with both 
adjacent protons and protons meta to it (Figure 3.2). The 3J values occur from ortho 
coupling while 4J values occur from meta coupling.  
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 Figure  3.2 An expansion of the aromatic region of the 1H spectrum of FAS24 
The addition of a substituent in the 5-position, affects the chemical shifts of the 
aromatic ring protons. For example, an electron-withdrawing nitro group in the 5-
position reduces the electron density around the aromatic protons. As a result these 
protons are deshielded from the external magnetic field and appear downfield.    
Likewise, the addition of a substituent in the 2-position, affects the chemical shifts of 
these protons. For example, ethyl, methanthiol and methanol groups in the 2-
position increase the electron density around the imidazole ring. As a result these 
protons are shielded from the external magnetic field and appear upfield, unlike the 
aminoalkyl groups which decrease the electron density around the imidazole ring. 
As a result these protons are deshielded from the external magnetic field and 
appear downfield. After the chlorination or oxidation of the 2-
methanolbenzimidazole, the chloromethyl and carboxylic acid groups decrease the 
electron density around the imidazole ring. As a result these protons are deshielded 
from the external magnetic field and appear downfield.  
The addition of a substituent in the 1-position affects the chemical shifts of these 
protons. For example, an electron withdrawing oxygen group in the 1-position 
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reduces the electron density around the imidazole ring. As a result these protons 
are deshielded and appear downfield. Moreover, the addition of methyl group in the 
1-position increases the electron density around the imidazole ring and appears 
upfield.  
The NH signal in the imidazole ring was sometimes absent in 1H NMR spectra. The 
OH peak of alcohols and acids were broad due to rapid intermolecular proton 
exchange and their presence was confirmed by deuterium exchange experiments. 
The aromatic region of the 1H NMR spectra of benzothiazole FAS65, which is 
unsubstituted in the fused benzene ring, showed two doublets corresponding to the 
4-H, 7-H and two doublet of doublets for 5-H and 6-H protons. These peaks all 
appeared in the aromatic region of the spectrum. FAS65 which has the methanthiol 
group in the 2-position, exhibits signals for SH and CH2 in the spectrum.  
Simple splitting for a 5-substituted benzoxazole FAS63 would be expected to be a a 
singlet arising from 4-H and another doublet arising from 7-H and 6-H as doublet of 
doublets. However, for compound FAS62, 4-H appears as a doublet, 6-H as a 
doublet of doublets and 7-H as a doublet. This occurs due to the coupling of 4-H 
and 6-H protons. Coupling of an aromatic benzoxzole proton occurs with both 
adjacent protons and protons meta to it (Figure 3.3).  
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 Figure  3.3 An expansion of the aromatic region of the 1H spectrum of FAS62 
 
The addition of a substituent in the 5-position affects the chemical shifts of the 
aromatic ring protons. For example, an electron-withdrawing nitro group in the 5-
position reduces the electron density around the aromatic protons. As a result these 
protons are deshielded from the external magnetic field and appear downfield.  
Compounds FAS61 and FAS62 contains the carbonyl group in the 2-position which 
also affects the chemical shifts and decreases the electron density around the 
oxazole ring by the resonance with the electron pair of the nitrogen atom. Therefore, 
the peaks appear to be shielded. Moreover, the 2-H peak will be absent in these 
compounds. On the other hand the NH appears as a single peak. In the 13C NMR 
spectrum, the the carbonyl group appears at 154 ppm.  
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3.2.2 Mass spectra of benzimidazoles 
Mass fragmentation patterns of the benzimidazoles synthesised showed similar 
characteristics and confirmed the structure. The major fragments present in the 
mass spectra of all the synthesised compounds were similar to the mass spectrum 
of 5-nitro-2-chloromethylbenzimidazole FAS49, which is shown in Figure 3.10. The 
chlorine isotope is seen as expected and supports the structure. The ratio of the M 
and M + 2 is 3: 1. The molecular ion was stable and fragmentation proceeded with 
loss of chlorine atom and then loss proton. The nitro group was lost then HC2N as 
demonstrated in the scheme (Figure 3.4).  
 
 
Figure  3.4 Fragmentations pattern of compound FAS49 
 
3.2.3 IR spectra  
The infrared spectra of the compounds exhibit the bands at 3250-3590 cm-1 and 
2900-3040 cm-1, assigned to ѵ(NH, OH) and ѵ(C-H, sp2) of the benzimidazole ring, 
respectively. The band appearing at about 2830-2790 cm-1 is assigned to ѵ(C-H, 
sp3) vibrations. The compounds containing carbonyl groups in their structures, 
exhibited a vibration in the range of 1624-1748 cm-1, while the peak at 1300-1343 
cm-1 is also attributed to C-O stretching vibrations. 
The silver complexes were fromed with benzimidazole derivatives as a ligand. The 
bands are shifted towards lower and higher frequencies respectively, depending on 
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the ligands. The IR spectra of the complexes are similar to those of the 
corresponding ligands. An upward shift of ѵ(C=N) in the spectra of complexes 
FAS69, 70, 72, 73 and FAS 74 as compared to their values for the free ligand, 
suggests coordination through the imidazole nitrogen of the benzimidazole 
derivatives of FAS19, 21, 29, and 30.The other bands in the spectrum of each 
complex are similar to those for the corresponding ligand, except for slight shifts in 
their positions and changes in their intensities due to coordination 
3.3 Synthesis of benzimidazoles 
The well-known method for the synthesis of the benzimidazole ring is the Phillips 
condensation, reported by Phillips in 1928 (Phillips, 1928). The formation of 
benzimidazoles by this procedure is achieved by the heating of a carboxylic acid 
with a 1,2-phenylenediamine in the presence of an acid catalyst. This method was 
selected to synthesise the target compounds, as it is reported to produce 
benzimidazoles in moderate yields.  
 
3.3.1 5-Substituted benzimidazoles 
Some of the target compounds required for this study were benzimidazoles which 
only varied at the 5-position. These compounds were synthesised from  
4-substituted-1,2-phenylenediamine and formic acid to give benzimidazole 
derivatives FAS15-21, 51. The reaction time for compounds FAS16-21 was 
between 60-480 min (Table 3.1). On the other hand, the synthesis of benzimidazole 
itself FAS15, from the reaction of 1,2-phenylenediamine with formic acid, is 
achieved within 30 min (Phillips, 1928). However, the reaction for 1H-
benzo[d]imidazole-5-cyano FAS51, was much longer than the synthesis of other 
derivatives. The reaction commences in the absence of an acid catalyst. The 
proposed mechanism of formation of the benzimidazole ring is described in (Figure 
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3.5). The yield here is obviously dependent on the nature of the substituent on 4-
position of the 1,2-phenylenediamine.  
 
Table  3.1 Reaction times, yields and melting points for 5-substituted benzimidazoles 
 
Compound R Reaction time (min) 
Yield 
(%) mp/ °C Lit. mp/ °C 
FAS15 H 30 74 170-172 170 (Phillips, 1928) 
FAS16 CH3 60 87 112-114 
112-114 (Mohammadpoor-Baltork 
et al., 2007) 
FAS17 OCH
3 
60 85 116-118 117-120 (Tanaka et al., 1981) 
FAS18 Cl 180 100 123-125 124-126 (Liu et al., 2011) 
FAS19 Br 180 97.5 130-133 130-131 (Evans and et al., 1978) 
FAS20 F 180 90.0 130-132 132 (Fisher and Joullie, 1958) 
FAS21 NO2 480 100 203-205 204-205 (Liu et al., 2011) 
FAS51 CN 1440 44 230-232 230-233 (Elshihawy, 2008) 
 
Table  3.2 Assignment of the 1H NMR spectra of 5-substituted benzimidazoles 
 
Compound δ/ppm 
R H4 H5 H6 H7 H2 
FAS15 H 7.63 7.20 7.20 7.63 8.27 
FAS16 CH3 7.40 - 7.01 7.50 8.18 
FA 17 OCH3 7.07 - 6.91 7.53 8.09 
FAS18 Cl 7.66 - 7.20 7.60 8.32 
FAS19 Br 7.81 - 7.32 7.56 8.27 
FA 20 F 7.25 - 7.75 7.56 9.05 
FAS21 NO2 8.49 - 8.07 7.74 8.54 
FAS51 CN 8.16 - 7.58 7.75 8.48 
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Figure  3.5 Proposed mechanism for the formation of 5-methylbenzimidazole 
 
Table  3.3 Assignment of the 13C NMR spectra of 5-substituted benzimidazoles 
1
2
34 3a
6 N
H7
NR5
7a
 
Compound δ/ppm R C4 C5 C6 C7 C2 C3a C7a 
FAS15 H 121.7 115.3 115.3 121.7 141.9 138.1 138.1 
FAS16 CH3 113.4 123.2 116.1 113.4 141.6 130.9 130.9 
FAS17 OCH3 97.6 156.1 113.1 116.4 141.6 130.9 130.9 
FAS18 Cl 116.3 126.2 122.0 115.1 143.4 139.2 136.5 
FAS19 Br 116.8 118.2 125.5 113.9 143.3 139.9 136.9 
FAS20 F 101.0 158.1 112.5 115.9 142.3 134.2 130.5 
FAS21 NO2 112.7 146.8 117.4 114.6 142.5 138.6 141.8 
FAS51 CN 123.4 103.8 125.3 119.8 145.2 142.0 142.0 
 
The structures of these compounds were verified by 1H NMR spectroscopy. The 
presence of a singlet peak at around 8 ppm for the hydrogen at the 2-position was 
indicative of successful benzimidazole ring formation (Table 3.2). The melting points 
also matched the literature data. The chemical shifts in the13C NMR spectra were as 
expected, and the presence of the peak around 141 ppm for the carbon at position 2 
confirmed the structure (Table 3.3). 
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3.3.2  (1H-Benzimidazole-2-yl)-methanol derivatives 
(1H-Benzimidazole-2-yl)-methanol derivatives (FAS 22-28, 52) were synthesised by 
the ring closure of 1,2-phenylenediamines with glycolic acid (2-hydroxyacetic acid) 
(Figure 3.7). Complete reaction was typically achieved within 10 hours even for the 
most electron deprived 1,2-phenylenediamines. The (1H-benzimidazole-2-yl)-
methanol derivatives were precipitated from the reaction mixture as brown solids on 
treatment with ammonia solution. They were purified by initially treating them with 
decolourising charcoal and followed by recrystallisation. 5-Nitro FAS28, 5-chloro 
FAS25, 5-bromo FAS26, 5-fluoro FAS27, 5-methyl FAS23, 5-methoxy FAS24, 5-
cyano FAS52, and (1H-benzimidazole-2-yl)methanol FAS22, were all successfully 
synthesised in good yields (Table 3.4). The structures of these compounds were 
confirmed by 1H NMR (Table 3.5) and 13C NMR spectroscopy (Table 3.6). These 
compounds all gave characteristic singlets around 4.7 ppm corresponding to the 
CH2 group and a broad signal corresponding to the hydroxyl group in the 1H NMR 
spectra. The CH2 peak of the starting material appears at a lower chemical shift 
(4.13 ppm) (Justino et al., 2000). 
Table  3.4 Reaction time, yields and melting points of (1H-benzimidazole-2-yl)methanol and 
derivatives 
N
H
NR
OH
 
Compound R Reaction time (min) Yield (%) m.p/ °C Lit. m.p/ °C 
FAS22 H 180 96 172-174 170-172 (Lahlou et al., 2003) 
FAS23 CH3 180 100 194-196 202-203 (Donkor, 2007) 
FAS24 OCH3 480 100 182-184 - 
FAS25 Cl 480 95 200- 202 202 (Lahlou et al., 2003) 
FAS26 Br 480 85 208- 210 208 (Khan  et al., 1972) 
FAS27 F 480 70 182-184 182 (Wagner and et al., 1972) 
FAS28 NO2 2880 56 198-200 198-200 (Donkor, 2007) 
FAS52 CN 60 57 170-172 172-173 (Rangarajan et al., 2000) 
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Table  3.5 Assignment of the 1H NMR spectra of the 1H-Benzimidazole-2-yl)methanol  
derivatives 
1
2
34
5
6 N
H7
N
OH
R 3a
7a
1'
 
Compound 
δ/ppm 
R H4 H5 H6 H7 
FAS22 H 7.50 7.14 7.14 7.50 
FAS23 CH3 7.29 - 6.97 7.38 
FAS24 OCH3 6.99 - 6.76 7.37 
FAS25 Cl 7.54 - 7.16 7.49 
FAS26 Br 7.67 - 7.27 7.45 
FAS27 F 7.28 - 6.99 7.49 
FAS28 NO2 8.39 - 8.08 7.66 
FAS52 CN 8.00 - 7.52 7.64 
C
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3.3.3 Reactions of (1H-benzimidazole-2-yl)methanol 
3.3.3.1 Conversion to chloromethyl group 
The hydroxyl group of (1H-benzimidazole-2-yl)methanol, was converted into a 
chloride through a reaction with thionyl chloride (Figure 3.7) and the proposed 
mechanism is shown in (Figure 3.6). The 2-chloromethylbenzimidazoles were 
required for the biological studies to provide a direct comparison with other 
functional groups in the 2-position of benzimidazole. 2-(Chloromethyl)-1H-
benzimidazole derivatives FAS43-49, 53 were formed from the reaction of the (1H-
benzimidazole-2-yl)methanol FAS22-28, 52 with thionyl chloride according to the 
method developed by Setoi which involved heating the mixture under reflux (Setoi et 
al., (2001)) or according to the Dirk method which involved stirring the reaction 
mixture at ambient temperature (Dirk et al., (2009)). The difference between the two 
methods is clear in terms of the purity of the synthesised compounds (Table. 3.7).  
2-Chloromethylbenzimidazoles are able to undergo reactions with amines and other 
nucleophiles to produce a new series of compounds. Two methods have been used 
in the synthesis of these derivatives. In the first method, according to Lohman et al. 
(1999), a solution of the 5-subistituted-2-hydroxymethyl-benzimidazole derivatives in 
thionyl chloride was heated under reflux until the starting material no longer exists 
(Lohmann et al., (1999), Dirk et al., (2009)). The second method, developed by Dirk 
et al., is similar except dichloromethane was required as a solvent and the reaction 
was conducted at ambient temperature (Lohmann et al., (1999), Dirk et al., (2009)). 
The procedure was superior in that the were products purer. 
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Figure  3.6 Proposed mechanism for the chlorination of hydroxyl group 
 
Table  3.7 Comparison of reaction times, yields and melting points for 5-substituted-2-H-
benzimidazoles. 
N
H
NR
Cl
 
Compound R Reaction time (min) Yield (%) Method mp/ °C Lit. mp/ °C 
FAS43 H 180 72 Hiroyuki, 2001 142-144 140-141 
FAS44 CH3 180 61 
Hiroyuki, 
2001 128-130 127-132 
FAS45 OCH3 180- 89 Dirk, 2009 200-202 - 
FAS46 Cl 300- 79 Dirk, 2009 210-212 213-214 (King et al., 1949) 
FAS47 Br 300- 91 Dirk, 2009 248-250 
249-250 
(Dandegaonker and 
Shastri, 1965) 
FAS48 F 300- 80 Dirk, 2009 212-214 - 
FAS49 NO2 480- 88 Dirk, 2009 170-172 
174 (Labas et al., 
2011) 
FAS53 CN 560- 57 Dirk, 2009 230-232 230-232 (Elshihawy, 2008) 
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Table  3.8 Assignment of the 1H NMR spectra of the 2-chloromethylbenzimidazole 
derivatives 
1
2
345
6 N
H7
N
Cl
R
1'
3a
7a
 
Compound 
δ/ppm 
R H4 H5 H6 H7 
FAS43 H 7.81 7.54 7.54 7.81 
FAS44 CH3 7.57 - 7.34 7.66 
FAS45 OCH3 7.25 - 7.16 7.72 
FAS46 Cl 7.85 - 7.49 7.78 
FAS47 Br 7.99 - 7.61 7.73 
FAS48 F 7.67 - 7.38 7.82 
FAS49 NO2 7.48 - 8.11 7.74 
FAS53 CN 7.99 - 7.64 7.52 
 
Table  3.9 Assignment of the 13C NMR spectra of the 2-chloromethylbenzimidazole 
derivatives 
1
2
345
6 N
H7
N
Cl
R
1'
3a
7a
 
Compound 
δ/ppm 
R C2 C3a C4 C5 C6 C7 C7a C-1’ 
FAS43 H 148.2 130.7 114.0 125.8 125.8 114.0 130.7 33.79 
FAS44 CH3 153.9 147.6 127.3 128.7 130.9 113.4 135.8 33.76 
FAS45 OCH3 157.4 146.8 114.5 115.6 124.8 95.47 131.5 35.15 
FAS46 Cl 156.1 150.2 116.1 125.9 129.7 114.4 134.1 35.1 
FAS47 Br 150.2 134.4 117.3 125.5 129.5 116.1 132.2 35.0 
FAS48 F 158.6 150.0 114.2 116.2 129.3 101.1 133.0 35.0 
FAS49 NO2 142.6 142.6 118.1 118.1 118.1 118.1 142.6 37.8 
FAS53 CN 142.6 141.0 113.8 110.2 120.2 112.1 131.0 57.0 
 
The structures of these compounds were confirmed by 1H NMR (Table 3.8) and 13C 
NMR spectroscopy (Table 3.9). These compounds all gave characteristic singlets 
around 5.15 ppm corresponding to the CH2 group and the broad signal 
corresponding to the hydroxyl group of the starting compounds had disappeared. 
The CH2 peak of the starting material appears at a lower chemical shift (4.7 ppm) 
(Karickal et al., 2010). 
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3.3.3.2 Oxidation of the hydroxyl group 
Benzimidazole-2-carboxylic acids are another series of compounds synthesised 
through the transformation of (1H-benzimidazole-2-yl)-methanol. (1H-
Benzimidazole-2-yl)-methanol derivatives can be readily converted into their 
corresponding acids through oxidation (Figure 3.7) using potassium permanganate. 
NMR spectroscopy confirmed the structure. The proton spectra of the 
benzimidazole-2-carboxylic acids lacked the peak at approximately 4.73 ppm 
corresponding to the CH2 group, which confirmed the conversion of the primary 
alcohol to the carboxylic acid. The position of the aromatic ring proton signals are 
shifted downfield as the electron-withdrawing nature of the 5-substituent is 
increased (Table 3.10). Also a broad peak corresponding to the carboxylic acid 
proton was observed. The carbon spectra gave rise to the carbonyl carbon signal at 
approximately 160 ppm which is also shifted downfield as the electron-withdrawing 
nature of the 5-substituent is increased (Table 3.11). All the products were obtained 
in high yields. The benzimidazole-2-carboxylic acids were not reacted further. 
 
Table  3.10 Assignment of the 1H NMR spectra of the benzimidazole-2-carboxylic acids 
1
2
34
5
6 N
H7
N
OH
R 3a
7a
O
 
Compound 
 δ/ppm 
R H4 H5 H6 H7 
FAS29 H 7.67 7.22 7.38 7.63 
FAS30 CH3 7.43 - 7.49 7.55 
FAS31 OCH3 7.50 - 7.50 7.50 
FAS32 Cl 7.73 - 7.38 7.70 
FAS33 Br 7.84 - 7.47 7.62 
FAS34 F 7.53 - 7.32 7.80 
FAS35 NO2 8.52  8.10 7.77 
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Table  3.11 Assignment of the 13C NMR spectra of the benzimidazole-2-carboxylic acids 
1
2
34
5
6 N
H7
N
OH
R 3a
7a
O
 
Compound δ/ppm R C2 C3a C4 C5 C6 C7 C7a C=O 
FAS29 H 144.5 141.8 121.8 136.4 124.2 115.5 137.7 159.1 
FAS30 CH3 143.0 136.4 115.5 131.1 124.5 114.6 134.3 158.6 
FAS31 OCH3 143.5 139.9 115.2 124.2 117.8 96.3 132.7 157.3 
FAS32 Cl 143.5 141.3 115.5 130.0 124.5 117.5 139.8 160.0 
FAS33 Br 144.3 139.8 116.3 127.3 124.8 119.7 137.8 160.1 
FAS34 F 142.7 141.8 104.2 159.6 113.9 112.0 132.3 165.4 
FAS35 NO2 142.6 136.9 111.3 142.3 116.3 113.2 143.6 159.8 
 
3.3.3.3 N-Alkylation and O-alkylation of (1H-benzimidazole-2-
yl)methanol 
Many studies (Das et al., 2005) showed that the N-linked benzimidazole displayed 
antibacterial activities comparable to C-linked benzimidazole. Some of the target 
compounds required for this study were N-alkyl-(1H-benzimidazole-2-yl)-methanol 
FAS36-38, 40-42, 50 and the N- and O-methyl derivative FAS39. The N-alkylation 
and O-alkylation of (1H-benzimidazole-2-yl)methanol, occurs by the addition of 
iodomethane in presence of acetone and sodium hydroxide, to give the 
corresponding N-methyl and O-methyl-5-substituted (1H-benzimidazole-2-
yl)methanol (Figure 3.7). Complete reaction was typically achieved within 24 hours.  
The N-methyl and O-methyl-(1H-benzimidazole-2-yl)-methanol derivatives were 
purified by recrystallisation. 5-Methyl FAS37, 5-chloro FAS38, 5-bromo FAS40, 5-
fluoro FAS41, 5-methoxy FAS42, 5-nitro FAS50, N-methyl(1H-benzimidazole-2-
yl)methanol FAS 36, and N-methyl(1H-benzimidazole-2-yl)methanol FAS39 were all 
successfully synthesised in good yields (Table 3.12). The structure of these 
compounds was confirmed by 1H NMR spectroscopy (Table 3.13). These 
compounds all gave characteristic singlets around 3.80 ppm, which corresponds to 
the N-CH3 group. For compounds FAS39 and FAS42 another singlet around 4.03 
ppm, which corresponds to the OCH3 group was also observed in the 1H NMR 
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spectrum. The carbon spectra displayed the NCH3 signal at approximately 31 ppm 
and around 55 ppm for the OCH3 signal (Table 3.14). 
Table  3.12 Reaction time, yields and melting points of N-methyl (1H-benzimidazole-2-yl)-
methanol and derivatives 
N
N
OR1
R
CH3  
Compound R R1 Reaction time (hrs) Yield (%) m.p./ °C Lit. mp/ °C 
FAS36 H H 24 43.4 128-130 125-130 (Bednyagina and Postovskii, 1960) 
FAS37 CH3 H 24 46.5 122-124 - 
FAS38 Cl H 24 8.8 136-138 - 
FAS39 Cl CH3 24 46 138-140 - 
FAS40 Br H 24 15.8 158-160 - 
FAS41 F H 24 53 132-134 - 
FAS42 OCH3 H 24 25 182-184 
183 (Khristich et al., 
1982) 
FAS50 NO2 H 24 19.4 160-162 
167-168 (Khristich et 
al., 1982) 
 
Table  3.13 Assignment of the 1H NMR spectra of the N-methyl-(1H-benzimidazole-2-
yl)methanol derivatives 
2
345
6 N
7
N
OR1
R 3a
7a
CH31  
Compound 
 δ/ppm 
R R1 H4 H5 H6 H7 
FAS36 H H 7.53 7.25 7.19 7.60 
FAS37 CH3 H 7.31 - 7.39 7.46 
FAS38 Cl H 7.64 - 7.19 7.58 
FAS39 Cl CH3 7.89 - 7.64 8.01 
FAS40 Br H 7.88 - 7.43 7.58 
FAS41 F H 7.28 - 6.99 7.49 
FAS42 OCH3 H 6.99 - 6.76 7.37 
FAS50 NO2 H 7.47 - 7.16 7.77 
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Table  3.14 Assignment of the 13C NMR spectra of the N-methyl-(1H-benzimidazole-2-
yl)methanol 
2
345
6 N
7
N
OR1
R 3a
7a
CH31  
Compound δ/ppm 
R R1 C2 C3a C4 C5 C6 C7 C7a C-1’ 
FAS36 H H 111.1 118.1 155.0 121.3 121.3 155.0 118.1 57.5 
FAS37 CH3 H 153.8 142.1 118.6 123.4 131.3 109.6 136.2 55.4 
FAS38 Cl H 155.6 142.5 111.4 126.6 122.2 120.1 136.8 56.3 
FAS39 Cl CH3 114.4 125.9 152.2 130.1 144.3 131.4 125.9 64.4 
FAS40 Br H 155.4 143.1 111.9 124.7 121.6 120.5 137.3 56.3 
FAS41 F H 114.8 121.5 156.7 156.7 156.7 125.6 121.5 57.6 
FAS42 OCH3 H 159.4 138.9 100.9 156.8 109.3 115.3 134.9 57.6 
FAS50 NO2 H 153.3 142.5 110.6 140.5 117.8 115.1 140.9 56.4 
 
 
 
 
Figure  3.7 Summary of the reactions of (1H-benzimidazole-2-yl)-methanol 
 
3.4 1H-(benzimidazole-2-yl)alkylamines 
3.4.1 Formation of (1H-benzimidazole-2-yl)alkylamines 
(1H-benzimidazole-2-yl)alkylamine FAS1 can be produced from the condensation of 
1,2-phenylenediamine and the appropriate amino acid as described for the 
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formation of simple benzimidazoles. However, amino acids are very reluctant to 
undergo ring closure with 1,2-phenylenediamines to produce the corresponding 
benzimidazoles, more so when the substituent in the 5 position of the 1,2-
phenylenediamine is an electron withdrawing, e.g. nitro group. This explains the low 
yield of the 5-nitro derivative FAS7.  
 
3.4.2 Glycine and alanine derived benzimidazoles 
The Phillips procedure was used to produce (1H-benzimidazole-2-yl)alkylamines 
and the derivatives prepared is shown in Figure 3.8. The mechanism of the ring 
closure between a 1,2-phenylenediamine and an amino acid is simiar to the 
mechanisim illustrated in Figure 3.5. The hydrochloric acid used in the reaction acts 
both as a catalyst to complete the reaction, and to convert the amines into their 
hydrochloride salts. 
 
 
 
Figure  3.8 Synthesis of (1H-benzimidazole-2-yl)alkylamine 
 
The effect of a substituent in the 5-position of 1,2-phenylenediamine affects the rate 
and ease of the ring closure of the reaction. An electron donating methyl group in 
the 5-position increases the rate of reaction whereas an electron-withdrawing nitro 
group makes the ring closure difficult. The reaction of 4-nitro- 
1,2-phenylenediamine with glycine is an extremely slow reaction. In the synthesis of 
(S)-1-(1H-benzimidazole-2-yl)ethanamine dihydrochloride FAS8 from 1,2-
phenylenediamine and alanine, completion was achieved after 264 hours reaction 
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time with high yield (Table 3.15). The progress of the reaction was monitored by 
TLC and the reaction was continued until all the starting material was consumed. 
Table  3.15 Reaction times, yields and melting points of (1H-benzimidazole-2-yl)alkylamines 
X : CH2 CHCH3
1' 1'a1'
,
N
H
N
X
NH2
R 45
6
7  
 R Amino acid Reaction time (h) Yield (%) mp/ °C Lit. mp/ °C 
FAS1 H Gly 300 89 270-272 268-270 (Cescon and Day, 1962) 
FAS2 CH3 Gly 170 52 208-210 208-210 (Donkor, 2007) 
FAS4 Cl Gly 216 39 252-254 251-252 (Donkor, 2007) 
FAS5 Br Gly 216 22 258-260 - 
FAS6 F Gly 216 16 262-264 258-262 (Donkor, 2007) 
FAS7 NO2 Gly 300 21 254- 256 248-251 (Donkor, 2007) 
FAS8 H L-Ala 264 67 138-140 133-138 (Cescon and Day, 1962) 
FAS9 CH3 L-Ala 264 68.5 212-214 212-213 (Donkor, 2007) 
FAS11 Cl L-Ala 288 41 154-156 152-154 (Donkor, 2007) 
FAS12 Br L-Ala 288 19 158-160. - 
FAS13 F L-Ala 288 33 296-298 - 
 
 
When the crude product was isolated as a solid, it was washed with acetone to 
remove the unreacted 1,2-phenylenediamine. However, in some cases the crude 
product was obtained as a bright blue thick sticky tar. In this case, the crude 
material was treated with triethylamine to convert the product to the free base which 
changed the bright blue hydrochloride reaction mixture into a bright red solution.  
This was followed by extraction with ethyl acetate. The organic phase was washed 
with water, and then filtered.  
 
3.4.3 Spectral characterisation of (1H-benzimidazole-2-yl)alkylamines 
The (1H-benzimidazole-2-yl)alkylamines were fully characterized by spectroscopy 
(Table 3.16). The cyclization of a 1,2-phenylenediamine with a carboxylic acid 
resulted in a change in the aromatic region of the NMR spectra. The aromatic 
benzene type protons of 1,2-phenylenediamine appear between 6-7 ppm whereas 
those of the imidazole ring appear downfield between 7-9 ppm. This difference in 
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chemical shift was also useful in determining how much starting material remained 
in the reaction mixture and gave a rough idea of the rate of reaction. The expansion 
of the NMR spectra (Figure 3.9) shows the incomplete reaction of 4-nitro-1,2-
phenylenediamine and alanine. The comparison of the benzimidazole peaks 
(downfield) with those of the starting material show the reaction had gone to about 
50% completion. The 13C NMR spectra obtained are also consistent with the 
structure of the desired target compounds (Table 3.17). The absence of a carbonyl 
signal proved that the amino acid reacted completely. Another very important signal 
in the carbon spectra was that arising from C-2, and confirmed successful ring 
closure.  
 
Figure  3.9 Expansion of aromatic region showing the incomplete ring closure of a (S)-1-(5-
nitro-1H-benzimidazole-2-yl)ethanamine (FAS14) 
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Table  3.16 Assignment of the 1H NMR spectra of (1H-benzimidazole-2-yl)alkylamines 
X : CH2 CHCH3
1' 1'a1'
,
N
H
N
X
NH2
R 45
6
7  
compound δ/ppm R H4 H5 H6 H7 H1’ H1’a H5’a 
FAS1 H 7.85 7.53 7.53 7.85 4.59 - - 
FAS2 CH3 7.65 - 7.73 7.38 4.58 - 2.48 
FAS4 Cl 7.49 - 7.83 8.17 4.54 - - 
FAS5 Br 7.36 - 7.77 8.11 4.38 - - 
FAS6 F 7.82 - 7.34 7.69 4.51 - - 
FAS7 NO2 8.10 - 8.43 8.43 4.41 - - 
FAS8 H 7.82 7.52 7.52 7.82 4.83 1.83 - 
FAS9 CH3 7.62 - 7.36 7.71 4.97 1.83 2.48 
FAS11 Cl 7.83-7.54 - 7.25 7.83-7.54 4.55 1.39 - 
FAS12 Br 7.33 - 7.78 8.13 4.73 1.39 - 
FAS13 F 7.62 - 7.54 8.18 4.87 1.39 - 
FAS14 NO2 8.48 - 8.10 7.74 3.48 1.77 - 
 
Table  3.17.Assignment of the 13C NMR spectra of selected (1H-benzimidazole-2-
yl)alkylamines 
X : CH2 CHCH3
1' 1'a1'
,
N
H
N
X
NH2
R 45
6
7  
compound δ/ppm R C2 C3a C4 C5 C6 C7 C7a C1’ C1’a C5a 
FAS1 H 150.16 132.20 114.48 125.47 125.47 114.48 132.20 38.78 - - 
FAS2 CH3 168.1 146.2 126.4 128.4 133.3 113.8 138.6 34.2 - 20.9 
FAS4 Cl 156.6 140.15 128.18 130.2 133.62 130.50 137.51 35.3 - - 
FAS5 Br 168.98 149.58 126.55 106.86 129.41 122.51 149.58 36.3 - - 
FAS6 F 149.10 134.4 106.3 164.30 113.2 115.3 129.70 34.5 - - 
FAS7 NO2 152.81 137.61 111.64 140.96 118.23 115.14 143.9 36.2   
FAS8 H 146.91 131.67 131.67 125.67 125.67 131.67 131.67 40.4 17.1 - 
FAS9 CH3 149.5 135.6 114.1 130.0 127.2 113.7 132.0 43.2 17.0 21.1 
FAS11 Cl 153.03 135.76 115.24 123.61 120.74 117.75 127.12 47.8 16.1 - 
FAS13 F 149.9 136.6 114.6 130.1 128.1 114.3 132.2 43.7 17.5 - 
FAS14 NO2 161.7 140.7 115.2 126.1 122.6 116.3 138.9 46.3 15.2 - 
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3.5 (1H-benzimidazole-2-yl)-ethyl derivatives 
(1H-benzimidazole-2-yl)-ethyl derivatives (FAS54, 55) were synthesised by the ring 
closure of 1,2-phenylenediamines with propionic acid. Complete reaction was 
typically achieved within 24 hours even for the most electron deprived 1,2-
phenylenediamines. The (1H-benzimidazole-2-yl)-ethyl derivatives were precipitated 
from the reaction mixture after treating the reaction mixture with ammonia solution. 
They were purified by the initial treatment with decolourising charcoal and then 
recrystallised. 5-Nitro FAS55, and (1H-benzimidazole-2-yl)-ethyl FAS54 were all 
successfully synthesised in good yields (Table 3.18). The structures of these 
compounds were confirmed by 1H NMR (Table 3.19), and 13C NMR spectrocsopy 
(Table 3.20).These compounds all gave a characteristic singlet around 2.8 ppm 
corresponding to the CH2 group and another signal corresponding to the methyl 
group at around 1.3 ppm in the 1H NMR spectra. 
 
Table  3.18 Reaction time, yields and melting points of 2- ethylbenzimidazole derivatives 
 
N
H
NR
45
6
7  
Compound R Reaction time (hrs) Yield (%) m.p/ °C Lit. mp/ °C 
FAS54 H 24 60 164-166 164-165(Aridoss and Laali, 2011) 
FAS55 NO2 24 40 175-177 178-179 (Willitzer et al., 1978) 
 
Table  3.19 Assignment of the 1H NMR spectra of the 2- ethylbenzimidazole derivatives 
N
H
NR
45
6
7  
Compound 
δ/ppm 
R H4 H5 H6 H7 
FAS54 H 7.47 7.11 7.11 7.47 
FAS55 NO2 8.33 - 8.01 7.59 
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Table  3.20 Assignment of the 13C NMR spectra of the 2- ethylbenzimidazole derivatives 
N
H
NR
45
6
7  
Compound δ/ppm 
R C2 C3a C4 C5 C6 C7 C7a C-1’ 
FAS54 H 156.1 138.7 114.2 121.0 121.0 114.2 138.7 21.95 
FAS55 NO2 161.1 117.1 107.4 139.3 114.2 111.0 142.0 22.1 
 
3.6  (1H-benzimidazole-2-yl)-methanthiol derivatives 
(1H-benzimidazole-2-yl)-methanthiol derivatives (FAS56, 57) were synthesised by 
the ring closure of 1,2-phenylenediamines with 2-mercaptoacetic acid. Complete 
reaction was typically achieved within 60-70 hours and isolated upon basic workup. 
(1H-benzimidazole-2-yl)-methanthiol FAS56 and 5-nitro FAS57 were successfully 
synthesised in good yields (Table 3.21) and characterized (Table 3.22 and Table 
3.23). The characteristic singlet around 4.2 ppm corresponded to the CH2 group and 
the thiol H appeared around 3.6 in the 1H NMR spectra. Comparing the methanthiol 
derivatives to the 2-ethyl, amino methyl, chloromethyl and methanol derivatives, it 
can be see that the peak corresponding to CH2 at position 1 is dependent on the 
nature of the attached substituents, R1. The SH, NH2, and OH have dual effects; 
one through the electron donating and the second through the inductive effect of the 
sulfur, nitrogen and oxygen. The inductive effect could be decreased when the 
electronegativity is decreased as well. Therefore, the substituents have the following 
inductive effect; Cl > OH > NH2 > SH. The methyl group also has the inductive 
effect. Accordingly the peak is deshielded and appears downfield in the spectra due 
to the effect of R1 (CH3, SH, NH2, OH, Cl) as shown in Table 3.24. Whereas in the 
13C NMR spectra for these compounds, it can be see that the most deshielded CH2 
is when it is attached to OH, while the most shielded one is when it is attached to 
CH3, but when CH2 is attached to SH, NH2 or Cl, the chemical shifts are similar to 
each other (Table 3.25).   
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Table  3.21 Reaction time, yields and melting points of 2- methanethiolbenzimidazole 
derivatives 
 
N
H
N
SH
R
 
Compound R Reaction time (hrs) Yield (%) m.p/ °C Lit. mp/ °C 
FAS56 H 60 82 170-172 173 (Gowda et al., 2011) 
FAS57 NO2 70 47.8 195-197 195 (Gowda et al., 2011) 
 
Table  3.22 Assignment of the 1H NMR spectra of the 2- methanethiolbenzimidazole 
derivatives 
N
H
N
SH
R
 
Compoun
d 
 δ/ppm 
R H4 H5 H6 H7 
FAS56 H 7.54 7.16 7.16 7.54 
FAS57 NO2 8.41 - 8.09 7.69 
 
Table  3.23 Assignment of the 13C NMR spectra of the2- methanethiolbenzimidazole 
derivatives 
N
H
N
SH
R
 
Compound 
δ/ppm 
R C2 C3a C4 C5 C6 C7 C7a C-1’ 
FAS56 H 150.6 121.7 114.5 118.5 118.5 114.5 121.7 35.7 
FAS57 NO2 155.3 135.5 112.0 140.0 117.7 114.3 142.5 35.4 
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Table  3.24 Comparison of 1H NMR spectra of 2- methanethiolbenzimidazole derivatives with 
their analogues  
1
2
34
5
6 N
H7
N
R1
R 3a
7a
1'
 
Compound 
δ/ppm 
R R1 H1’ 
FAS56 H SH 4.21 
FAS57 NO2 SH 4.27 
FAS54 H CH3 2.84 
FAS55 NO2 CH3 2.89 
FAS1 H NH2 4.59 
FAS7 NO2 NH2 4.41 
FAS43 H Cl 5.28 
FAS49 NO2 Cl 5.01 
FAS22 H OH 4.71 
FAS28 NO2 OH 4.76 
Table  3.25 Comparison of 13C NMR spectra of 2- methanethiolbenzimidazole derivatives 
with their analogues 
1
2
34
5
6 N
H7
N
R1
R 3a
7a
1'
 
Compound 
δ/ppm 
R R1 C1’ 
FAS56 H SH 35.72 
FAS57 NO2 SH 35.39 
FAS54 H CH3 21.95 
FAS55 NO2 CH3 22.05 
FAS1 H NH2 38.78 
FAS7 NO2 NH2 36.16 
FAS43 H Cl 33.79 
FAS49 NO2 Cl 37.82 
FAS22 H OH 57.51 
FAS28 NO2 OH 56.90 
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3.7 1H-benzothiazole-2-yl)-methanol derivatives 
(1H-Benzothiazole-2-yl)-methanol (FAS65) was synthesised by the ring closure of 
2-aminothiophenol with glycolic acid (2-hydroxyacetic acid) in excellent yield (Table 
3.26). The NMR spectra (Table 3.27 and Table 3.28) confirmed the structure. This 
compound gave a characteristic doublet at 4.88 ppm, corresponding to the CH2 
group, and a triplet signal at 6.26 ppm, corresponding to the hydroxyl group, in the 
1H NMR spectrum. 
 
Table  3.26 Reaction time, yields and melting points of benzothiazole derivative 
S
N
OH  
Compound Yield (%) m.p/ °C Lit. mp/ °C 
FAS65 91 100-102 100-102 (Asselin et al., 2010) 
 
Table  3.27 Assignment of the 1H NMR spectra of the benzothiazole derivative 
S
N
OH  
Compound 
δ/ppm 
H4 H5 H6 H7 
FAS65 8.11 7.44 7.44 7.93 
 
Table  3.28 Assignment of the 13C NMR spectra of the benzothiazole derivative 
S
N
OH  
Compound 
δ/ppm 
C2 C3a C4 C5 C6 C7 C7a 
FAS65 175.5 153.1 122.3 125.9 124.6 122.2 134.2 
 
Due to the electronic effects of the sulfur atom with a large β-effect, which results in 
the appearance of all the proton peaks in the 1H NMR spectrum to move downfield 
when compared to the bezimidazole derivative FAS22 (Table 3.29). This is also 
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observed in the the 13C NMR spectra, which showed that the signals for FAS65 to 
be more deshielded than the signals for FAS22 (Table 3.30) (Abraham and Reid, 
2002). 
Table  3.29 Comparison of 1H NMR spectra of benzothaizole derivatives with benzimidazole 
derivatives 
1
2
34
5
6 X
7
N3a
7a OH
1'
 
Compound 
δ/ppm      
X H1’ OH H2 H4 H5 H6 H7 
FAS22 NH 8.32 5.73 4.71 7.50 7.14 7.14 7.50 
FAS65 S 9.72 6.26 4.88 8.11 7.41 7.49 7.93 
 
Table  3.30 Comparison of 13C NMR spectra of benzothaizole derivatives with benzimidazole 
derivatives 
1
2
34
5
6 X
7
N3a
7a OH
1'
 
Compound 
δ/ppm 
X C2 C3a C4 C5 C6 C7 C7a C-1’ 
FAS22 NH 155.0 121.3 111.1 118.1 118.1 111.1 121.3 57.5 
FAS65 S 175.5 153.1 122.3 125.9 124.6 122.2 134.2 61.25 
 
3.8 N-Bromoalkylation of (1H-benzimidazole-2-yl)-chloromethyl 
Some of the target compounds required for this study were N-alkylbromo-(1H-
benzimidazole-2-yl)-chloromethyl FAS67-68 derivatives. The N-bromoalkylation of 
(1H-benzimidazole-2-yl)chloromethyl FAS43 was achieved by addition of the 
dibromoalkane in the presence of ethanol and potassium hydroxide and stirring for 
48 hours at room temperature. The N-bromoalkyl-(1H-benzimidazole-2-yl)-
chloromethyl derivatives were purified by column chromatography. The structure of 
these compounds was confirmed by 1H NMR spectra (Table 3.32).  
Chapter 3     Synthesis 
149 
 
Some new N-bromoalkyl substituted bromides of (E)-4-azachalcone revealed good 
antimicrobial activity against some Gram +ve and Gram -ve strains. Moreover, the 
antimicrobial activity of these compounds relied on the length of the N-bromoalkyl 
chain. When the number of the carbon atoms in the bromoalkyl chain was 
increased, the antimicrobial activity also increased (Nowakowska et al., 2001). And 
as the substituent at the N position of the heterocyclic rings was shown to be 
significant from the biological point of view, it was important to investigate this in this 
project. There are not many studies on the synthesis of N-bromoalkyl-2-
chloromethylbenzimidazole derivatives in the literature. Several methods were 
investigated. One of the methods was based on Meyers procedure, and it was 
successful for the reaction of (1,2- and 1,10) dibromoalkanes with 2-
chloromethylbenzimidazole (Meyers et al., 2005). 2-Chloromethylbenzimidazole 
was combined with an excess of potassium hydroxide and dissolved in ethanol. 
Then an ethanol solution of dibromoalkane derivatives was added dropwise to the 
2-chloromethylbenzimidazole solution, and the combined mixture was heated under 
reflux for 48 hours. After workup, the crude product was purified by column 
chromatography. The disadvantage about this method was the number of side 
products formed which required multiple rounds of column chromatography to be 
performed in order to isolate the pure compounds. This resulted in poor yields. 
The Romashkina method (2011) is another method for the synthesis of these 
derivatives. This method involved using sodium hydride as a base in DMF. The 
difficulty of this method was that the use of sodium hydride, a strong base, could 
react with any acidic proton in the starting material. In addition, DMF has a high 
boiling point and it was difficult to get rid of this solvent. The high temperature 
required to remove the DMF may have contributed to the impurities which were very 
difficult to separate from the desired compound. Therefore, this method had been 
avoided and other methods were explored. In addition, calcium hydride was also 
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tried as the base but this resulted in the isolation of starting material only 
(Romashkina et al., 2011).   
Another method explored the use of ionic liquids. The synthesis of N-bromodecyl-2-
chloromethylbenzimidazole FAS68 was attempted using a modification of the 
method by Wang et al. (Wang et al., 2012). KOH and 2-chloromethylbenzimidazole 
FAS43 were added to tri-n-butylphosphonium octyl bromide FAS 75 (the ionic liquid) 
and the mixture was stirred for 5 min. Then, 1,10-dibromodecane was added and 
the mixture was stirred for another 5 hours and no reaction was observed even 
when the reaction time was increased.  
 
Table  3.31 Comparison of yields and melting points of N-bromoalkyl-2-
chloromethylbenzimidazole derivatives 
  
Compound n Reaction time (hrs) Yield (%) m.p/ °C Lit. mp/ °C 
FAS67 2 48 10 108-110 - 
FAS68 10 48 3 154-156 - 
 
Table  3.32 Assignment of the 1H NMR spectra of the N-bromoalkyl-2-
chloromethylbenzimidazole derivatives 
 
Compound 
 δ/ppm 
n H4 H5 H6 H7 
FAS67 2 7.52 7.17 7.17 7.52 
FAS68 10 7.65 7.21 7.21 7.65 
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3.9 5-Nitro-1(3)-oxidebenzimidazoles  
Some of the target compounds required for this study were benzimidazoles with 
oxidation at position 3 to assess the importance of position 1 in the biological 
studies. These compounds were synthesised from 5-nitro-(1H-benzimidazole), and 
5-nitro-(1H-benzimidazole)-2(3H)-one, and hydrogen peroxide to give the desired 
benzimidazole derivatives FAS59-60. Comparing compound FAS59 to its N-methyl 
analogue FAS58, both compounds revealed the same pattern in the 1H NMR 
spectra except for the signal for N-CH3 group in FAS58 (Table 3.36). The 13C NMR 
chemical shifts showed the same pattern too apart for the methyl group signal 
(Table 3.37).  
 
Table  3.33 Comparison of yields and melting points of 1-oxidebenzimidazole derivatives 
 
N
H
NO2N
O
FAS59                      
Compound X Yield (%) m.p/ °C Lit. mp/ °C 
FAS59 H 48.7 200-202 201-203 (Elshihawy, 2008) 
FAS60 O 50 298-300 296-298 (Elshihawy, 2008) 
 
Table  3.34 Assignment of the 1H NMR spectra of the 1-oxidebenzimidazole derivatives 
N
H
NO2N
O
FAS59                      
Compound 
 δ/ppm 
X H4 H5 H6 H7 
FAS59 H 8.51 - 8.12 7.77 
FAS60 O 7.69 - 7.92 7.09 
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Table  3.35 Assignment of the 13C NMR spectra of the 1-oxidebenzimidazole derivatives 
 
N
H
NO2N
O
FAS59                      
Compound δ/ppm 
X C2 C3a C4 C5 C6 C7 C7a 
FAS59 H 146.7 138.5 117.5 133.1 115.3 112.3 142.6 
FA 60 O 155.4 135.6 117.7 129.6 108.0 103.6 141.6 
 
Table  3.36 Comparison of 1H NMR spectra of 1-oxidebenzimidazole derivative with its  
N-methyl analogue 
 
Compound 
δ/ppm    
R R1 H1 H2 H4 H6 H7 
FAS58 CH3 - 3.93 8.51 8.58 8.16 7.78 
FAS59 H O - 8.55 8.51 8.12 7.77 
 
Table  3.37 Comparison of 13C NMR spectra of 1-oxidebenzimidazole derivative with its  
N-methyl analogue 
 
Compound 
δ/ppm 
R R1 C2 C3a C4 C5 C6 C7 C7a 
FAS58 31.18 - 146.7 138.5 117.5 133.1 115.3 112.3 142.6 
FAS59 - O 142.68 142.61 117.79 148.73 119.52 110.85 142.39 
 
3.10 Benzoxazole derivatives 
Benzoxazole derivatives were some of the target compounds required for this study 
in order to compare their antimicrobial activity to benzimidazole. These compounds 
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were synthesised from 4-substituted-2-hydroxyaniline and phosgene or urea to give 
benzoxazole derivatives FAS61-62. On the other hand, the reaction of 5-
substituted-2-hydroxyaniline with formic acid gave benzoxazole derivative FAS63. 
The reaction time for compounds FAS61-63 was between120-180 min. The reaction 
commences in the absence of an acid catalyst. The proposed mechanism for the 
formation of the benzoxazole ring is similar to the mechanism described in Figure 
3.5. 
The 1H NMR spectrum confirmed the structure and the peak of CH at position 2 
appeared at downfield spectra for the benzoxazole derivative FAS63 (Table 3.41). 
In addition, the 13C NMR spectrum also support this by displaying the chemical shift 
for OCH (position 2) which is more deshielded than the NCH (position 2) peak in the 
benzimidazole derivative FAS 18 (Table 3.42).  
 
Table  3.38 Comparison of yields and melting points of benzoxazole derivatives 
 
Compound R1 Time (min) Yield (%) m.p/ °C Lit. mp/ °C 
FAS61 Cl 120 75 154-156 155-157(Elshihawy, 2008) 
FAS62 NO2 120 71.6 240-242 
238-241 (Abdelaal et al., 
1992) 
FAS63 Cl 180 90 58-60 61-62 (Wertz et al., 2011) 
 
Table  3.39 Assignment of the 1H NMR spectra of the benzoxazole derivatives 
 
 
Compound 
δ/ppm 
R1 H4 H5 H6 H7 
FAS61 - Cl 7.11 - 6.82 7.24 
FAS62 - NO2 
8.14 - 8.09 7.25 
FAS63 H Cl 8.31 - 6.95 6.85 
  
Chapter 3     Synthesis 
154 
 
Table  3.40 Assignment of the 13C NMR spectra of the benzoxazole derivatives 
 
Compound δ/ppm R1 C2 C3a C4 C5 C6 C7 C7a 
FAS61 Cl 154.3 136.9 116.7 129.1 113.0 106.9 143.4 
FAS62 NO2 154.2 142.0 120.8 136.7 109.3 105.4 142.7 
FAS63 Cl 160.3 127.2 122.2 123.3 119.7 115.9 145.4 
 
Table  3.41 Comparison of 1H NMR spectra of benzoxazole derivative with its analogue 
1
2
34
5
6 X
7
NCl 3a
7a  
Compound 
δ/ppm 
X H2 H4 H5 H6 H7 
FAS18 NH 8.32 7.66 - 7.20 7.60 
FAS63 O 9.72 8.31 - 6.95 6.85 
 
Table  3.42 Comparison of 13C NMR spectra of benzoxazole derivative with its analogue 
 
Compound 
δ/ppm 
X C4 C5 C6 C7 C2 C3a C7a 
FAS18 NH 116.3 126.2 122.0 115.1 143.4 139.2 136.5 
FAS63 O 122.2 123.3 119.7 115.9 160.3 127.2 145.4 
 
3.11 Synthesis of silver complex of benzimidazole derivatives 
As mentioned in (Section 1.10.1.4) some silver complexes of benzimidazoles were 
effective against a series of bacteria and fungi (Özdemir et al., 2010). For this 
reason, one of the aims of this project was to synthesise silver complexes of 
benzimidazole to explore the activity of these complexes against the selected 
microorganisms.   
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The complexes were synthesised according to Podunavac-Kuzmanovic 
(Podunavac-Kuzmanovic et al., 2004), by stirring a mixture at 50 ºC of an ethanolic 
solution of AgNO3 with an ethanolic solution of 5-substituted-1H-benzo[d]imidazole 
and 5-substituted-1H-benzo[d]imidazole-2-carboxylic acid FAS 19,21,29-30 (1 or 2 
equivalent) to form 1:1 and 1:2 M:L complexes (Figure 3.10). 
 
 
Figure  3.10 Synthesis of silver complexes 
 
The silver complexes were fromed from chelating ring of benzimidazolewith the 
silver ion. The IR spectrum of complex FAS69 showed strong bands at 1631 and 
1520 cm-1 that can be assigned to the groups ѵ(C=O) and ѵ (C=N), respectively. 
The spectrum of ligand FAS29 showed the bands of these groups at 1647 and 1516 
cm-1. The bands are shifted towards lower and higher frequencies, respectively. On 
the other hand, the silver salt of the complexes FAS70-74 formed a bond with the 
nitrogen atom of the benzimidazole ring. The IR spectra of complexes FAS70,71,73, 
and 74 showed band for the ѵ (C=N) which are shifted towards lower or higher 
frequencies depending on the structure of the formed complexes (Table 3.44). The 
elemental analysis data were sometime in good agreement with the calculated 
values and confirmed the structure.  
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Table  3.43 Assignment of the 1H NMR spectra of the silver complexes 
N
H
N
R
R1
 = Ligand 
Compound 
δ/ppm 
R R1 H4 H5 H6 H7 
FAS69 H H 7.70 7.35  7.35 7.70 
FAS70 Br Br 8.01 - 7.50 7.71 
FAS71 NO2 NO2 8.65 - 8.19 7.84 
FAS72 CH3 CH3 7.19 - 7.45 7.52 
FAS73 Br Br 8.01 - 7.48 7.70 
FAS74 NO2 NO2 8.72 - 8.21 7.89 
 
1H NMR spectroscopy also confirmed the structure of the desired complexes and 
was similar to the spectrum of the ligand but either deshielded or shielded. The 
proton spectra of the complexes FAS70, 71, 73 and 74 showed the peak at 
approximately 8.70 ppm corresponding to the proton of CH at position 2 (Table 
3.43).  
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4 Biological evaluation  
 
4.1 Introduction 
The synthesised compounds were evaluated in vitro for their antimicrobial activity 
against a set of reference isolates of bacteria and fungi as listed in sections 2.4.1 
and 2.4.2 (Table 2.1 and Table 2.3). The methods used were  namely; the disc (or 
well) diffusion test as described in sections 2.4.1.5 and 2.4.2.5, and the Agar 
dilution method as described in sections 2.4.1.6 and 2.4.2.6. The biological results 
for these compounds are reported in this chapter as; the antibacterial study (section 
4.2) which combined the results for disc diffusion tests, and Agar dilution MIC tests 
(sections 4.2.1 and 4.2.2). This is followed by the antifungal study (section 4.3) 
which includes the results for well diffusion tests, and MIC determination (section 
4.3.1 and 4.3.2). 
4.2 Antibacterial study  
4.2.1 Screening for antibacterial activity by disc diffusion tests 
The strains used in this project included Reference and clinical isolates, and it has 
to be noted that some strains were resistant to Ciprofloxacin, the comparater drug 
that is widely used in medicine. Ciprofloxacin is one of the synthetic 
chemotherapeutic antibiotics from the fluoroquinolone drug class, which have a 
broad range of therapeutic indications against Gram +ve and -ve bacteria. Thus, 
ciprofloxacin resistant strains were included to see if any of the synthesised 
compounds had activity against them, as such strains are increasingly problematic 
to inhibit  
Activity was determined through measuring diameters of the inhibition zones 
surrounding discs saturated with 10 μg, 100 μg, and 200 μg of test compounds 
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(Figure 4.1). The formation of the zones represents the dynamic interaction between 
the diffusing compound and bacteria trying to grow on the surface of the agar. A 
lack of activity is confirmed when bacterial growth occurs upto the edge of the disc. 
The results of disc diffusion tests are given in Tables 4.1-8. It should be noted that 
the filter paper discs themselves have a diameter of 6 mm, but for clarity,growth up 
to the edge of the disc (i.e. no antibacterial activity) is indicated by a diameter of “0 
mm” in the tables. Control discs saturated with just the DMSO solvent showed no 
inhibition of growth. Moreover, 12 mm diameter (i.e. no growth within 3 mm of the 
disc) was selected to be the cutoff point for an ‘appreciable’ level of activity, so if the 
zone of inhibition was wider than this, it was considered as a promising result, and 
is highlighted on the tables.  
Due to a lack of observed activity, results for screening at 10 μg are not shown in 
most of the tables, except for compounds FAS12 and FAS56.  
 
Figure  4.1 Example of disc diffusion test: 
Activity of 2- carboxylic acid benzimidazole (FAS30) against S. epidermidis NCTC 
2749  
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4.2.1.1 Results of disc diffusion tests of 2- aminoalkylbenzimidazole 
derivatives (series 1 and 2) 
The results for the 11 tested compounds from the series 2- amino-methane 
benzimidazole derivatives showed positive results for seven compounds from series 
1(FAS1, FAS2, FAS6, FAS7), and from series 2 (FAS8, FAS11, and FAS12), and 
the results for the most active of these are shown in Table 4.1. However, there was 
no activity with compounds FAS4, FAS5, FAS9, and FAS13. Weak antibacterial 
activity was exhibited by compound FAS1 against (one Gram +ve) S. epidermidis 
NCTC 2749 and against (one Gram -ve) Burkholderia cepacia NCTC 10744 only. 
There was a very borderline result for compound FAS2 against S. epidermidis 
NCTC 2749, and for compounds FAS6 and FAS7 against just B. cepacia NCTC 
10744 (at 200 μg only). Only 2 compounds (FAS11 and FAS12) as shown in Table 
4.1, were active against multiple strains, giving zone diameters of 12 – 14 mm. 
Antibacterial activity was exhibited by these compounds against some Gram +ve 
and Gram -ve strains, including some ciprofloxacin resistant strains. Compound 
FAS12 exhibited activity against some strains even at 10 μg with zone diameters of 
12 – 13 mm. 
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4.2.1.2 Results of Disc diffusion tests of 2-methanolbenzimidazole 
derivatives (series 4) 
The results for the eight compounds from the series of 2-methanolbenzimidazole 
derivatives showed antibacterial activity with only three compounds; namely FAS24, 
FAS25 and FAS28 as shown in Table 4.2. Very weak antibacterial activity was 
exhibited against two Gram -ve strains; Serratia marcescens NCTC 1377 and 
Burkholderia cepacia NCTC 10744 with a range of just 9 – 10 mm. 
 
4.2.1.3 Results of Disc diffusion tests of 2-carboxylic acid-
benzimidazole derivatives (series 5) 
The results for the seven compounds from the series of 2-carboxylic acid-
benzimidazole derivatives showed a positive result for only FAS30 as shown in 
Table 4.3. Antibacterial activity was exhibited by this compound against the Gram 
+ve S.epidermidis NCTC 2749, and against one Gram –ve B. cepacia NCTC 10744, 
but only when 200 μg of compound was on the disc.   
 
4.2.1.4 Results of Disc diffusion tests of N-methyl-2-(methanol, 
methoxy)benzimidazole derivatives (series 6) 
The results for the eight scompounds from the series of N-methyl-2-(methanol, 
methoxy)benzimidazole derivatives showed some activity with only two compounds 
(FAS39 and FAS42) as shown in Table 4.4. Antibacterial activity was exhibited by 
these compounds against some Gram +ve and Gram –ve strains, especially against 
the ciprofloxacin resistant strains. FAS42 recorded good activity with a range of 
zone diameter of 12 – 17 mm. 
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4.2.1.5 Results of Disc diffusion tests of 2-chloromethylbenzimidazole 
derivatives (series 7) 
The results for the five most active compounds from this series tested, is shown in 
Table 4.5. Antibacterial activity was exhibited against some Gram +ve and Gram -ve 
strains. Interestingly, this was observed against the ciprofloxacin resistant strains. 
These compounds recorded good activity with zones of 12 – 17 mm. FAS47 was 
the most active compound of this series with zone diameters of 13 – 17 mm (at 200 
μg) against some strains. 
 
4.2.1.6 Compounds which did not display any antibacterial activity 
(series 3 and 13)  
None of the compounds tested from the series of 5-sbstituted-benzimidazole, 2-
ethanebenzimidazole derivatives, and the silver complexes showed any activity 
against the selected strains.  
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4.2.1.7 Results of Disc diffusion tests of 2-methylthiolbenzimidazole 
derivatives (series 9) 
The results of the two compounds tested from the series of 2-
methanolbenzimidazole derivatives showed that both had some activity (Table 4.6). 
Antibacterial activity was exhibited by FAS56 against most of the Gram +ve strains, 
with zone diameters of 13-16 mm (100 μg discs) to 12-18 mm (200 μg discs). The 
results for Gram -ve strains were only against the B. cepacia isolate (12-15 mm 
diameter). Compound FAS57 had good activity only against one strain of the S. 
epidermidis with zone of inhibition of 20 mm (100 μg discs), and 25 mm (200 μg 
discs) respectively.   
 
4.2.1.8 Results of Disc diffusion tests of benzoxazole derivatives 
(series 11)  
The three compounds tested from this series gave very few positive results as 
shown in Table 4.7. Appreciable antibacterial activity was exhibited against by just 
two strains, with zone diameter of 16– 20 mm when using the 200 μg discs.  
 
4.2.1.9 Results of Disc diffusion tests of benzothiazole derivative 
(series 12)  
The results of the one compound tested FAS65 showed activity against all but three 
of the Gram +ve strains as shown in Table 4.8. Also, there was a weak inhibition of 
the Gram -ve B. cepacia NCTC 10744.  
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4.2.1.10 Conclusion  
A cut off point of ≥ 12 mm zone diameter was used to define ‘activity’. The Disc 
diffusion tests of the 67 compounds revealed that 14 had some degree of 
antibacterial activity; 12 compounds were active against some of two S. aureus 
species, and the eight against MRSA species. Five compounds were active against 
the two strains of EMRSA. Nine compounds were active against the strains of S. 
epidermidis. Five compounds were active against the single strain of S. 
haemolyticus. Regarding the Gram -ve bacteria, none of the compounds tested 
were active against any of the five strains of E. coli, or the four strains of P. 
aeruginosa. Three compounds were active against the single strain of Serratia 
marcescens. Eight compounds had some activity against the single strain of B. 
cepacia used in the screening panel.  
The most active compounds overall were selected on the basis of a broad spectrum 
of activity, and / or wide zones of inhibition, or novel chemical structure. These 
compounds are summarised in Table 4.9, and were investigated further in minimum 
inhibitory concentration (MIC) assays to quantify their activity against the reference 
isolates.  
 
4.2.2 Results of agar dilution MIC tests 
The MIC of the synthesised compounds was determined by the agar dilution 
technique as outlined in section 2.4.1.6. The agar dilution range used was: 0.5, 1, 2, 
4, 8, 16, 32, 64, 128, 256, and 512 μg/ml. Bacteria were seeded onto agar 
containing different conecntrations of the compounds using a multipoint inoculator 
(using the 37 pin head-each pin delivers 1 μl of the test organism onto the agar). 
The plates were then incubated overnight at 37˚C and the MIC was defined as the 
lowest concentration of the compounds which inhibited bacterial growth completely, 
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as indicated by the absence of any visible colony formation on the agar surface 
(Figure 4.2). Moreover, 256 μg/ml was selected to be the cutoff point for an 
appreciable level of activity, so if the MIC was lower than this, it should be 
considered as a promising result and is highlighted in the tables.  
 
Table  4.9 The most active compounds which were taken forward to determination of MICs 
Compound  Chemical structure Note 
FAS11 
 
? Active against multiple strains with zone diameter of 12 – 14 
mm. 
? Antibacterial activity was exhibited against some Gram +ve and 
Gram -ve strains, and included some ciprofloxacin resistant 
strains 
FAS12 
 
? Active against multiple strains with zone diameter of 12 – 14 
mm. 
? Antibacterial activity was exhibited against some Gram +ve and 
Gram -ve strains, and included some ciprofloxacin resistant 
strains 
? Exhibited activity against some strains even at 10 μg with zone 
diameter of 12 – 13 mm 
FAS39 
 
? Slightly active against multiple strains  
FAS42 
 
? Antibacterial activity was exhibited against some Gram +ve and 
Gram -ve strains, and included some ciprofloxacin resistant 
strains 
? Recorded good activity with a range of zone diameter of 12 – 17 
mm 
FAS43 
 
? Antibacterial activity was exhibited against some Gram -ve 
strains with zone diameter of 12-15 mm 
? Selectively active against one strain of the S.aureus (Oxford) 
with zone of diameter of 13 mm at 200 μg 
FAS44 
 
? Some activity against some Gram +ve and Gram –ve strains 
FAS46 
 
? Selectively active against one strani of S. epidermidis  with zone 
diameter of 14 at 200 μg 
? Selectively active against the B. cepacia isolate with zone 
diameter of 12, and 15 mm at 100 μg and 200 μg respectively 
FAS47 
 
? The most active member of this series against some strains with 
zone diameters of 13 – 17 mm at 200 μg. 
FAS48 
 
? Slightly active against multiple strains  
FAS49 
 
? To study the variation in the antibacterial activity of the 
compounds of this series 
FAS56 
 
? Antibacterial activity against most of the Gram +ve strains, with 
zone diameter of 13-16 mm (100 μg discs) to 12-18 mm (200 μg 
discs). 
? The results against Gram -ve strains were only against the B. 
cepacia isolate with a range of 12-15 mm diameter. 
FAS61 
 
? Recorded activity against S. aureus (Oxford) with zone of 
diameter of 13, 15, and 16 mm at 10, 100, and 200 μg 
respectively 
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Compound  Chemical structure Note 
FAS65 
 
? Recorded some activity against some Gram +ve strains with 
zone of diameter of 12-14mm at 100 μg, and 12-15 mm at 200 
μg respectively 
 
 
 
Figure  4.2 MIC screening by agar dilution of FAS47 at 64μg/ml VS the growth control 
 
4.2.2.1 MIC results of the 2-amino-alkylbenzimidazole derivatives 
(series 1 and 2) 
The results of the two tested compounds from the series 2-amino-
ethanebenzimidazole derivatives FAS11 and FAS12, showed promising results 
especially against Methicillin-resistant Staphylococcus aureus (HG-1), and MRSA 
BIG 0050; with an MIC of 32 μg/ml, which is equivalent to the MIC of the 
ciprofloxacin (control drug) against this strains. The antibacterial activity of these 
compounds against the rest of the selected strains was in the range of 32 to > 512 
μg/ml. The results are summarised in Table 4.10.   
 
4.2.2.2 MIC results of the N-methyl-2-methanolbenzimidazole 
derivatives (series 6) 
The results of the most active compounds from this series (FAS39 and FAS42), 
where the methoxy is present either at the position 2 or 5, is not promising. The 
Table 4.9 (continued) 
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results are shown in Table 4.11. The antibacterial activity of these compounds 
against all selected strains was on the range of 128 to > 512 μg/ml. 
 
4.2.2.3 MIC results of the 2-cholromethylbenzimidazole derivatives 
(series 7) 
Six compounds from this series were the most active in the initial screen and 
therefore were selected to determine their MICs. The results for FAS43, FAS44, 
FAS46, FAS47, FAS48, and FAS49, are presented in Table 4.12. The antibacterial 
activity of these compounds against all selected strains was on the range of 
to 32 > 512μg/ml. Only FAS46 and FAS47 were capable of inhibiting some strains 
at a concentration below 256 μg/ml. 
 
 
4.2.2.4 MIC results of the 2-methylthiolbenzimidazole derivatives 
(series 9) 
Only one compound FAS56 was active against most of the Gram +ve strains, in the 
range 32 - 64 μg/ml. The results against all Gram -ve strains showed MICs ≥ 512 
μg/ml, except when it was against the B. cepacia; where the MIC was 64 μg/ml 
(Table 4.13). 
 
4.2.2.5 MIC results of the benzoxazole derivatives (series 11) 
Only one compound FAS61 was active against most of the Gram +ve strains, with 
MIC≥ 64 μg/ml. The results against Gram -ve strains were ≥ 256 μg/ml (Table 4.14). 
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4.2.2.6 MIC results of the benzothaizole derivative (series 12) 
Compound FAS65 showed no activity against the refernce selected for this study 
with MICs ≥ 512, the results are presented in Table 4.15. 
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4.2.2.7 Conclusion  
The agar dilution tests of the most active compounds (13 compounds out of 67) 
revealed that two (FAS11and FAS12) were active against multiple strains with zone 
diameter of 12 – 14 mm. Also, activity was exhibited against some Gram +ve and 
Gram -ve strains, and, for compounds FAS11, FAS12, and FAS42, this included 
some ciprofloxacin resistant strains. Moreover, FAS11 exhibited activity against 
some strains even at 10 μg with zone diameter of 12 – 13 mm. FAS47 was the most 
active compound of the series of 2-chloromethylbenzimidazole derivatives against 
some strains with zone diameter of 13 – 17 mm at 200 μg. FAS61 recorded good 
activity against Staphylococcus aureus (Oxford) with zone diameter of 13, 15, and 
16 mm at 10, 100, and 200 μg respectively.The rest of the compounds were unlike 
this and therefore were not better than ciprofloxacin (control drug). 
To summarise, 5 out of the 13 compounds exhibited antibacterial activity against 
two MRSA strains with MIC values which correspond to the control drug. This is 
significant and provides lead compounds for further development.  
 
4.3 Antifungal study  
4.3.1 Screening for antifungal activity by well diffusion tests  
The strains used were unicellular fungi; Candida albicans RCMB 05035, Candida 
krusei RCMB 05051, Candida parapsilosis RCMB 05065, Candida tropicalis RCMB 
05049, and the filamentous fungi; Absidia corymbifera RCMB 09635, Aspergillus 
clavatus RCMB 2593, Aspergillus fumigatus RCMB 02564, Mucor circinelloides 
RCMB 07328, Penicillium marneffei RCMB 01267, and Syncephalastrum 
racemosum RCMB 05922, and all were clinical isolates. Amphotericin B was used 
as a comparator drug. Amphotericin B is a polyene macrolide antifungal agent 
derived from the actinomycete Streptomyces nodosus. Out of 200 known polyene 
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agents, amphotericin B is the only one with toxicities that are sufficiently limited to 
permit intravenous administration (Gallis et al., 1990). Moreover, it has a broad 
spectrum of action and is useful in treating cases of candidosis, cryptococcosis, 
histoplasmosis, blastomycosis, paracoccidioidomycosis, coccidioidomycosis, 
aspergillosis, extracutaneous sporotrichosis and mucormycosis, and some cases of 
hyalohyphomycosis and phaeohyphomycosis (Ellis, 2002). However, it has been 
studied as an empirical antifungal agent in patients with persistent fever and 
neutropenia and the results showed it has a limited spectrum of activity. It has to be 
noted that there is a need for new classes of antifungal agents to use in the therapy 
of patients with persistent fever and neutropenia (Walsh et al., 2004).  
Activity was determined through measuring diameters of the inhibition zones 
surrounding the wells in the agar loaded with 250 μg of the compound (see section 
2.4.2.6). The formation of the zones represents the dynamic interaction between the 
diffusing compound and fungus trying to grow on the surface of the agar. A lack of 
activity is confirmed when fungal growth can be seen right up to the edge of the 
well. The results of the zone of inhibition tests are given in Tables 4.12-23. It should 
be noted that the wells themselves had a diameter of 6 mm. Growth up to the edge 
of the well (i.e. no activity) is indicated by a diameter of “0 mm” in the tables. Control 
wells containing just the DMSO solvent showed no inhibition of growth. 
Furthermore, 15 mm was selected to be the cutoff point, so if the zone of inhibition 
was wider than this, then it was considered a promising result, which is highlighted 
on the tables.  
 
4.3.1.1 Results of well diffusion tests of the 2-amino alkylbenzimidazole 
derivatives (series 1 and 2) 
The results from the 11 compounds tested from this series o showed activity for 
eight of them (FAS1, FAS2, FAS4, FAS5, FAS6, FAS7, FAS8, and FAS9), and the 
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results are shown in Table 4.16. However, there was no activity displayed by 
compounds FAS11, FAS12, and FAS13. Slight activities were exhibited by 
compounds FAS1 and FAS2 against all the filamentous fungi selected for the study 
except Syncephalastrum racemosum RCMB 05922, although good activity, which is 
equivalent to the control drug, was recorded against this species by compound 
FAS7. Moreover, compound FAS7 was the most active compound of this series, 
especially against Mucor circinelloides RCMB 07328 and Absidia corymbifera     
RCMB 09635, which showed activity more than amphotericin B with zone of 
inhibition 20.85 ± 0.05 mm . No activity was recorded for compounds FAS1 and 
FAS2 against the unicellular fungi.  
 
4.3.1.2 Results of well diffusion tests of the 5-substituted-
benzimidazole derivatives (series 3) 
The eight compounds tested showed activity for all compounds, especially for 
compounds FAS18, FAS19, and FAS20 which were more active against most of the 
fungal strains selected. This was more than the control drug (zone of inhibition was  
19.2 to 28.7 mm) (Table 4.17). 
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4.3.1.3 Results of well diffusion tests of the 2-methanolbenzimidazole 
derivatives (series 4) 
All seven compounds tested from this series showed some activity (Table 4.18). 
However, there was no activity of any of  the compounds against Syncephalastrum 
racemosum RCMB 05922 except compound FAS26 which was more active than the 
control drug with +0.3 mm on the zone of inhibition. Compound FAS 26 was slight 
active compound of this series against two species of Candida; Candida krusei 
RCMB 05051 and Candida parapsilosis RCMB 05065 with the zone of inhibition on 
the range of 19.4 to ≤20.6 mm. 
4.3.1.4 Results of well diffusion tests of the 2-carboxylic acid-
benzimidazole derivatives (series 5) 
The results of the seven compounds tested from the series showed activity for only 
five compounds. Compound FAS33 was the only compound which that showed 
activity more than amphotericin B by +1.2 mm on the zone of inhibition (Table 4.19). 
No activity was seen with compounds FAS 32 and FAS 35. Furthermore, all the 
other compounds did not inhibit two strains; Syncephalastrum racemosum RCMB 
05922, and Candida krusei RCMB 05051. 
 
4.3.1.5 Results of well diffusion tests of the N-methyl-2-
methanolbenzimidazole derivatives (series 6) 
In this series, only two compounds FAS42, and FAS50 were active against all the 
strains except against Absidia corymbifera RCMB 09635, and were more active 
than the control drug against the following species; Mucor circinelloides RCMB 
07328, Penicillium marneffei RCMB 01267, Syncephalastrum racemosum RCMB 
05922, and Candida  krusei RCMB  05051 (zone of inhibition 20.6 - 24.5 mm). No 
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activity was observed for FAS38 (Table 4.20). Compound FAS50 was the most 
active compound against Aspergillus clavatus RCMB 02593, and more active than 
amphotericin B with zone of inhibition + 0.4 mm. FAS41 was the most active 
compound against Absidia corymbifera RCMB 09635, which showed greater activity  
compared to amphotericin B with zone of inhibition +0.3 mm.  
 
4.3.1.6 Results of well diffusion tests of the 2-
chloromethylbenzimidazole derivatives (series 7) 
All the compounds from this series showed some antifungal activity, especially 
compounds FAS44, FAS45, and FAS49 which were the most active compounds 
against Mucor circinelloides RCMB 07328, and they were more active than 
amphotericin B (zone of inhibition 18.1-19.9 mm). Moreover, FAS49 was the most 
active compound against Absidia corymbifera RCMB 09635. FAS45 was not active 
against all the unicellular fungi selected for the study (Table 4.21). 
 
4.3.1.7 Results of well diffusion tests of the 2-ethylbenzimidazole 
derivatives (series 8) 
The results for the two compounds tested of the series of 2-methanebenzimidazole 
derivatives showed good activity for compound FAS54 and compound FAS55 
showed slight activity. Both had some activity but not against Absidia corymbifera 
RCMB 09635. FAS55 was active against some species namely; Aspergillus 
clavatus RCMB 02593, Mucor circinelloides RCMB 07328, Syncephalastrum 
racemosum RCMB 05922, Candida albicans RCMB 05035, Candida  krusei RCMB  
05051, and Candida parapsilosis RCMB 05065. The activities were greater than 
amphotericin B (zone of inhibition in the range 19.9 - 23.9 mm). Moreover, 
compound FAS55 had no activity against the unicellular fungi (Table 4.22). 
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4.3.1.8 Results of well diffusion tests of the 2-
methanthiolbenzimidazole derivatives (series 9) 
Both compounds tested from this series showed some activity, but not against 
Absidia corymbifera RCMB 09635. Moreover, compound FAS57 had no activity 
against all the unicellular fungi except for weak inhibition of Candida tropicalis 
RCMB 05049, with zone diameter of just 14.5 mm (Table 4.23). Furthermore, 
FAS57 was more active than amphotericin B active against Mucor circinelloides 
RCMB 07328 and Syncephalastrum racemosum RCMB 05922 (zone of inhibition 
19.8 - 20.9 mm). 
  
4.3.1.9 Results of well diffusion testsof the silver complexes (series 13) 
The results for the six complexes tested showed that all had some antifungal 
activity. None were active against Absidia corymbifera RCMB 09635, except for 
compound FAS72, which revealed some limited activity with zone diameter of 16.3 
mm. Moreover, compounds FAS69, FAS70, and FAS71 had higher activity 
compared to the control drug against Syncephalastrum racemosum RCMB 05922 
(zone of inhibition 20.8 - 22.6 mm) (Table 4.24).  
 
4.3.1.10 Results of well diffusion test of the N-oxidebenzimidazole 
derivatives (series 10) 
Both N-oxidebenzimidazoles had activity. Compound FAS60 was more active than 
amphotericin B against some species namely; Mucor circinelloides RCMB 07328, 
Penicillium marneffei RCMB 01267, Syncephalastrum racemosum RCMB 05922, 
Candida albicans RCMB 05035, Candida  krusei RCMB  05051, and Candida 
parapsilosis RCMB  05065 (zone of inhibition 20.9 - 25.8 mm). However, both 
compounds lacked activity against Absidia corymbifera RCMB 09635 (Table 4.25). 
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4.3.1.11 Results of well diffusion tests of the benzoxazole 
derivatives (series 11) 
Only one compound, FAS63 recorded good activity against all the strains except 
against Absidia corymbifera RCMB 09635. Moreover, it was more active than 
amphotericin B against Mucor circinelloides RCMB 07328, Syncephalastrum 
racemosum RCMB 05922, Candida krusei RCMB 05051, and Candida parapsilosis 
RCMB 05065, in terms of zone diameter (zone of inhibition 19.9 - 23.7 mm) (Table 
4.26). 
 
4.3.1.12 Results of well diffusion tests of the benzothiazole 
derivative (series 12) 
The results for the single benzothiazole derivative tested showed FAS65 had some 
antifungal activity. Weak activity was recorded against all the strains except against 
Absidia corymbifera RCMB 09635, and Candida krusei RCMB 05051 (Table 4.27). 
It was more active against Candida tropicalis RCMB 05049 with zone diameter 17.9 
mm, although this was less than the activity of amphotericin B (zone diameter of 
25.4 mm). 
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4.3.1.13 Conclusion 
The well diffusion tests of the 67 compounds revealed very interesting results: 
Failmentous fungi 
? 30 had some antifungal activity; and were active against Aspergillus clavatus 
RCMB 2593; 
? 36 had some activity against Aspergillus fumigatus RCMB 02564; 
? 31 compounds were active against Penicillium marneffei RCMB 01267; 
? 29 compounds were active against Mucor circinelloides RCMB 07328;  
? 23 compounds were active against Absidia corymbifera RCMB 09635;  
? 29 compounds were active against Syncephalastrum racemosum RCMB 05922 
Unicellular fungi  
? 36 compounds were active against Candida albicans RCMB 05035;  
? 38 compounds were active against Candida tropicalis RCMB 05049;  
? 19 compounds were active against Candida parapsilosis RCMB 05065 and  
? 18 compounds had some activity against Candida krusei RCMB 05051. 
The most active compounds overall were selected on the basis of a broad spectrum 
of activity, and / or wide zone of inhibition, or novel chemical structure. These 
compounds are summerised in Table 4.28, and were investigated further in 
minimum inhibitory concentration (MIC) assays to quantify their activity against the 
reference isolates.  
 
4.3.2 MICs of antifungal of compounds 
The MIC of the compounds was determined by the microdilution assay (see section 
4.3.2). Wells of Microtiter trays were prepared in the dilution: 0.003, 0.007, 0.015, 
0.03, 0.06, 0.12, 0.24, 0.49, 0.98, 1.95, 3.9, 7.8, 15.63, 31.25, 62.5, 125, 250, and 
500 μg/ml and the method is described in section 2.4.2.6.   
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Table  4.28 The most active compounds which were taken forwardfor MIC determination 
Compound 
code Chemical structure Note 
FAS4 
 
? Active against multiple strains with zone diameter of 14 – 
20.6 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 19.3 mm. 
FAS5 
 
? Weak activity against multiple strains with zone diameter 
of 12.3 – 14.5 mm. 
? To study the vairation in the antifungal activity on the 
compounds of this series. 
FAS6 
 
? Active against all strains with zone diameter of 11.7 – 22.1 
mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 22.1 mm. 
FAS7 
 
? Active against multiple strains with zone diameter of 17.3 
– 23.9 mm. 
? parapsilosis RCMB  05065, with zone diameter of 23.9 
mm. 
? Antifungal activity more than the control drug against 
Absidia corymbifera RCMB 09635, with zone diameter of 
20.9 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
20.8 mm. 
FAS8 
 
? Active against multiple strains with zone diameter of 13.6– 
19.4 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 18.9 mm. 
FAS9 
 
? Active against multiple strains with zone diameter of 13.1– 
16 mm. 
 
FAS16 
 
? Active against all strains with zone diameter of 16.8– 22.1 
mm. 
? Antifungal activity more than the control drug against 
Absidia corymbifera RCMB 09635, with zone diameter of 
20.8 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 21.4 mm. 
FAS17 
 
? Active against all strains with zone diameter of 16.4– 21.4 
mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
20.7 mm. 
? Antifungal activity more than the control drug against 
Absidia corymbifera RCMB 09635, with zone diameter of 
20.7 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 21.3 mm. 
FAS18 
 
? Active against all strains with zone diameter of 18.9– 24.9 
mm. 
? Active against all strains more than the control drug, 
except against Candida tropicalis  RCMB  05049 and 
Candida  krusei  RCMB  05051. 
FAS19 
 
? Active against all strains with zone diameter of 19.2– 26 
mm. 
? Active against all strains more than the control drug, 
except against Candida  krusei  RCMB  05051 
FAS20 
 
? Active against all strains with zone diameter of 17.6– 25 
mm. 
? Active against all strains more than the control drug, 
except against Aspergillus fumigatus RCMB 02564, 
Candida tropicalis RCMB 05049 and Candida krusei 
RCMB 05051. 
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Compound 
code Chemical structure Note 
FAS 21 
 
? Active against multiple strains with zone diameter of 12.9– 
20.6 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 19.3 mm. 
FAS51 
 
? Active against multiple strains with zone diameter of 17.4– 
24.6 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
24.6 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 20.6 mm. 
? Antifungal activity more than the control drug against 
Candida  krusei  RCMB  05051, with zone diameter of 
20.2 mm 
FAS22 
 
? Weak active against multiple strains compounds with zone 
diameter of 10.3 – 12.9 mm. 
? To study the variety in the antifungal activity on the 
compounds of this series. 
FAS23 
 
? Weak activity against multiple strains with zone diameter 
of 12.9 – 15 mm. 
? To study the vairation in the antifungal activity on the 
compounds of this series. 
FAS24 
 
? Weak activity against multiple strains with zone diameter 
of 10.4 – 13.6 mm. 
? To study the vairation in the antifungal activity on the 
compounds of this series. 
FAS25 
 
? Weak activity against multiple strains with zone diameter 
of 12.9 – 15.6 mm. 
? To study the vairation in the antifungal activity on the 
compounds of this series. 
FAS26 
 
? Active against multiple strains with zone diameter of 14.9– 
21.3 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 20 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
20.6 mm. 
FAS27 
 
? Active against multiple strains with zone diameter of 13.8– 
19.1 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 19.1 mm. 
FAS28 
 
? Active against multiple strains with zone diameter of 12.7– 
19.4 mm. 
FAS29 
 
? Active against multiple strains with zone diameter of 11.6– 
17 mm. 
FAS30 
 
? Active against multiple strains with zone diameter of 12.1– 
17.7 mm. 
 
FAS31 
 
? Active against multiple strains with zone diameter of 12.2– 
18.4 mm. 
FAS32 
 
? To study the viration in the antifungal activity on the 
compounds of this series. 
FAS33 
 
? Active against multiple strains with zone diameter of 13.6– 
19.6 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 19.6 mm. 
Table 4.28 (continued 
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Compound 
code Chemical structure Note 
FAS34 
 
? Active against multiple strains with zone diameter of 12.5– 
16.9 mm. 
FAS36 
 
? Active against multiple strains with zone diameter of 11.3– 
16.7 mm. 
FAS39 
 
? Active against multiple strains with zone diameter of 11.4– 
17.4 mm. 
FAS41 
 
? Active against multiple strains with zone diameter of 16.3– 
20.3 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
19.8 mm. 
? Antifungal activity more than the control drug against 
Absidia corymbifera RCMB 09635, with zone diameter of 
20.1 mm. 
FAS42 
 
? Active against all strains with zone diameter of 17.9– 23.4 
mm, except against Absidia corymbifera RCMB 09635. 
FAS50 
 
? Active against all strains with zone diameter of 18.3- 24.5 
mm, except against Absidia corymbifera RCMB 09635. 
FAS43 
 
? Active against multiple strains with zone diameter of 12.6– 
17.9 mm. 
FAS44 
 
? Active against multiple strains with zone diameter of 
14.73– 21.2 mm. 
FAS45 
 
? Active against filamentous strains with zone diameter of 
17.7– 19.9 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
19.9 mm. 
FAS48 
 
? Active against multiple strains with zone diameter of 13.6– 
18.2 mm. 
FAS49 
 
? Active against multiple strains with zone diameter of 18.1- 
22.3 mm. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
18.1 mm. 
? Antifungal activity more than the control drug against 
Absidia corymbifera RCMB 09635, with zone diameter of 
20 mm. 
FAS54 
 
? Active against all strains with zone diameter of 19.9– 23.9 
mm, except against Absidia corymbifera RCMB 09635. 
? Antifungal activity more than the control drug against 
Aspergillus clavatus RCMB 02593, with zone diameter of 
23.2 mm. 
? Antifungal activity more than the control drug against all 
strains except against Aspergillus fumigatus RCMB 
02564, Absidia corymbifera RCMB 09635, and Candida 
tropicalis  RCMB  05049 with rang of zone diameter of 
19.9-23.9 mm. 
FAS56 
 
? Active against all strains with zone diameter of 14.5– 20.9 
mm, except against Absidia corymbifera RCMB 09635. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
19.8 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 20.9 mm. 
Table 4.28 (continued 
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Compound 
code Chemical structure Note 
FAS57 
 
? Active against multiple strains with zone diameter of 11.2- 
17.4 mm. 
? To study the vairation in the antifungal activity on the 
compounds of this series. 
FAS69 
 
? Active against multiple strains with zone diameter of 10.5- 
17.4 mm. 
FAS70 
 
? Active against all strains with zone diameter of 15.7– 20.8 
mm, except against Absidia corymbifera RCMB 09635. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 20.8 mm. 
FAS71 
 
? Active against all strains with zone diameter of 13.6– 19.3 
mm, except against Absidia corymbifera RCMB 09635. 
?  
FAS72 
 
? Active against all strains with zone diameter of 16.36– 
22.6 mm, except against Candida  krusei  RCMB  05051. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
18.9 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 22.6 mm. 
FAS73 
 
? Active against all strains with zone diameter of 10– 16.4 
mm, except against Absidia corymbifera RCMB 09635, 
and Candida  krusei  RCMB  05051. 
FAS74 
 
? Active against all strains with zone diameter of 13– 21 
mm, except against Absidia corymbifera RCMB 09635, 
and Candida  krusei  RCMB  05051 
FAS59 
 
? Active against all strains with zone diameter of 13.6– 19.8 
mm, except against Absidia corymbifera RCMB 09635, 
and Candida  krusei  RCMB  05051. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
19.8 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 19.8 mm. 
FAS60 
 
? Active against all strains with zone diameter of 20.3– 25.8 
mm, except against Absidia corymbifera RCMB 09635. 
FAS63 
 
? Active against all strains with zone diameter of 19.9– 23.7 
mm, except against Absidia corymbifera RCMB 09635. 
? Antifungal activity more than the control drug against 
Mucor circinelloides RCMB 07328, with zone diameter of 
21.9 mm. 
? Antifungal activity more than the control drug against 
Syncephalastrum racemosum RCMB 05922, with zone 
diameter of 23.7 mm. 
? Antifungal activity more than the control drug against 
Candida  krusei  RCMB  05051, with zone diameter of 
20.1 mm. 
? Antifungal activity more than the control drug against 
Candida parapsilosis RCMB  05065, with zone diameter 
of 19.9 mm. 
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4.3.2.1 MIC results of the 2-amino-alkylbenzimidazole derivatives 
(series 1 and 2) 
The results of the six compounds tested from the series 2- amino-
alkylbenzimidazole derivatives showed activity for FAS4 and FAS7 especially 
against Mucor circinelloides RCMB 07328 with low MICs of, 3.9 and 0.49μg/ml, 
respectively. Compounds FAS4, FAS6, FAS7, and FAS8 showed good activity 
against Candida parapsilosis RCMB 05065; with MICs in the range of 1.95 -
0.06μg/ml, which is less or equivalent to the MIC of the amphotericin B. The 
antifungal activity of these compounds against the rest of the selected strains was 
on the range of 500 - 0.06μg/ml (Table 4.29). 
 
4.3.2.2 MIC results of the 5-substituted benzimidazole derivatives 
(series 3) 
The results of the seven compounds tested from the series 5-substituted 
benzimidazole derivatives showed activity for six of them especially for compounds 
FAS18, FAS19, and FAS20 with MICs range of MIC ≥ 0.06 μg/ml, which were thus 
as active as the amphotericin B or less in some cases. All the compounds were 
active against Mucor circinelloides RCMB 07328 better than the control drug by 
three to six folds, except for FAS 21. Moreover, all compounds were active against 
Candida parapsilosis RCMB 05065, better than the control drug by two to nine folds, 
except FAS21. The antifungal activity of these compounds against the rest of the 
strains was in the range of 0.98 - 003μg/ml (Table 4.30). 
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4.3.2.3 MIC results of the 2-methanolbenzimidazole derivatives (series 
4) 
The results for the seven compounds tested from the series of 2-methaol-
benzimidazole derivatives showed good activity for only one compound FAS26 
against some species namely; Absidia corymbifera RCMB 09635, Syncephalastrum 
racemosum RCMB 05922, Candida krusei RCMB 05051, and Candida parapsilosis 
RCMB 05065, with MICs in the range of 0.49-0.98 μg/ml, which was active as the 
control drug or more active by two folds. The antifungal activity of this compound 
against the rest of the selected strains was on the range of 31.25 to 0.49 μg/ml 
(Table 4.31)  
 
4.3.2.4 MIC results of the2-carboxylic acid benzimidazole derivatives 
(series 5) 
The results for the six compounds tested from the series of 2-carboxylic acid 
benzimidazole derivatives showed activity for three compounds FAS31,FAS32 and 
FAS33, with low MICs of 0.98 μg/ml against Candida parapsilosis RCMB 05065, 
which is one fold more potent than the control drug or equal. The antifungal activity 
of these compounds against the rest of the selected strains was in the range of MIC 
0.98- ≥ 500μg/ml (Table 4.32).  
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4.3.2.5 MIC results of the N – methyl-2- methanol-benzimidazole 
derivatives (series 6) 
The results of the five compounds tested from the of series N–methyl-2- 
methanolbenzimidazole derivatives showed activity for three compound, FAS41, 
FAS42, and FAS50 against Mucor circinelloides RCMB 07328 with MICs in the 
range of  0.98 - 0.12-μg/ml, which were more potent than the control drug by two, 
four, and five folds respectively. The antifungal activity of these compounds against 
the rest of the selected strains was in the range of ≤ 500 to 0.12 μg/ml (Table 4.33). 
FAS42 and FAS50 were the most active compounds against; Syncephalastrum 
racemosum RCMB 05922, and Candida krusei RCMB 05051 with MICs in the range 
of 0.98 - 0.12μg/ml, which were more active than the amphotericin B by one, two, 
and three folds potent or equivalent. 
 
4.3.2.6 MIC results of the 2-chloromethylbenzimidazole derivatives 
(series 7) 
The results for the four compounds tested from the of series 2-
chloromethylbenzimidazole derivatives showed activity for two of them, FAS44 and 
FAS49, with MICs of 1.95 μg/ml against Mucor circinelloides RCMB 07328, which is 
one fold potent than the amphotericin B. Moreover, the MICs for those compounds 
were more potent than the control drug by three to four folds against Candida 
parapsilosis RCMB 05065, wheras FAS48 was as potent as the control drug against 
the selected strain.The antifungal activity of these compounds against the rest of the 
selected strains was in the range of ≤ 500 to 0.12- μg/ml (Table 4.34). 
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4.3.2.7 MIC results of the 2-ethanebenzimidazole derivatives (series 48) 
The results of the single compound tested from the series of 2-ethanebenzimidazole 
derivatives showed activity for this compound, FAS54 against Mucor circinelloides 
RCMB 07328, Syncephalastrum racemosum RCMB 05922, and Candida 
parapsilosis RCMB  05065, with MICs of 0.12, 0.24, and 1.95 μg/ml respectively, 
which is five, two, and equivalent folds potent than the amphotericin B.The 
antifungal activity of this compound against the rest of the selected strains was in 
the range of 500 - 0.12 μg/ml (Table 4.35)  
Table  4.35 MIC results of the 2-ethanebenzimidazole derivative 
 Fungal  MIC μg/ml FAS54 Amphotericin B 
Aspergillus fumigatus RCMB 02564 0.49 0.06 
Aspergillus clavatus RCMB 02593 0.24 0.12 
Mucor circinelloides RCMB 07328 0.12  3.9 
Absidia corymbifera RCMB 09635 >500 0.98 
Penicillium marneffei RCMB 01267 1.95 0.49 
Syncephalastrum racemosum RCMB 05922 0.24  0.98 
Candida albicans  RCMB  05035 0.24 0.12 
Candida tropicalis  RCMB  05049 1.95 0.015 
Candida  krusei  RCMB  05051 1.95 0.98 
Candida parapsilosis RCMB  05065 1.95 1.95 
MICs < MICs of Amphotericin B are highlighted 
 
 
4.3.2.8 MIC results of the silver complexes (series 13) 
The results of the two compounds tested from the series of silver complexes 
showed activity for FAS70 and FAS72 with MICs of 0.98, and 0.49 μg/ml 
respectively, against Syncephalastrum racemosum RCMB 05922, which were equal 
to the control drug or more potent by one fold.The antifungal activity of these 
compounds against the rest of the selected strains was in the range of 500 - 0.49 
μg/ml (Table 4.36). 
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Table  4.36 MIC results of the silver complexes 
Fungal  MIC μg/ml 
FAS70 FAS72 Amphotericin B 
Aspergillus fumigatus RCMB 02564 3.9 1.95 0.06 
Aspergillus clavatus RCMB 02593 1.95 0.98 0.12 
Mucor circinelloides RCMB 07328 15.63 7.8 3.9 
Absidia corymbifera RCMB 09635 >500 62.5 0.98 
Penicillium marneffei RCMB 01267 3.9 62.5 0.49 
Syncephalastrum racemosum RCMB 05922 0.98 0.49 0.98 
Candida albicans  RCMB  05035 7.8 1.95 0.12 
Candida tropicalis  RCMB  05049 1.95 0.49 0.015 
Candida  krusei  RCMB  05051 7.8 >500 0.98 
Candida parapsilosis RCMB  05065 31.25 7.8 1.95 
 
4.3.2.9 MIC results of the 2-methanthiolbenzimidazole derivatives 
(series 9) 
The results of the only compound tested from the of series 2-
methanthiolbenzimidazole derivatives showed activity for this compound, FAS56 
with low MICs of 1.95 μg/ml against Mucor circinelloides RCMB 07328, which is one 
fold more potent than the amphotericin B. Furthermore, the compound showed good 
activity against Syncephalastrum racemosum RCMB 05922 with an MIC of 0.98 
μg/ml, which is equal to the MIC of the control drug .The antifungal activity of this 
compound against the rest of the selected strains was on the range of 500 - 0.98 
μg/ml (Table 4.37). 
 
4.3.2.10 MIC results of the N-oxidebenzimdazole derivatives (series 
10) 
The results of the only compound tested from the series of N-oxidebenzimdazole 
derivatives showed activity for FAS60 against some of the filamentous strains, with 
Chapter.4       Biological evaluation 
209 
 
MICs of 0.03, 0.24, and 0.12 μg/ml; Mucor circinelloides RCMB 07328, Penicillium 
marneffei RCMB 01267, and Syncephalastrum racemosum RCMB 05922 
respectively. As a result of this, FAS60 is seven, three, and one folds more potent 
than the amphotericin B. Furthermore, the compound recorded good activity against 
two strains of the unicellular fungi; Candida krusei RCMB 05051, Candida 
parapsilosis RCMB 05065, with MICs more potent than the control drug by two, and 
one folds (MICs of 0.24, and 0.98 μg/ml, respectively). The antifungal activity of this 
compound against the rest of the selected strains was on the range of 500 - 0.03 
μg/ml (Table 4.38). 
Table  4.37 MIC results of the 2-methanthiolbenzimidazole derivative 
Fungal  MIC μg/ml 
FAS56 Amphotericin B 
Aspergillus fumigatus RCMB 02564 7.8 0.06 
Aspergillus clavatus RCMB 02593 3.9 0.12 
Mucor circinelloides RCMB 07328 1.95 3.9 
Absidia corymbifera RCMB 09635 >500 0.98 
Penicillium marneffei RCMB 01267 31.25 0.49 
Syncephalastrum racemosum RCMB 05922 0.98 0.98 
Candida albicans  RCMB  05035 31.25 0.12 
Candida tropicalis  RCMB  05049 62.5 0.015 
Candida  krusei  RCMB  05051 15.63 0.98 
Candida parapsilosis RCMB  05065 125 1.95 
 
Table  4.38 MIC results of the N-oxidebenzimdazole derivative 
Fungal  MIC μg/ml 
FAS60 Amphotericin B 
Aspergillus fumigatus RCMB 02564 0.49 0.06 
Aspergillus clavatus RCMB 02593 1.95 0.12 
Mucor circinelloides RCMB 07328 0.03 3.9 
Absidia corymbifera RCMB 09635 >500 0.98 
Penicillium marneffei RCMB 01267 0.24 0.49 
Syncephalastrum racemosum RCMB 05922 0.12 0.98 
Candida albicans  RCMB  05035 0.49 0.12 
Candida tropicalis  RCMB  05049 0.49 0.015 
Candida  krusei  RCMB  05051 0.24 0.98 
Candida parapsilosis RCMB  05065 0.98 1.95 
MICs < MICs of Amphotericin B are highlighted 
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4.3.2.11 MIC result of the benzoxazole derivative (series 11) 
The results of the only single compound tested from the series of benzoxazole 
derivatives showed activity against Mucor circinelloides RCMB 07328, and 
Syncephalastrum racemosum RCMB 05922 respectively for FAS63 with low MICs 
of 0.49 and 0.12 μg/ml,. As a result of this, FAS63 appears three folds more potent 
than the Amphotericin B. Moreover, the most activity recorded against unicellular 
fungi selected for this study was against Candida parapsilosis RCMB 05065, with 
MIC equivalent to the MIC of the control drug. The antifungal activity of this 
compound against the rest of the selected strains was in the range of 500 - 0.12 
μg/ml (Table 4.39). 
 
Table  4.39 MIC results of the benzoxazole derivative 
Fungal  MIC μg/ml 
FAS63 Amphotericin B 
Aspergillus fumigatus RCMB 02564 1.95 0.06 
Aspergillus clavatus RCMB 02593 0.98 0.12 
Mucor circinelloides RCMB 07328 0.49 3.9 
Absidia corymbifera RCMB 09635 >500 0.98 
Penicillium marneffei RCMB 01267 1.95 0.49 
Syncephalastrum racemosum RCMB 
05922 0.12 0.98 
Candida albicans  RCMB  05035 0.49 0.12 
Candida tropicalis  RCMB  05049 0.98 0.015 
Candida  krusei  RCMB  05051 1.95 0.98 
Candida parapsilosis RCMB  05065 1.95 1.95 
MICs < MICs of Amphotericin B are highlighted 
 
4.3.2.12 Conclusion 
The microdilution tests of the most active 41 compounds of the 65 compounds 
revealed that; FAS18 and FAS20 had some antifungal activity against Aspergillus 
fumigatus RCMB 02564 with MIC equal of the control (0.06 μg/ml). Three 
compounds showed good antifungal activity against Aspergillus clavatus RCMB 
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02593, with MIC range 0.06-0.12 μg/ml. The rest of the compounds were unlike this 
and therefore were not better than the amphotericin B (control drug). 18 compounds 
had activity against Mucor circinelloides RCMB 07328 with MIC range 3.9 - 
0.06μg/ml. Nine compounds showed good activity against Absidia corymbifera 
RCMB 09635 with MIC in range 0.98-0.03 μg/ml. Five compounds showed good 
activity against Penicillium marneffei RCMB 01267 with MIC in range 0.49-0.03 
μg/ml. 13 compounds showed good activity against Penicillium marneffei RCMB 
01267 with MICs in the range of 0.98 - 0.12μg/ml. only two compounds, FAS18 and 
FAS20 showed good activity against Candida albicans RCMB  05035 with MIC 0.03 
μg/ml equivalent to the MIC of the control drug. Moreover, FAS18 and FAS19 are 
the only two compounds that showed good activity against Candida tropicalis RCMB 
05049 with MICs of 0.015 and 0.007 μg/ml respectively. Six compounds showed 
good activity against Candida krusei RCMB 05051 with MIC of 0.98 μg/ml which 
equal, to the MIC of the control drug. 20 compounds showed good activity against 
Candida parapsilosis RCMB 05065 with MIC in range 0.98 - 0.003μg/ml. 
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5 DISCUSSION AND FUTURE WORK 
 
5.1 Discussion  
A total of 70 compounds were synthesised belonging to three different classes; 
these include 66 benzimidazoles, three benzoxazoles, and one benzothiazole 
derivative. These compounds were prepared according to literature procedures or 
by adapting conventional methods (Phillips, 1928, Podunavac-Kuzmanovic et al., 
2004, Meyers et al., 2005, Harisha et al., 2009). The latter two classes were 
included to help evaluate the importance of the benzimidazole framework. The 
compounds were screened to see if they had any antibacterial or antifungal 
activities. Unfortunately, not all of the compounds synthesised could be used in the 
biological studies. One compound; FAS 14, which could not be purified to 
acceptable standards was excluded. In addition, two of the compounds (FAS67 and 
FAS68), which were synthesised and isolated in extremely low yield from a mixture 
containing many by-products, proved to be insufficient for the biological evaluation.  
From the literature review (Table 2.4), it can be seen that eleven compounds are 
novel (have not been previously synthesised) and some compounds were found to 
have incomplete analytical data. The majority of compounds (62) were evaluated for 
their antibacterial and antifungal properties for first time in this project and the 
results are considered to be novel. 
5.1.1 Factors affecting the yield  
Figure 5.1 displays the range of yields obtained for the benzimidazole derivatives. 
The yield of these compounds was affected by several factors such as difficulties in 
purification where the Rf of the desired products were too close to the Rf of the 
impurities and some starting materials were reluctant to undergo cyclisation. 

Chapter 5 Discussion and Future work 
214 
 
Furthermore, some early literature reports support this by stating that no reaction 
was observed even with the extended reaction times, and concluded that the 
reaction was not feasible (Hughes and Lions, 1938). However, other researchers 
have found that the reaction with amino acids, where the amino group is at the β-
carbon had been proved to be more reactive than when the amino group is on the 
α-carbon. Moreover, increasing the substituents on the α-carbon of the amino acid 
also reduced the reactivity of the amino acids and, as expected, glycine was more 
reactive than alanine (Cescon and Day, 1962). For example, (S)-1-(5-nitro-1H-
benzoimidazol-2yl)ethanamine FAS14, after 336 hours reaction time still contained 
50% starting material (see section 3.3.3).   
In addition, the yields were influenced by the reactivity of the 4-substituted 1,2-
phenylenediames. This is dictated by the nature of the substituent. The effect of the 
substituent in position 4 of 1,2-phenylenediamine could either enhance or diminish 
the reaction rate. From the proposed mechanism for the formation of these 
derivatives, it can be seen that the reaction starts with the nucleophilic attack by the 
electron pair of the nitrogen of an amino group on the 1,2-phenylenediamine. When 
there is no substituent at position 4, or there is a donating substituent, the reaction 
tends to be faster and the yield higher. In contrast, when the substituent is an 
electron withdrawing type, the reaction tends to be slower and the yield is lower. 
This phenomenon could be explained by the engagement of the electron pair in the 
resonance of the aromatic ring and is observed when an electron withdrawing 
group, such as the nitro group, is involved. So the existence of the nitro group 
removes the electrons from the aromatic ring by π-π resonance and hinders the 
reaction. Therefore the electron pair of the amino group will be engaged in this 
resonance which reduces its reactivity (Figure 5.2).  
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Figure  5.2 Resonance structures of 4-nitro-1,2-phenylenediamine 
 
Excellent yields were obtained for 21 compounds (80-100%) and good yields were 
obtained for 11 compounds (60-80%).  Only eight compounds were isolated in 
yields ≤ 20% (Figure 5.1).  
 
5.1.2 Attempts to improve the yield 
Researchers have used several strategies to improve the reaction and the yield of 
benzimidazole derivatives. In this project one method was chosen which had the 
possibility to enhance the synthesis of the desired product. This method involved 
the use of ionic liquids as solvents. The ionic liquids are fluid at ambient 
temperature, have low viscosity and are easily handled (Sheldon, 2001). The 
reactions in ionic liquids are often quicker than in conventional organic solvents, and 
they are considered as green solvents because of their lack of vapor pressure 
(Martyn and Seddon, 2000). There is also the possibility of recycling the ionic liquid 
after its use in the reaction (Hu, 2006). An example of the advantage of using ionic 
liquids is the multistep synthesis of the benzimidazole linked pyrrolo[1,2-
a]benzimidazolones, pyrido[1,2-a]benzimidazolones and isoindolo[1,2-
a]benzimidazoles. These reactions could also be conducted under microwave 
conditions, in a short time with high yields and this was supported by many studies 
(Sapkal et al., 2009, Thummanagoti et al., 2011). The products were also easy to 
isolate.  
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The Phillips method is well known as the reaction of 1,2-phenylenediamines with 
organic acids to give benzimidazoles in the presence of hydrochloric acid. The 
reaction produces the desired product in low yields (Wright, 1951). However, the 
imidazolium-based ionic liquid has been used in an attempt to improve the reaction 
(Martyn and Seddon, 2000, Thummanagoti et al., 2011). Also, it had been reported 
that the Phillips method did not work for the synthesis of benzimidazoles from amino 
acids and 1,2-phenylenediamines, although Cescon and Day (1962) found that the 
method could be successful when the reaction period was greatly extended 
(Cescon and Day, 1962).  
In the present work, improvement to the Phillips’ method was also attempted by 
using a series of phosphonium-based ionic liquids (Bu4P+ Cl-, Oct4P+ Br-, i-Bu3P+Me 
OTs-, Bu3P+Et Br-, Bu3P+Oct Br-, -) at RT, 40ºC and 80ºC for 24h. The reaction at 
80ºC gave the best yields which are displayed in Table 5.1. Bu3P+Oct Br was the 
only ionic liquid to give the product for glycine (29%) while two ionic liquids,  
i-Bu3P+Me OTs- and Bu3P+Et Br-, afforded the product in 37% and 51% yield 
respectively. Not surprisingly, the results with β-alanine were more promising; three 
ionic liquids yielded the product in yields of 13%, 37% and 75%. The highest yield 
was obtained in Bu4P+ Cl-. 
Additionally, microwave-mediated synthesis in the ionic liquids (after just 5 minutes 
reaction at 80ºC) was also successful. The reactions with gycine and β-alanine gave 
the desired benzimidazoles in 27% and 25% yield in Bu3P+Oct Br and Oct4P+ Br- 
respectively. The conventional Phillips method for glycine resulted in 89% yield after 
heating under reflux for 13 days, followed by extremely slow evaporation over 
several days. The benzimidazole derivative from alanine was obtained after 11 days 
in 67% Yield. β-Alanine required eight days reaction time and gave 66% yield 
(Donkor, 2007). 
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The results obtained are very encouraging as there are currently no alternatives to 
the Phillips method for the construction of benzimidazoles from amino acids. 
However, it is difficult at this stage to understand why some ionic liquids gave the 
product and others were unsuccessful. Alternative reaction conditions using 
different ionic liquids (varying the anions and cations), including the use of the 
imidazolium-based ionic liquids need to be considered in future modifications. In 
addition, the application of ultrasound at different temperatures could be 
investigated. 
Table  5.1 Reactions conducted in ionic liquids and in a microwave 
Entry Ionic liquid Amino acid Microwave method yield (%) 
Conventional 
method yield (%) 
1 Bu4P+Cl- glycine 0 0 
2 Oct4P+Br- glycine 0 0 
3 i-Bu3P+Me OTs- glycine 0 0 
4 Bu3P+Et Br glycine 0 0 
5 Bu3P+Oct Br glycine 27 29 
6 Bu4P+Cl- alanine 0 0 
7 Oct4P+ Br- alanine 0 0 
8 i-Bu3P+Me OTs- alanine 0 37 
9 Bu3P+ Et Br alanine 0 51 
10 Bu3P+Oct Br alanine 0 0 
11 Bu4P+  Cl- β-alanine 0 75 
12 Oct4P+ Br- β-alanine 25 39 
13 i-Bu3P+Me OTs- β-alanine 0 13 
14 Bu3P+Et Br β-alanine 0 0 
15 Bu3P+Oct Br β-alanine 0 0 
 
The ionic liquid, Bu3P+Oct Br-, was used specifically in the synthesis of N-
bromodecyl-2-chloromethyl-benzimidazole FAS68 (Figure 5.3), but even with the 
extended reaction times, no product was detected (see section 3.7).  
N
H
N
Cl BrBr
FAS 68
Bu3 P+ Oct Br-
X
8 N
N
Cl
Br
8
RT
 
 
Figure  5.3 Synthesis of N-bromodecyl-2-chloromethylbenzimidazole FAS75 
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5.2 Methodology for biological evaluation 
Sections 2.4.1 and 2.4.2 describe the methods which were used in this project to 
assess the antibacterial and antifungal activity of the compounds. However, the 
experiments were done in vitro, and the results could be different if they are tested 
in vivo. This depends on the factors that must be taken into account, such as 
absorption of the drug or the level of the toxicity.  
Overall, 67 benzimidazole derivatives were screened for their biological activity 
against a set of reference bacteria and fungi by using a disc (well) diffusion and 
MICs test (see section 2.4.3) (Table 2.4).  
The following methods were used for screening the biological activity of the 
compounds: The first method used was the disc (well) diffusion test, which 
measures the diameter of the zone of inhibition of a compound. This can vary and 
depends on many factors, including local moisture levels, solubility, diffusibility, 
stability of the compound, and stability of concentration gradients that can form 
across the surface of agar. Moisturising can affect the inhibition zone by sometimes 
showing a margined zone. In this method, it was hard to pick a single amount to 
help in studying the activity of the compounds against the selected strains. If only 
100 μg had been used on the disc for studying the antibacterial activity, this could 
have displayed no activity for some compounds. Therefore, three different amounts 
(10, 100, and 200 μg) were selected to study any activity of the compounds. 
Furthermore, there is a need to be careful in screening the compounds at fix 
concentration as this could have resulted with a distorted set of data due to the 
occurrence of Eagle’s phenomena. Sometimes this rare situation is observed when 
the antibiotics effect is paradox lower at higher concentration of the drug, whereas 
the drug is more active against the selected strains at lower concentration (Eagle 
and Musselman, 1948). Moreover, more than one level of concentration was 
required for this study which gave a broad range of activity, and it would also give a 
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reliable investigation to determine the MICs of each compound. So, for all above 
mentioned reasons, a three fixed concentrations approach was selected for the disc 
diffusion assay. In addition to this, for economic reasons this approach was selected 
instead of using one concentration which may have led to many tests on the 
compound at different concentration levels. Furthermore, reproducibly, quick, and 
easy means for screening compounds for any inhibitory results of replicate tests 
were generally in good agreement with each other. The second method used was 
the agar dilution test and broth dilution test, which provides a convenient method for 
determining minimum inhibitory concentration (MICs) for a variety of antimicrobial 
agents as a quantitative measurement of antimicrobial sensitivity.  Both methods 
gave good results and were easy to implement, but the MIC test was better in 
identifying the level of resistance in less sensitive strains (Bala et al., 2005, Erfani et 
al., 2011). 
In conclusion, five derivatives showed good activity against some of the Gram +ve 
and Gram –ve strains, and especially against the ciprofloxacin resistant strains (see 
Table 4.9). For the antifungal studies, 26 compounds were as active as 
amphotericin B, or more potent against some of the selected fungi (see Table 4.28).  
 
5.3 Antimicrobial activity in relation to molarity 
In the previous section, the activity of different compounds was compared on the 
basis of their zone diameters or MIC values recorded as μg/ml. However, such 
comparisons are by necessity over simplifying the situation because they are based 
on the same weight of each compound being used in the assay. This does not 
necessarily mean that the same amount i.e. number of moles was present, because 
some of the compounds have widely different molecular weights.   
In the case of the antibacterial screening, the compounds tested were inoculated on 
the discs in 10 μg, 100 μg, and 200 μg, which vary in what amounts are present. So, 
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when the amount of the compound increases on the disc, the molarity increases 
too, and this is reflected on the amount of activity recorded against the selected 
strains, which also increases. None of the compounds tested in this study showed 
appreciable activity against the selected Gram –ve strains, except some compounds 
which revealed activity against Burkholderia cepacia NCTC 10744, and only FAS42 
(series 6) was active against Escherichia coli NCTC 10418, Serratia marcescens 
NCTC 1377 (Table 5.2).  
While the molecular weights for compounds FAS39 (series 6) and FAS42 (series 6) 
(FAS39 is 210.66 g/mol and FAS42 is 192.21 g/mol) (Table 5.2), are not very 
different, the compounds behave differently against the Gram –ve strains.  Their 
biological properties must arise from the different groups on the benzimidazole 
which affects their movement through the cell wall. As mentioned earlier (section 
1.1.1), the cell wall structure of the Gram –ve strains have a thin layer of 
peptidoglycan and another outer membrane which functions as a permeability 
barrier. 
The most potent compound against Gram +ve species were two compounds from 
series 2 (FAS11 (5-Cl), FAS12 (5-Br), one compound from series 6 FAS42 (5-OMe), 
one compound from series 7, FAS47 (5-Br), one compound from series 9, FAS56 
(5-H), and one compound from series 11, FAS61 (5-H). However, the most potent 
compounds against Gram –ve species were one compound from series 2 FAS12 (5-
Br), one compound from series 6, FAS42 (5-OMe), one compound from series 7, 
FAS47 (5-Br), and one compound from series 9, FAS56 (5-H), So compounds 
FAS12 (series 2), FAS42 (series 6), FAS 47 (series 7) and FAS56 (series 9) were 
the most active compounds against both Gram +ve and Gram –ve species.  
In the case of antifungal screening, the compounds were inoculated on the discs in 
250 μg amounts. Most of the compounds tested were active against all the 
filamentous strains, although the activity against Absidia corymbifera RCMB 09635, 
Syncephalastrum racemosum RCMB 05922, Mucor circinelloides RCMB 07328, 
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and Aspergillus clavatus RCMB 02593, was not at the same level to the other 
filamentous strains (Table 5.3). 
The activity of the compounds against the unicellular strains selected for this study 
was superior against two strains; Candida albicans RCMB 05035 and Candida 
tropicalis RCMB 05049. Moreover, not all the compounds tested were active against 
Candida parapsilosis RCMB 05065. In addition to this, only 25 compounds were 
active against Candida krusei RCMB 05051. The differences observed in activity 
against the filamentous and the unicellular strains could be explained by the 
difference type of cell structure of each strain (section 1.1.2).   
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5.4 Structure Activity Relationships (SAR) 
5.4.1 Effect of substituents on the structure 
 
An investigation into the antimicrobial activity of the series of substituted 
benzimidazoles depends on the substituents attached to the bicyclic aromatic 
heterocycle.  Therefore, in order to study the significance of the substituents and the 
SAR, i.e., the importance of the substituent attached at positions 1, 2, and 5, the 
effect of each substituent on the benzimidazole ring, is initially described (Table 
5.4). 
When the substituent at position-5 of the benzimidazole system is a methyl group, it 
will act as an activating group through the inductive effect (Table 2.4 and Table 5.4). 
Podunavac-Kuzmanovic and Cvetkovic (2007) observed that the unsubstituted 
analogue was more potent than the methyl analogues of the 2-
aminobenzimidazoles (Figure 1.27). The methoxy group will also activate the 
aromatic system, and this is through resonance. The literature suggests that this 
results in increased antimicrobial activity. For example, the study by 
Sambanthamoorthy (2011) determined that 5-methoxy-2-[(4-methylbenzyl)sulfanyl]-
1H-benzimidazole, Figure 5.4, inhibited the biofilm formation by multiple bacterial 
pathogens (Sambanthamoorthy et al., 2011). Furthermore, the study by Vidaillac et 
al. (2007) developed some analogues of omeprazole in restoring the bactericidal 
activity of norfloxacin over a prolonged period and concluded that the compound, 
shown in Figure 1.30, was more effective than omeprazole. They also found that 
when the methoxy substituent was present on either the benzimidazole or the 
pyrrolo[1,2-a]quinoxaline nucleus, the compounds were more potent than the 
unsubstituted compounds (Vidaillac et al., 2007). 
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Figure  5.4 Structure of 5-methoxy-2-[(4-methylbenzyl)sulfanyl]-1H-benzimidazole 
(Sambanthamoorthy et al., 2011) 
 
When the halogen substituent is present, overall it acts as a deactivating group 
(Table 5.4).  
When the halogen substituent is chloro or bromo, this has the potential of 
significantly improving the biological activity. Also, increasing the acidity of the 
compound could increase the biological activity. Tavman’s study (2009) showed that 
the chloro derivative of 2-(5-substituted-1H-benzo[d]imidazol-2-yl)-6-methoxyphenol 
(Figure 5.5) was the most active compound against selected strains; 
Staphylococcus epidermidis and Staphylococcus aureus (Tavman et al., 2009). 
However, they did not study the fluoro and bromo analogues. Some benzimidazole 
ribonucleoside derivatives possessing dichloro substituents (Figure 1.24) appear to 
be more biologically stable and orally active (Stedman and Barclay, 2000) 
 
 
Figure  5.5 Structure of 2-(5-substituted-1H-benzo[d]imidazol-2-yl)-6-methoxyphenols. 
(Tavman et al., 2009) 
 
The nitro group will deactivate the aromatic system, by the electron withdrawing 
effect through the conjugation effect (Table 5.4). A SAR study by González-Chávez 
et al., (2011) suggested that the presence of an electron withdrawing group on the 
benzimidazole ring increases the antimicrobial activity, especially, for compounds 
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possessing a nitro group in either the 5- or 7-position of N-(2-methyl-4,5,7-
substituted-1H-benzo[d]imidazol-6-yl)benzenesulfonamide (Figure 5.6) against 
Staphylococcus aureus, MRSA and Bacillus subtilis (González-Chávez et al., 2011). 
Clearly the sulfonamide group is well known to enhance antimicrobial activity 
(Kalidhar and Kaur, 2011).  
 
 
Figure  5.6 Structure of N-(2-methyl-4,5,7-substituted-1H-benzo[d]imidazol-6-
yl)benzenesulfonamides (González-Chávez et al., 2011) 
 
Substitution at position 2 of the benzimidazole ring also has a significant role in 
determining the biological activity. Therefore, different groups have been used for 
the SAR.  The effect of the groups is described according to their nucleophilicity and 
is summarised in Table 5.4. There is a large amount of research published on the 
effect of different groups on biological activity (Puratchikody et al., 2008, Tuncbilek 
et al., 2009). For example, the 2-amino, 2-(6-fluorochromyl), 2-methyl, 2-
aminomethyl, 2-thiomethyl, 2-phenoxymethyl, and 2-chloromethyl substituents have 
been studied by many researchers (Kumar et al., 2006, Madkour et al., 2006, 
Podunavac-Kuzmanovic and Cvetkovic, 2007, Vaidehi and Deepika, 2012). The 2-
chloromethyl group has been selected for this study, although it had been previously 
studied by other researchers for the antimicrobial activity against helminthes, 
bacterial, and fungal strains (Table 2.4). Some of the strains which were studied 
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with this compound were the same as the strains selected for this project, but were 
of a different species (Different species of Staphylococcus aureus (≥ 512 μg/ml), 
Escherichia coli (> 512 μg/ml), Pseudomonas aeruginosa (≥ 512 μg/ml), Aspergillus 
fumigatus (125 μg/ml), and Penicillium marneffei (17.9 mm) as mentioned in Table 
2.4). Therefore, there was interest in studying this compound with a variety 
substituents at position 5 of the 2-chloromethyl derivatives (FAS43-49,53, Table 2.4) 
of the benzimidazole to investigate the SAR further (Karuvalam et al., 2012, Vaidehi 
and Deepika, 2012, Zhang et al., 2012b).  
 
The substitution of the methyl group at position 1 will increase the electron density 
on the aromatic system through the inductive effect. The presence of the methyl 
group at this position has biological importance, and this has been proved by many 
studies. A study by Pawar et al., (2004) found that the N-methyl derivative of 2-(4-
thiazolyl)-1H-benzimidazole (Figure 1.31) showed lower antifungal activity, and no 
antibacterial activity compared to the unmethylated derivative(Pawar et al., 2004).  
 
In the N-oxide derivative, the electrons of the oxygen do not interfere with the π 
orbitals of the benzimidazole ring (Table 5.4). A study by Boiani et al., (2009), which 
selected an N-oxide moiety and developed new 2H-benzimidazole-1,3-dioxides, 
found they were less toxic and more selective antichagasic drugs. Another study 
also found that some N-oxide benzimidazole derivatives (Figure 5.7) were more 
potent DNA topoisomerase I inhibitors, than their analogues without N-oxide bond 
(Boiani et al., 2009, Blaszczak-Swiatkiewicz and Mikiciuk-Olasik, 2013). 
N
H
N
R
O2N
R= 4-Cl-Ph, 2-NO2-Ph
O
 
Figure  5.7 Structure of 5-nitro-1H-benzimidazole-N-oxides   
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Table  5.4 The effect of each substituent on the benzimidazole ring 
 
Substituent  Effect  
5-CH3 Electron releasing through the inductive effect 
H3C H3C H3C H3C
N
H
N
N
H
N
N
H
N
N
H
N
 
5-OCH3 Electron releasing through conjugation effect 
H3CO H3CO H3CO H3CO
N
H
N
N
H
N
N
H
N
N
H
N
 
5-Cl, Br, F Electron releasing through conjugation effect and electron withdrawal by inductive effect 
X X X X
N
H
N
N
H
N
N
H
N
N
H
N
 
5-NO2 Electron withdrawal through conjugation effect 
N
O
O
N
O
O
N
O
O
N
O
O
N
H
N
N
H
N
N
H
N
N
H
N
 
2-CH2X 
X: NH2, OH, 
SH, OMe, 
Cl, 
The nucleophilicity of sulfur is much greater than other atoms and  its lone pairs of 
electrons are readily accessible 
SH>NH2>OMe>OH>Cl,  
2-COOH 
N
H
N
N
H
N
OH OH
O O
 
N-CH3 
N
N
N
N
CH3 CH3  
N-Oxide 
N
H
N
O
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5.4.2 Antibacterial evaluation 
5.4.2.1 The effect of substituent at position 5  
From the series of 2-ethanamine benzimidazole derivatives (series 2), only two 
compounds; FAS11 (5-chlorobenzimidazole) and FAS12 (5-bromobenzimidazole) 
showed activity against two MRSA strains; Methicillin-resistant Staphylococcus 
aureus (HG-1), and MRSA BIG 0050; with MIC of 32 μg/ml, which is equivalent to 
the MIC of ciprofloxacin (control drug). This suggests that the higher 
electronegativity of bromine and chlorine, increased the antibacterial activity and 
this was also observed by Tavman (Table 2.4 and Table 5.4) (Tavman et al., 2009).  
FAS39 (5-chloro) from the series of N-methyl-2-methoxymethyl-benzimidazole 
(series 6) showed activity only against three species of MRSA (Table 4.11), but this 
was not as good as the control drug, and hence cannot be a competitor to 
ciprofloxacin.This is in contrast to the observation by Vidaillac (2007), where the 
presence of the methoxy group increases the biological activity. However, this also 
agreed with another study done by Reddy et al. (2009), which revealed that the 2-
phenoxymethylbenzimidazole derivatives have potential antitubercular activity and 
may be worth further study. Furthermore, some researchers have also found that 
the presence of halogen and methoxy substituents on fluoroquinolone (well-known 
drug) increased the activity against Gram +ve cocci including the resistant strains 
(Peterson, 2001, Vidaillac et al., 2007, Reddy et al., 2009). 
In the 2-chloromethylbenzimidazole derivatives (series 7), six compounds were 
active, and therefore their MICs were determined. Unfortunately, no promising 
results were observed for all the compounds tested. This observation agrees with 
the finding by others for the unsubstituted derivative (Table 2.4). In spite of this, as 
shown in Table 4.12, FAS47, the brominated derivative, was the most active 
compound followed by FAS46 which is the chlorinated derivative. This could support 
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the hypothesis that there is a direct relationship between biological activity and the 
electron withdrawing effect (Table 5.4) (Tavman et al., 2009). 
For the 2-methanthiol benzimidazole derivatives (series 9), one compound was 
active, the unsubstituted derivative at position 5 FAS56, which was selectively 
active against most of the Gram +ve strains with MIC of 64 μg/ml, except against 
Staphylococcus haemolyticus NCTC 11042, the MIC value was 32 μg/ml. The 
activity recorded against Gram -ve strains, was only against Burkholderia cepacia 
with MIC of 64 μg/ml (Table 4.13). The inhibition activity decreases when position 5 
is methylated as in compound FAS57. This was also observed by Podunavac-
Kuzmanovic and Cvetkovic (2007), who found that the unsubstituted analogue was 
more potent than the methyl analogues of the 2-aminobenzimidazole (Table 5.4).  
The -CH2NH2, -CH2OH, and -COOH substituents at position 2, did not impart any 
activity as seen in the determination of the zone inhibition. Therefore, their MICs 
were not considered. 
 
5.4.2.2 The effect of the substituent at position 2  
Only two compounds from the series derived from 1,2-phenylenediamine displayed 
activity according to their zones of inhibition; these were compounds FAS43 (series 
7) and FAS56 (series 9). However, FAS56 containing CH2SH, was the most active 
compound in terms of MICs, which was three to four folds more potent than FAS43 
which possesses the CH2Cl substiuent. This may indicate that the thiol at position 2 
(FAS56) is the main reason for the activity. This has also been observed by others 
who reported a similar impact on the antimycobacterial activity on some 2-
alkylsulphanylbenzimidazoles derivatives, which showed considerable activity 
(Table 5.4) (Klimesˇova´ et al., 2002). Another review by Goswami and Singh (2012) 
reported that 2-substituted benzimidazole derivatives possess biological activity, 
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and the 2-thiolakyl and 2-thioaryl exhibited good antiprotozoal and antibacterial 
activity. 
Additionally, a series of 2-[(2-nitro-1-phenylalkyl)thiomethyl]benzimidazole 
derivatives (with R=Br, N(CH3)2) (Figure 5.8) synthesised by Utku et al., (2008) were 
found to be active as ampicillin against two strains Staphylococcus aureus and 
Streptococcus faecalis. Interestingly, the unsubstituted compound showed 
antifungal activity close to the control drug (Ketoconazole) (Utku et al., 2008).  
 
Figure  5.8 Structure of 2-[(2-nitro-1-phenylalkyl)thiomethyl]benzimidazole derivatives 
 
From the 5-chloro substituted benzimidazoles, only three derivatives showed activity 
against the tested strains, -CH2NH2, -CH2Cl and -CH2OMe derivatives, (FAS11 
(series 2), FAS46 (series 7), and FAS39 (series 6) respectively). FAS11 from series 
2 was selectively the most active against three species of Staphylococcus aureus; 
(Oxford) NCTC 6571, Methicillin-resistant Staphylococcus aureus (HG-1) 
(equivalent to MIC of ciprofloxacin 32 μg/ml), and MRSA BIG 005 (equivalent to MIC 
of ciprofloxacin 32 μg/ml), and the most active against one strain of Gram –ve; 
Burkholderia cepacia NCTC 10744. Other researchers found that the presence of 
an amino group at position 2 of the benzimidazole ring increased the antibacterial 
activity (Figure 1.27) (Podunavac-Kuzmanovic and Cvetkovic, 2007).   
 
In the 5-bromobenzimidazole series, only two derivatives showed activity against 
the tested strains, -CH2NH2, -CH2Cl (FAS12 (series 2), FAS47 (series 7) 
respectively). FAS12 was selectively the most active (the same as FAS11), against 
three species of Staphylococcus aureus, and the most active against one strain of 
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Gram –ve; Burkholderia cepacia NCTC 10744. Although FAS47 showed the most 
activity amongst the rest of the Gram +ve strains with MIC of 32,64 μg/ml. The 
results proved that the presence of a halogen in both positions (2 and 5) increased 
the antibacterial activity. An early study was done by Hughes and Lions on 2-
chloromethylbenzimidazole (where all the other substituents at position 1 and 5, are 
H). FAS43 did not show an appreciable activity against some bacteria strains, which 
agrees with this study (see section 5.1.1). Therefore the activity of the 5-bromo 
derivatives can be attributed to the presence of the bromine (See section 2.4.3) 
(Table 2.4 and 5.5) (Hughes and Lions, 1938, Tavman et al., 2009). 
Only compound, FAS42 (series 6), from the 5-methoxy substituted benzimidazole 
series which has -CH2OH group at position 2, showed activity against multiple 
strains according to its zones of inhibition The studies by Sambanthamoorthy and 
Vidaillac found that the methoxy group increases the biological activity, but in terms 
of the MIC values for this compound, it is not active (Vidaillac et al., 2007, Tavman 
et al., 2009, Sambanthamoorthy et al., 2011).  
From the 5-methyl derivatives, compound FAS44 (series 7), which had a -CH2Cl 
group attached at position 2, demonstrated good activity against the selected strains 
(which was more than the other methyl derivatives) according to its zones of 
inhibition, but was not as active according to the MIC values. However, the activity 
of this compound could be due to the existence of the chlorine atom at position 2, 
whereas the presence of the 5-methyl group was not as effective compared to the 
rest of the substituents. This is in agreement with the results obtained by 
Podunavac-Kuzmanovic and Cvetkovic (2007) (Table 5.4) (Podunavac-Kuzmanovic 
and Cvetkovic, 2007, Tavman et al., 2009). 
The compounds having a nitro group at position 5 of the benzimidazole were 
disappointing; except for one derivative, with -CH2SH group at position 2 (FAS57 
from series 9), which exhibited activity against only Staphylococcus epidermidis 
NCTC 11047 according to the zone of inhibition. This result could be either due to 
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the presence of the sulfur atom (-CH2SH) at position 2 and this agreed with many 
studies, or with the presence of the nitro group at position 5 which helped in 
deactivating the aromatic ring. When comparing the antibacterial activity of FAS57 
(5-NO2, 2-CH2SH) from series 9 with FAS21 (5-NO2, 2-H) from series 3, there was 
no activity for FAS21. Therefore, the activity observed for FAS57, was due to the 
presence of the –CH2SH group at position 2 (not active as FAS56 (5-H)) (Table 5.4) 
(Klimesˇova´ et al., 2002, Utku et al., 2008, González-Chávez et al., 2011). 
 
5.4.2.3 The effect of the substituent at position 1  
Only N-methylation was studied. In this series (series 6) only two compounds, 
FAS39 (5-Cl) and FAS42 (5-OMe), were active according to their zones of inhibition. 
But according to their MIC values, FAS39 was the most active compound against 
three species of MRSA, with MIC of 128 μg/ml. This result contradict the results of 
the Pawar study, which found that the unmethylated derivatives were more active 
(Pawar et al., 2004). 
Two N-oxide derivatives, FAS59 and FAS60 from series 10, were synthesised to 
assess their activity against the selected strains; unfortunately none of them were 
active. This was a little surprising since studies done by Blaszczak-Swiatkiewicz and 
Mikiciuk-Olasik, and Boiani et al., (2009) found different derivatives of 
benzimidazole N-oxides to be potent (See Section 5.1.1) (Boiani et al., 2009, 
Blaszczak-Swiatkiewicz and Mikiciuk-Olasik, 2013). 
 
5.4.2.4 The antibacterial activity of silver complexes  
Silver complexes were synthesised using some benzimidazole derivatives as 
ligands (series13). These ligands (series 3 and 5) were selected because they 
exhibited no activity themseleves. Therefore any activity of the complexes would be 
attributed to the presence of the silver. Unfortunately, none of the complexes 
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showed any activity. A study done by Podunavac-Kuzmanovic also supported this 
observation. The silver ion, which has ten electrons in a d valence shell, which 
make it a polarizable metal, is almost saturated. Therefore, if there is an increase in 
the polarizability of the metal, this could diminish the lipophilicity of the complexes, 
leading to decreasing or lack of the antimicrobial activity (Shoeib et al., 2001, 
Podunavac-Kuzmanovic et al., 2004) 
 
5.4.2.5 The effect of different heterocycles  
A small series of benzoxazole (series 11) and one benzothiazole (series 12) were 
assessed against the selected strains to compare their activity to the benzimidazole 
derivatives. The benzothiazole derivative FAS65 (benzo[d]thiazol-2-ylmethanol) 
according to the zone of inhibition, showed slightly more activity against most of the 
Gram +ve strains except against Staphylococcus aureus (Oxford) NCTC 6571, and 
Staphylococcus epidermidis NCTC 2749. From the entire Gram –ve strains selected 
for this project, the only activity was recorded against Burkholderia cepacia NCTC 
10744. FAS65 was more active than the other derivatives, although there were no 
promising results in terms of their MICs in comparison to the MIC of ciprofloxacin. 
FAS61 (benzo[d]oxazol-2(3H)-one) from series 11 was the most active compound 
according to MIC values against multiple strains as in Table 4.14. Some 
benzothiazole derivatives have been found to be more potent antimycobacterial 
agents compared to benzimidazole and benzoxazole derivatives (Pytela and 
Klimešová, 2011). 
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5.4.3 Antifungal evaluation 
5.4.3.1 The effect of the substituent at position 5  
Six compounds from the series of 5-substituted benzimidazole derivatives (series 3) 
showed promising results, especially compounds FAS18 (5-Cl), FAS19 (5-Br), and 
FAS20 (5-F) with MICs in the range of MIC ≥ 0.06 μg/ml. All the compounds were 
more active against Mucor circinelloides RCMB 07328 than the control drug by 
three to six folds. This suggests that when there is no substituent at position 2 and 
an electron withdrawing substituent is present at position 5, the antifungal activity is 
increased (Table 5.4). This confirms the hypothesis that there is a direct relationship 
between the antifungal activity and the electron withdrawing effect of substituents. 
Only FAS18 (5-Cl) has previously been studied for its antifungal activity (Karuvalam 
et al., 2012), against different species of Aspergillus fumigatus NCIM No. 902, and 
Penicillium marneffei, but no activity was recorded. This is in contrasts to the results 
obtained in this project which showed that FAS18 was highly active against the 
selected strains with MIC equivalent to amphotericin B, and two folds potent 
(Karuvalam et al., 2012).    
From the series of 2-alkylamine benzimidazole derivatives (series 1 and 2), 
promising results were observed for FAS4 (5-Cl) and FAS7 (5-NO2), especially 
against Mucor circinelloides RCMB 07328 with MICs of 3.9 and 0.49 μg/ml, 
respectively. However, no activity was observed for the 5-bromo analogue (FAS5). 
Both FAS4 and FAS7 were active and their activity was equivalent to the control 
drug, and FAS7 was three folds potent than the control. This suggests that the more 
electron withdrawing the substituent is, the higher the antifungal activity (Table 5.4). 
Furthermore, compounds FAS4 (5-Cl), FAS6 (5-F), FAS7 (5-NO2), and FAS8 (5-H) 
showed good activity against Candida parapsilosis RCMB 05065; with a MIC range 
of 1.95-0.06 μg/ml for compounds FAS4 and FAS8, which is equivalent to the MIC 
of amphotericin B (control drug). FAS6, the 5-fluoro analogue, was 3 times more 
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potent, while FAS7 (5-NO2) was fivefold more potent than the control drug. This 
suggests that when the electron withdrawing effect increases, the antifungal effect 
also increases. When comparing FAS7 (5-NO2, 2-CH2NH2) with FAS21 (5-NO2, 2-H) 
in terms of their antifungal activity, FAS7 was more potent and this may be due to 
the existence of the –CH2NH2 group at position 2 (Table 5.5), and hence this result 
agrees with the study by Dhua and Biswas (2011) (Tavman et al., 2009, Dhua and 
Biswas, 2011, González-Chávez et al., 2011). 
From the series of 2-methanol benzimidazole derivatives (series 4), compound 
FAS26 (5-Br) exhibited promising results against Absidia corymbifera RCMB 09635, 
Syncephalastrum racemosum RCMB 05922, Candida krusei RCMB 05051 with 
MICs equivalent to the control, but two folds more potent against Candida 
parapsilosis RCMB 05065 than the control. This suggests that the more 
electronegative bromine increases the antifungal activity (Table 5.4) (Tavman et al., 
2009). 
In the 2-carboxylic acid benzimidazole series (series 5), promising results were 
obtained for two compounds, FAS32 (5-Cl) and FAS33 (5-Br), with MICs of 0.98  
μg/ml only against Candida parapsilosis RCMB 05065, which is one fold more 
potent than the control drug. But when comparing these results with the results of 
their unsubstituted (at position 2) analogues from series 3 (FAS18, 5-Cl and FAS19, 
5-Br), the latter compounds were more active antifungals. Therefore, this result 
confirmed that the activity is dependent on the halogen substituents at position 5 
(Table 5.4) (Tavman et al., 2009). 
Promising results were obtained for two compounds in the 2-chloromethyl 
benzimidazole series (series 7). FAS44 (5-Me) and FAS49 (5-NO2), showed MICs 
of 1.95 μg/ml against Mucor circinelloides RCMB 07328, which is one fold more 
potent than the amphotericin B. Also, the MICs for these compounds were higher 
than the control drug by three to four folds against Candida parapsilosis RCMB 
05065. This can be explained, in case of FAS49 (5-NO2), which was more active 
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than the methyl derivative FAS44, by the presence of the highly electron 
withdrawing substituent. As a result of this, FAS49 (5-NO2) is almost two folds more 
active than FAS44 (5-Me) (Table 5.4) (González-Chávez et al., 2011). 
From the 2-ethylbenzimidazole series (series 8), good activity was exhibited by 
compound FAS54 (5-H) with MICs of 0.12 μg/ml against Mucor circinelloides RCMB 
07328 and against Syncephalastrum racemosum RCMB 05922, with MIC of 0.24 
μg/ml, which was five and three folds potent than the amphotericin B, respectively. 
Interestingly, FAS54 which is unsubstituted at position 5, showed promising activity, 
while the nitro derivative FAS55 showed no activity. Surprisingly, the inhibition 
activity decreases when the electron withdrawing effect of the substituent on 
position 5 increases; this is in contrast with previous results (Table 5.4) (González-
Chávez et al., 2011).  
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5.4.3.2 The effect of the substituent at position 2  
Only two of the unsubstituted compounds at position 2, FAS54 (series 8), and 
FAS56 (series 9) displayed a broad spectrum of activity against many of the tested 
strains. Compound FAS54 from series 8, was active with MICs of 0.12-1.95 μg/ml, 
which was almost two to seven folds more potent than FAS56 from series 9, against 
all strains except against Absidia corymbifera RCMB 09635. This may indicate that 
the presence of the ethyl group at position 2 (in FAS54) is the reason for this 
activity. When comparing this result with the result for the unsubstituted analogue 
(FAS15, 2-H) at position 2, no promising activity was recorded for FAS15. However, 
the MICs for FAS56 were in the range 0.98 -500 μg/ml. It is the thiol which 
contributes to the antibacterial activity since FAS22 (2-CH2OH) from series 4, was 
not as active. It should be noted that no antibacterial activity was recorded for 
compound FAS54, whereas FAS56 was active. This suggests that the presence of 
the thiol group is required for antibacterial activity, but decreases the antifungal 
activity. Other studies have highlighted the biological importance of the thiol group 
(Table 5.4) (Klimesˇova´ et al., 2002, Utku et al., 2008, Goswami and Singh, 2012). 
 
Two 5-methyl derivatives FAS16 (2-H) from series 3 and FAS44 (2-CH2Cl) from 
series 7, showed antifungal activity against all strains. While both compounds 
exhibited the same activity (MIC 0.24 μg/ml) against one strain of unicellular fungal, 
Candida parapsilosis RCMB 0506, FAS16 (2-H), was more active (by one to eight 
folds) than FAS44 (2-CH2Cl).  
 
In the 5-methoxy series, two compounds FAS17 (2-H) from series 3 and FAS42 (N-
Me, 2-CH2OH) from series 6, were active. FAS42 was selectively more active than 
FAS17 by two to four folds against three strains of the filamentous fungal; 
Aspergillus clavatus RCMB 02593, Mucor circinelloides RCMB 07328, and 
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Syncephalastrum racemosum RCMB 05922, and only one strain of the unicellular 
fungal; Candida tropicalis RCMB  05049.  
FAS18 (5-Cl) from series 3 was the only active compound in the 5-chloro series. It 
was more active than Amphotericin B by two to six, or in equivalent folds potent. 
The antifungal activity can be attributed to the presence of the halogen atom. In the 
5-bromo series, only FAS19 showed promising activity. FAS19 (5-Br) was more 
active than Amphotericin B by one to nine, or in equivalent folds against the fungal 
strains. FAS20 (5-F) was the most active fluorinated derivatives, and it was more 
active than amphotericin B by two to five, or in equivalent folds against the fungal 
strains. In conclusion, FAS19 (5-Br) was the derivative which displayed the best 
antifungal activity out of the other halogenated derivatives (Table 5.4). 
 
In the 5-nitro series, FAS7 from series 1 was the only derivative which showed good 
activity against some of the selected strains. It was more active than Amphotericin B 
by one to five, or in equivalent folds. This can be due to presence of –CH2NH2 at 
position 2. Dhua and Biswas (2011) studied other 2-aminomethylbenzimidazole 
drivatives and found that they were active against Staphylococcus aureus, Bacillus 
subtilis, and Salmonella typhyi.  
 
5.4.3.3 The effect of the substituent at position 1  
From the N-methyl-2-methanol benzimidazole series (series 6), three compounds 
were active. FAS41 (5-F), FAS42 (5-OMe), and FAS50 (5-NO2) showed MIC values 
of MIC ≤ 0.12 μg/ml. This can be explain in case of FAS42 (5-OMe) more active 
than the fluorinated derivative FAS41 (5-F), due to the methoxy substituent which is 
the most potent electron donating substituents in all the substituents. Regardless of 
the activity of compound FAS42 (5-OMe) against many of the tested strains which 
inhibited the fungi strains with MIC ≤ 0.24 μg/m, compound FAS50 (5-NO2) almost 
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double potent against the selected strains, and this keep the nitro group on position 
5, the most active compounds against the tested fungal (Table 5.6) (Vidaillac et al., 
2007, González-Chávez et al., 2011, Sambanthamoorthy et al., 2011).  
 
From N-oxide derivatives (sereis 10)only one compound recorded antifungal activity 
against some of the selected strains. FAS60 (5-NO2), was more active than 
Amphotericin B by one to seven folds potent. The existence of –C=O at position 2 
increases the antifungal activity (Table 5.4). Literature review supported that the 
presence of the carbonyl group at position 2 of the benzimidazolin, showed some 
fungicide activity in case of  benzoimidazol-2-one (Kadyrov and Khalikov, 1983). 
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5.4.3.4 The activity of the silver complexes  
The antifungal screening test was done against selected strains, and showed 
promising activity, which were recorded for two complexes against 
Syncephalastrum racemosum RCMB 05922. FAS70 (ligand = 5-
bromobenzimidazole) was as active as the control drug, while FAS72 (ligand = 5-
methyl-1H-benzo[d]imidazole-2-carboxylic acid) was more active by one fold. When 
comparing the antifungal activity of the complexes, with the activity of the ligand, it 
can be seen in case of FAS70 that the complex showed equivalent activity as the 
ligand against Syncephalastrum racemosum RCMB 05922, and less activity against 
the remainder of the strains. FAS72 was more active than the ligand against all the 
selected strains except against Candida parapsilosis RCMB 05065, Absidia 
corymbifera RCMB 09635, and Penicillium marneffei RCMB 01267. This provides 
evidence that silver improved the antifungal activity. Abu-Youssef (2007) tested 
some newly prepared silver (I) compounds and found that they possessed 
antimicrobial activity. 
 
5.4.3.5 The effect of different heterocycles  
Benzoxazole (series 11) and benzothiazole (series 12) were synthesised and were 
assessed against the selected strains to compare their activity to the benzimidazole 
derivatives (series 3, 4). As a result of this, only benzimidazole derivative FAS18 (5-
Cl) from series 3 showed the most activity against some of the selected strains than 
Amphotericin B by two to six or equivalent folds potent MIC. However, the 
benzimidazole compound FAS18 (5-Cl) from series 3 was more active than the 
benzoxazole FAS63 (5-Cl) from series 11, with MICs of one to twelve, or equivalent 
folds more potent, against all the strains except against Syncephalastrum 
racemosum RCMB 05922. FAS63 (5-Cl) from series 11, was more active by three 
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folds with MIC value of 0.12 μg/ml. Moreover, the benzimidazole derivative FAS22 
(5-H) from series 4, was more active than the benzothiazole FAS65 (5-H) from 
series 12. So it can be concluded, that the most activity were recorded, when the 
bezimidazole core was present. A previous study found that benzimidazoles were 
on of the most important class of compounds which are fungicides (Kaplancikli et 
al., 2004). 
 
5.5 Next generation of antimicrobial agents of benzimidazole and 
future work 
In this section, suggestions for the next generation of optimized antimicrobial agents 
are made. This is based on the results of the MICs (Section 4.3.2) and the SAR 
study (Section 5.4). In each case, the five most promising antibacterial and 24 
antifungal molecules have been selected.  
Alternative reaction conditions were explored in attempts to address the sluggish 
reaction of 1,2-phenylenediamine with amino acids. A marked improvement of the 
Phillips method was found during the microwave mediated synthesis of 
benzimidazoles in ionic liquids as solvents. Although, this was only a preliminary 
study and a further more extensive study is required to establish the optimum 
reaction conditions. 
5.5.1 Next generation antibacterial  
The MRSA species which causes serious infection was of particular interest from all 
the bacteria strains selected for this study. Therefore, if any compound was active 
against this strain, it would be considered to be promising lead. Figure 5.9 shows 
the molecules which have been identified as the most effective antibacterial 
compounds during the biological assays against bacteria, especially MRSA species 
(see Table 5.2).  
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N
NR
2
R
R1
Code R R1 R2
FAS11 H CH(CH3)NH2 Cl
FAS12 H CH(CH3)NH2 Br
FAS39 CH3 CH2OCH3 Cl
FAS47 H CH2Cl Br
FAS56 H CH2SH H  
Figure  5.9 Structures of the most active compounds against MRSA bacteria species  
In terms of the SAR, the key factor in this case is the presence of the chlorine or 
bromine substituent at position 5 of the benzimidazole ring, and the presence of –
CH(CH3)NH2 or -CH2Cl at position 2. Moreover, the presence of –CH2SH at position 
2 (H at position 5), proved effective for antimicrobial activity. Derivatives with  
–CH2NH2 were not active against bacteria, but when a branched methyl group is 
added (–CH(CH3)NH2), the antibacterial activity improved. The latter compounds 
were prepared from S-alanine. Therefore the product, which is also chiral and has 
the S-stereochemistry, showed selectively active against the MRSA species. 
Chirality is a feature for most drugs, with one of the stereoisomers to be active 
biologically and the other inactive or even toxic. Therefore, the chirality has a 
significant impact on enhancing the biological activity of the compound (Sekhon, 
2013, Shen et al., 2013).  
Future work should concentrate on further modifications on these compounds, 
including testing the R-isomer and racemic mixture, (Figure 5.10) which may be 
beneficial in increasing the antibacterial activity. Therefore, the next generation 
compounds proposed for further development are based on the chirality at position 
2 as shown in Figure 5.10. Thus, based on the activity of the 2-methanthiol 
benzimidazole derivative, further work could study the chiral derivative prepared by 
the condensation of (S) and (R)-2-mercaptopropanoic acid and 5-substituted (H, Cl, 
Br)-1,2-phenylendiamines (Chimirri et al., 2000). 
Similarly, based on activity of the 2-chloromethyl derivative (Figure 5.10), new 
research could focus on reacting (S) and (R)-2-chloro-propionic acid with 5-
substituted (H, Cl, Br)-1,2-phenylendiamines (Yadav and Pal, 1996). Moreover, 
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work needs to be carried out to complete the series of compounds to fully 
investigate the structure activity relationships.  
SHN
H
N MeR
ClN
H
NR Me
Both (R) and (S) and racemic mixture R= H, Cl, Br  
 
Figure  5.10 Proposed next generation antibacterial agents  
 
5.5.2 Next generation antifungal 
There were more compounds which were potent fungicides against selected fungal 
strains as shown in Figure 5.11. This includes two silver complexes; FAS70 (ligand 
=FAS19 ), and FAS72 (ligand =FAS30 ). These compounds were the most effective 
antifungal compounds during the biological assays against fungi species with 
equivalent or greater potentency in their MIC values than amphotericin B. In 
particular, compounds FAS18, 19, and 20 showed broad spectrum activity.  
According to the SAR study, an extremely important factor is the nature of the 
substituent attached to the aromatic ring. The presence of the halogen atom (Cl, Br, 
F) at position 5, increased the antifungal activity. For the 5-nitro derivative, the 
presence of –CH2NH2 at position 2 increased the activity. The N-methylated-2-
methanolbenzimidazole derivatives (series 4) were more active than the 
unmethylated analogues and this is observed when the substituent at position 5 was 
F, OMe, or NO2. 
Future work should focus on further modifications on these compounds as 
presented in Figure 5.12, which may improve the antifungal activity. Moreover, 
future work could explore the silver complexes of different ligands of benzimidazole 
such as the proposed next generation compounds which are shown in Figure 5.12. 
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N
NR
2
R
R1
Code R R1 R2
FAS31 H COOH OMe
FAS32 H COOH Cl
FAS33 H COOH Br
FAS41 CH3 CH2OH F
FAS42 CH3 CH2OH OMe
FAS50 CH3 CH2OH NO2
FAS44 H CH2Cl CH3
FAS48 H CH2Cl F
FAS49 H CH2Cl NO2
FAS54 H CH2CH3 H
FAS56 H CH2SH H
FAS60 O H NO2
Code R R1 R2
FAS4 H CH2NH2 Cl
FAS7 H CH2NH2 NO2
FAS8 H CH(CH3)NH2 H
FAS16 H H CH3
FAS17 H H OCH3
FAS18 H H Cl
FAS19 H H Br
FAS20 H H F
FAS21 H H NO2
FAS51 H H CN
FAS26 H CH2OH Br
FAS27 H CH2OH F  
 
Figure  5.11 Structures of the most active compounds against fungal species 
 
N
NR
2
R
R1
R = alkyl, aryl, alkylhalide, arylhalide
R1 = alkylamine
R2 = OMe, OH, Cl, Br, F, NO2  
Figure  5.12 Proposed of some of the next generation of antifungal agents 
 
5.5.3 Biological future work  
One of the most important steps in the further biological work is the study of the 
toxicity of the compounds in order to see if they can be used clinically. Therefore, 
the toxicity assay will also be required to explore the potential of these compounds 
as selective antimicrobial drugs which target the microbe cells rather the human 
cells. In addition, the mechanism of the antibacterial and antifungal action of the 
benzimidazoles needs to be understood so that more effective antimicrobial 
inhibitors can be designed and synthesised.  
A study done by Sambanthamoorthy et al. identified a novel benzimidazole 
compound (see section 5.4.1) which does not inhibit the growth of bacteria, but they 
found it prevented bacterial biofilm formation in multiple Gram +ve and Gram -ve 
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bacterial pathogens (Sambanthamoorthy et al., 2011). Therefore there is still hope 
that the compounds prepared in these compounds could exhibit antibiofilm activity 
by targeting the biofilm formation between the microbe cells. Therefore, further 
biological studies on behaviour of the benzimidazoles on the biofilm of bacteria 
strains is required in order to identify the antibiofilm activity of the synthesised 
compounds.  
Despite the promising results obtained in this project, this does not mean that these 
compounds will replace the well-known drugs, such as fluoroquinolones, which have 
the required potential to be used clinically. The duration for the development of a 
new drug is in the range of 10-15 years, starting from the stage of determining the 
biological activity down to the stage where the drug come to the market 
(Department of Health, 2013b). In this period, i.e. drug development duration, there 
are several stages, which includes assessing the toxicity of the compound, and if 
the compound is highly toxic, it will be eliminated from the rest of the stages of 
development. Several researchers had reported that even when their preliminary 
results were promising, but unfortunately, these compounds could not be developed 
into new drugs because of their high toxicity towards the normal cells. An example 
of this is aziridinyl substituted benzimidazolequinones (Donkor, 2007, Fahey et al., 
2010). In addition, the toxicity issue is more problematic for antifungal agents. As 
mentioned earlier in chapter 1.5, human cells and fungi cells are all eukaryotic. 
Thus, it is challenging to design drugs which target the fungi cells without affecting 
the human cells. For example, amphotericin B is a clinically antifungal drug which 
targets the yeast and it can also be a major cause of toxicity the human cells 
(Wilcock et al., 2013). Despite this, the investigation continues to find new drugs 
with low toxicity and high therapeutic effect. However, there are more challenges 
which hinder the development strategies in order to achieve the optimal drugs.  
One of the most important of these challenges is the increasing resistance of the 
microbes against the well-known drugs. This is an extremely challenging issue 
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which researchers in this field are focusing on in order to find strategies to resolve 
the problem through the development of new drugs. One of the solutions would be 
through cooperation between several research organizations, as is the case in the 
campaign 10/20, which was launched in 2010 and which aimed to get 10 new drugs 
by 2020. This was agreed by U.S. President Barack Obama, who signed an 
agreement with the representative of the European Union (the Swedish Prime 
Minister Fredrik Reinfeldt) to establish a transatlantic task force to focus on solving 
the problem of the antibacterial drugs pipeline (IDSA, 2010). Thus, it is clear that the 
issue has escalated and has reached the stage which required political intervention. 
This is issue of antibacterial resistance is now acknowledged as a worldwide 
problem. 
It is worth mentioning how resistance occurs and then spreads. Two figures, taken 
from the CDC report (2013) illustrate this. Figure 5.13 shows how resistance occurs, 
and Figure 5.14 shows how it spreads. The CDC report also highlighted the 
estimated minimum number of illnesses and deaths caused by antibiotic resistance, 
which is at least 2,049,442 illnesses, and 23,000 deaths, respectively. For 
clostridium difficile infections in particular, the annual mortality rate in United States 
is no less than 14,000 people, whereas the morbidity rate is almost 250,000 every 
year. However, the healthcare-associated infection, is the most serious Gram –ve 
infection which is produced by common pathogens such as Enterobacteriaceae, 
Pseudomonas aeruginosa, and Acinetobacter. Moreover, these pathogens reached 
the acute levels of concern because they are "pan resistant pathogens" (resistant to 
almost all therapeutic drugs). Therefore, these pathogens are difficult to treat. 
Besides the mentioned challenges which hinder the development of new drugs, 
there are several factors which may also contribute to the dwindling “antimicrobial 
agents pipeline” (see section 1.6, 1.7, and 1.8), including economic impact 
incidence, transmissibility, availability of effective antibiotics, and barriers to 
prevention (Centers for Disease Control and Prevention, 2013).  
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importance. In order to achieve this, 66 compounds were synthesised based on the 
2-benzimidazole derivatives and compared to other heterocycles, benzoxazole and 
benzothaizole. Eleven compounds were novel and more than 50 compounds were 
tested for the first time against a library of bacteria and fungi strains. Moreover, the 
Phillips method was improved in this project by using ionic liquids and microwave 
assisted synthesis. Some silver complexes of benzimidazole derivatives were also 
screened against the selected strains to evaluate the importance of the silver metal.  
According to the SAR analysis, it can be concluded that the derivatives of 
benzimidazole offer enormous possibilities for the development of new broad 
spectrum antimicrobials. Through appropriate modification and fine-tuning of 
substituents at positions 1, 2, and 5, new microbial inhibitors are possible. 
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